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Overt loss of skeletal muscle tissue, or volumetric muscle loss (VML), overwhelms its inherent 
regenerative ability and is associated with robust scar tissue deposition and loss of function. 
VML is a significant problem in both military and civilian medicine. Current treatment options 
including muscle flaps, grafts, orthotics, and cell-centric strategies remain ineffective. Over the 
past decade, bioscaffolds composed of mammalian extracellular matrix (ECM) have been 
investigated as an acellular, inductive template to promote functional myogenesis for VML 
repair. ECM bioscaffolds obviate the need for exogenous stem cell delivery through the 
recruitment of endogenous stem / progenitor cells and promote a pro-remodeling 
microenvironment through modulation of the innate immune response. This immune-stimulatory 
approach, paired with endogenous stem / progenitor cell recruitment, represents a novel 
therapeutic strategy for treating VML. Mounting evidence suggests that site-appropriate 
mechanical loading can contribute to this pro-regenerative microenvironment. The objectives of 
the present thesis include determination of the spatial and temporal response of macrophages and 
progenitor cells within the ECM-treated VML injury site, investigation of the effects of ECM 
bioscaffolds upon macrophage phenotype and function, and determination of the effects of 
concomitant mechanical loading upon both macrophages and progenitor cells in the context of 
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ECM-mediated VML repair. Results show that ECM bioscaffolds can promote a shift in 
macrophage phenotype which is associated with downstream stem / progenitor cell recruitment. 
ECM bioscaffolds activate macrophages towards a pro-remodeling phenotype. Mechanical 
loading augments a pro-regenerative cross-talk between macrophages and myogenic progenitor 
cells following exposure to ECM degradation products. These preclinical investigations, among 
others, have driven the clinical translation of ECM bioscaffolds. Thirteen VML patients have 
been treated to date, with results that include strength and functional improvement and evidence 
of new muscle formation and innervation. This strategy which considers the responding innate 
immune response, stimulates endogenous progenitor cells, and includes early, site-appropriate 
mechanical loading, represents a promising and translatable approach to VML treatment.  
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1.0  SKELETAL MUSCLE RESPONSE TO INJURY 
1.1 CLINICAL SIGNIFICANCE OF SKELETAL MUSCLE INJURY 
Volumetric muscle loss (VML) is a problem with significant clinical and economic 
consequences. VML is defined as the loss of at least 20% of a given muscle’s mass resulting in 
functional impairment1. Such injuries can occur as the result of traumatic injury, excessive 
exercise, tumor ablation, or degenerative disease. It is estimated that 35-55% of all sports injuries 
and 53% of all battlefield extremity injuries involve damage to soft tissue and myofibers, 
resulting in approximately 4.5 million reconstructive surgical procedures annually, which 
contribute to billions of dollars in healthcare expenses2. Current treatment options include 
physical therapy or orthotics, which do not correct underlying strength deficits, and/or surgical 
tendon or muscle transfers, which are associated with issues including donor site morbidity, graft 
infection, and necrosis3-5. All of these treatment options fall short of restoring function which 
negatively impacts patient quality of life.  
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1.2 ACUTE SKELETAL MUSCLE REGENERATION 
1.2.1 Skeletal muscle response to acute injury 
Skeletal muscle tissue accounts for 40-45% of total body mass, and because of its relatively 
superficial location, it is subject to frequent injury. Efficient endogenous regeneration is critical 
to maintain normal muscle function. Fortunately, skeletal muscle is a tissue that possesses a 
robust capacity to regenerate following minor injury and is resilient to minor tears and strains, 
exercise-induced injuries, or minor experimentally induced injuries such as muscle freeze or 
crush6-8. This inherent regeneration is attributed to the activation of resident multipotent 
myogenic precursors known as satellite cells that reside in the interstitial space between the 
sarcolemma of myofibers and the basal lamina9. Satellite cells remain in a quiescent state, are 
activated in response to injury, and begin to proliferate to either replenish the satellite cell pool 
or to give rise to myogenic cells that differentiate to form myoblasts and eventually fuse to form 
myofibers that repair and replace the injured muscle tissue.  
 In cases of severe injury, however, skeletal muscle is unable to compensate with these 
endogenous mechanisms. Traditional signaling cascades needed for stem cell activation are 
overwhelmed and a pro-inflammatory microenvironment prevents myoblast formation and 
differentiation resulting in a fibrotic or adipogenic response and downstream functional 
deficits10. Loss of mechanical function in VML injuries is associated with physical deformities, 
significant loss of muscle volume, and a compromised quality of life11,12.  
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1.2.2 The role of the innate immune system in acute skeletal muscle regeneration 
The skeletal muscle injury microenvironment is complex, involving many cell types in addition 
to myogenic stem / progenitor cells that contribute to the injury response. In fact, upon injury, 
the majority of the first responding cells are macrophages, which have been shown to be positive 
regulators of skeletal muscle regeneration13. Specifically, previous work has shown that reducing 
macrophage numbers slows muscle regeneration following acute injury, and that distinct 
macrophage phenotypes are required for efficient muscle repair14,15. Macrophages are a 
heterogeneous cell population capable of activation along a spectrum of phenotypes dictated by 
cues from their local microenvironment16. Classically activated, M1-like, pro-inflammatory 
macrophages dominate the skeletal muscle injury scene as early as 1-2 days following injury and 
have been associated with early stages of muscle progenitor cell activation and proliferation. By 
4 days after injury, proper muscle regeneration requires a phenotypic switch from this pro-
inflammatory, M1-like macrophage, to a pro-remodeling, M2-like phenotype. M2-like 
macrophages have been associated with early stages of myogenic differentiation13. Without this 
phenotypic switch, regeneration is impaired and characterized by slowed growth of regenerative 
muscle fibers. Further, not only is the sequence of the phenotypic switch important, but the 
timing of the switch is also a critical factor in determining skeletal muscle remodeling outcomes 
following injury15. Macrophage-directed muscle regeneration is a complex and tightly controlled 
endogenous process that becomes perturbed in VML. Development of effective therapies for 
VML therefore lies in the understanding and manipulation of this complex microenvironment 
and the regulators of macrophage activation.   
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1.2.3 Macrophage-progenitor cell crosstalk 
Macrophages influence stem / progenitor cell behavior in many tissue types, including skeletal 
muscle17-25.  Interestingly, emerging evidence has shown that stem / progenitor cells can 
reciprocally regulate macrophage activation. Mesenchymal stem cells (MSCs) can promote 
expression of M2-like proteins including arginase-1 (Arg1). Additionally, co-culture of MSCs 
with bone-marrow-derived macrophages has been associated with a reduction in 
proinflammatory M1-like marker expression including inducible nitric oxide synthase (iNOS) 
and interleukin-6 (IL-6) and an increased expression of M2-like markers including interleukin-10 
(IL-10), interleukin-4, (IL-4), and CD20626. Other work has shown that MSC-educated 
macrophages are a novel phenotype with distinct protein expression profiles when compared to 
activated M1-like and M2-like macrophage phenotypes27. It is plausible that the beneficial 
effects of MSC transplantation are partially attributed to their influence on macrophage 
phenotype. Targeting macrophage – stem / progenitor cell bidirectional crosstalk could be an 
important consideration for tissue remodeling therapies.  
1.3 TREATMENT STRATEGIES FOR VOLUMETRIC MUSCLE LOSS 
1.3.1 Current standard of care 
Current, noninvasive treatment standards for patients suffering from volumetric muscle loss 
include maximization of the strength of the remaining muscle tissue with bracing / orthotics. 
Unfortunately, this approach cannot make up for the notable loss of strength which results from 
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VML. Muscle transposition (i.e. free flaps or grafts) or tendon transfer can replace muscle 
function, but have less-than-satisfactory success rates1,3-5. Such procedures typically involve 
significant donor-site morbidity and fail to provide efficient reconstruction or functional re-
innervation of the lost muscle tissue. There is also a risk of graft infection which may lead to 
necrosis and the need for amputation. Overall, the current standard of care approaches for VML 
do not address persistent strength and functional deficits which ultimately contribute to 
disability, weakness, and poor quality of life for patients with VML. 
1.3.2 Cell-centric regenerative medicine approaches 
Tissue engineering and regenerative medicine-based strategies for the reconstruction of 
functional skeletal muscle tissue have included both cellular and acellular approaches. Cell-based 
strategies have attempted to augment skeletal muscle’s natural regenerative response through the 
delivery of exogenous (typically autologous) stem / progenitor cells to the VML defect site28,29. 
Utilization of enriched muscle-derived stem cells, capable of long-term proliferation and 
myogenic potential, has been somewhat successful and increases the regenerative index when 
injected into sites of skeletal muscle injury in preclinical studies30. In addition to associated strict 
FDA regulatory restrictions, cell-based tissue engineering approaches are typically limited, 
however, by chronic pro-inflammatory activation of the host innate immune system and failure 
of the cells to incorporate within the host tissue31-33. The results of this approach have shown low 
cell viability34, poor cell migration and engraftment35, and the need for immunosuppressive 
therapy36,37, as shown in Table 1. 
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Table 1. Stem-cell based strategies for skeletal muscle repair 
Cell type Description Progress towards 
therapeutic potential 
Challenges  
Satellite cells 38,39  • Adult stem cells 
• Express Pax7 transcription 
factor 
• Necessary for proliferation 
and maintenance of muscle 
stem cell pool  
• Took nearly 50 years from 
first identification to a pure 
cell isolation.  
• Surface markers identified 
for satellite cell isolation 
are not necessarily reflected 
in human physiology.  
• There is a need for 
optimized isolation and 
more efficient expansion 
• Very difficult to isolate 
and expand in culture 
to obtain enough cells 
for expansion 
• Limited engraftment 
efficiency 
Muscle-derived stem cells 
40,41 
• Adult stem cells 
• Identified in the interstitial 
space in mice 
• Non-adherent cell 
population  
• Shown to improve muscle 
regeneration upon injection 
in preclinical murine 
models 
• Can be expanded in vitro up 
to 30 passages while 
retaining myogenic capacity 
• Poor engraftment 
efficiency 
• No functional 
improvement  
Perivascular stem cells 42,43 • Adult stem cells 
• Found in muscle 
microvasculature typically 
vessel associated 
• CD146+/NG2+/ALP+ 
• Express satellite cell 
markers 
• Assume satellite cell 
position after injection 
• Promising preclinical 
results have led to ongoing 
phase I/II clinical trial for 
pediatric muscular 
dystrophy 
• Grow extensively in culture 
• Better engraftment 
efficiency than satellite 
cells  
• Improve both morphology 
and function of muscle  
• Variability in in-vitro 
scalability gives them 
a finite culture life-
span 
Embryonic stem cells 44-46 • Pluripotent cells isolated 
from inner cell mass of 
blastocyst  
 
• Generation of large 
quantities in vitro is 
possible  
• Engraftment ability has 
been demonstrated in 
murine models  
• Difficult to 
recapitulate the 
skeletal muscle lineage 
in vitro  
• Potential immunologic 
mismatch  
• Ethical concerns  
Induced pluripotent stem 
cells (iPS) 47 
• Genetically reprogrammed 
somatic cells inducing a 
pluripotent state 
• Generation of Pax7+ iPS 
cells is possible  
• Generation of functional, 
human skeletal myogenic 
progenitors has been 
accomplished 
• Promote skeletal muscle 
regeneration and functional 
improvements 
• Requirement for 
genetic correction 
• Risk of tumor 
generation 
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In fact, immunosuppressive therapy contributes to myoblast apoptosis48. Even if an ideal 
cell source and effective delivery method are identified, transplanted cells are often associated 
with less-than-optimal proliferative and differentiation potential within the host injury site48. 
Injected cells, lacking a scaffold material, are typically unable to redistribute throughout the 
injection site and do not migrate more than 200µm in vivo. Intravenous (IV) cell delivery 
frequently results in unintentional cell engraftment within tissues such as liver and spleen. Cells 
that are able to be adequately delivered to intended tissues are typically unable to engraft. In fact, 
it is widely accepted that myogenic stem / progenitor cell transplantation typically does not result 
in a significant engraftment of donor cells within the host tissue. Cell-centric strategies are also 
associated with a high economic burden due to the need for ex vivo cell expansion and 
manipulation. While some cell-based approaches have shown promise in preclinical studies, 
regulatory challenges and a lack of notable efficacy have prevented their widespread adoption 
for VML treatment.  
1.3.3 Physical rehabilitation / the benefits of mechanical loading 
There is mounting evidence to suggest that mechanical stimulation of the skeletal muscle 
microenvironment and its associated cells is an important determinant of remodeling outcomes 
after injury. Mechanical loading has been shown to be important in musculoskeletal strength 
maintenance, endurance, fatigue resistance, and development. Mechanical load has been shown 
to control skeleton and tendon development and is a key regulator of cartilage morphogenesis, 
joint formation, bone morphogenesis, and tendon homeostasis and repair49. More recently, the 
benefits of mechanical loading have been implicated in skeletal muscle’s inherent regenerative 
capacity following acute injury. Specifically, mechanical loading has been associated with 
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activation of quiescent satellite cells, enhancement of muscle-derived stem cell proliferation and 
transplantation efficacy, improved alignment of regenerating myotubes, minimization of atrophy 
of surrounding myotubes, enhancement of immunomodulatory players, and modulation of niche 
elasticity, among other benefits50. The specific effects of mechanical loading at a cellular level in 
biomaterial-mediated skeletal muscle remodeling are unknown. Advances in the science of 
mechanotransduction, a process by which mechanical stimuli are translated into biologic 
responses, suggest that changes in both cellular and extracellular matrix mechanics may be 
contributing factors in the pathogenesis of certain muscle-related diseases. By applying 
mechanical stimuli in the form of targeted rehabilitation, there may be potential to augment the 
tissue remodeling response in severe, critical sized defects as is the case in VML.  
 
1.4 FUTURE PERSPECTIVES 
A multidisciplinary approach that considers the complex microenvironment of skeletal muscle 
injury is required for promoting effective functional and constructive remodeling, especially in 
the case of critically sized defects such as volumetric muscle loss. Favorable outcomes 
associated with the cell-based skeletal muscle tissue engineering approaches are most likely 
associated with a paracrine effect of the donor cells upon the host injured microenvironment 
rather than by direct myogenesis from the delivered cells51-56. Recent preclinical rodent studies 
have shown that skeletal muscle progenitor cells delivered in concert with an acellular biologic 
scaffold derived from mammalian extracellular matrix (ECM) have the potential to obviate the 
limitations associated with exogenous cell delivery57,58. Specifically, the studies combine 
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allogeneic muscle-derived cells (MDCs) and bladder acellular matrices (BAMs) which are then 
subjected to a period of ex vivo bioreactor mediated preconditioning prior to surgical placement. 
The most recent study showed that acellular BAMs were able to promote a 26% functional 
improvement while MDC seeded BAMs showed a 61% functional improvement in a rodent 
model of tibialis anterior (TA) VML58. These studies suggest that combination approaches may 
be able to augment a constructive remodeling outcome.  
Additionally, positive outcomes associated with implantation of acellular biologic 
scaffolds for VML repair have been partially attributed to an aggressive, targeted physical 
therapy regimen which was implemented within 24-48 hours after ECM bioscaffold 
implantation. The application of a physiologic mechanical load during bioscaffold and tissue 
remodeling following injury promotes favorable preclinical and clinical outcomes including an 
increased cellular infiltrate, more rapid and extensive neovascularization, more organized and 
aligned connective tissue matrix, and a beneficial influence upon gene expression and cellular 
behavior50,59-61. While there is mounting evidence to suggest that mechanical stimulation of the 
extracellular matrix and its associated cells is an important determinant of remodeling outcomes, 
the specific effects of mechanical loading at a cellular level in extracellular matrix-mediated 
skeletal muscle remodeling is unknown and represents an important area of future investigation. 
1.5 CONCLUSIONS 
The ECM plays an important role in regulating the immune response to injury, especially in the 
context of acute skeletal muscle regeneration.  The concept of dynamic reciprocity which 
describes the continuous cross talk between cells and matrix, and the influence of external 
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factors that affect the microenvironmental niche, is central to the understanding of the role of the 
ECM in musculoskeletal remodeling.  While cell-centric regenerative medicine approaches have 
been extensively investigated, the use of an acellular approach that stimulates endogenous repair 
in the form of a biologic scaffold derived from extracellular matrix offers opportunities for 
circumventing the need for exogenous cell delivery. Tissue engineering/regenerative medicine 
efforts have shown promising early results in utilizing ECM bioscaffolds for VML remodeling.  
Furthermore, while mechanical loading has the potential to promote improved muscle 
remodeling outcomes, there remains a need to evaluate the mechanisms associated with the 
synergy between the immune response to bioscaffold implantation in concert with targeted 
rehabilitation to advance clinical practice and provide superior treatment options for skeletal 
muscle disease and injury.  
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2.0  ECM BIOSCAFFOLDS AS IMMUNOMODULATORY MATERIALS1 
2.1 ABSTRACT 
Suppression of the recipient immune response is a common component of tissue and organ 
transplantation strategies, and has also been used as a method of mitigating the inflammatory and 
scar tissue response to many biomaterials. It is now recognized, however, that long-term 
functional tissue replacement not only benefits from an intact host immune response, but 
depends on such a response. The present manuscript reviews the limitations associated with the 
traditionally held view of avoiding the immune response, the ability of acellular biologic scaffold 
materials to modulate the host immune response and promote a functional tissue replacement 
outcome, and current strategies within the fields of tissue engineering and biomaterials to 
develop immune-responsive and immunomodulatory biomaterials.  
 
 
                                                 
1 Portions of this chapter were adapted from the following publication: 
Dziki JL, Huleihel L, Scarritt M, Badylak SF. ECM bioscaffolds as immunomodulatory biomaterials. Tissue 
Engineering Special Edition. April 2017. DOI: 10.1089/ten.TEA.2016.0538 
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2.2 INTRODUCTION 
The host response to whole organ transplant has been studied extensively and is well 
characterized. In contrast the host response to decellularized tissues and organs (i.e. bioscaffold 
materials composed of extracellular matrix (ECM)), or to synthetic biomaterials, has received 
much less attention and is relatively poorly understood. Tissue engineering (TE) strategies that 
include a biomaterial component but fail to consider the immune response are likely to yield sub-
optimal outcomes. The immediate host response to any biomaterial involves blood/plasma 
protein adsorption on the material surface, and activation of the innate immune response 
including infiltration of neutrophils, macrophages, and the release of a diverse array of 
inflammatory cell-secreted signaling molecules62,63. Resolution of this pro-inflammatory 
microenvironment is necessary for a successful clinical outcome following the use of any 
biomaterial. Normal adult wound healing processes, tissue homeostasis, and normal fetal 
development easily navigate this transition, partly as a result of the endogenous signals 
embedded within the extracellular matrix (ECM) which regulate the immune response64-67.  
For example, when vascular endothelial cells are injured or denuded from their basement 
membrane, von Willebrand Factor (vWF) embedded within the ECM facilitates rapid tethering 
and adhesion of platelets68. In addition, interactions between sub-endothelial ECM proteins and 
platelet surface receptors such as immunoblugulin GPVI and integrins αllbβ3 and α2β1 drive 
platelet activation and adhesion, respectively69. Separate from the effects of embedded signaling 
molecules, mechanotransduction, the mechanism by which cells translate mechanical stimulus 
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into biochemical responses, has been shown to influence cell fate. Within every tissue, variations 
in ECM composition, crosslinking, and 3-dimensional ultrastructure contribute to the 
biochemical and biophysical environment that regulates cell migration, proliferation, apoptosis, 
differentiation, and development70,71. 
Recently, mechanotransduction has been specifically implicated as a regulator of immune 
cell phenotype. McWhorter and colleagues demonstrated that cell shape, specifically degree of 
elongation can be influenced by micropatterning and subsequently modulate macrophage 
phenotype72. ECM remodeling in both post-injury healing environments and during homeostasis 
provides a mechanical feedback loop for the resident and/or infiltrating cells. As the ECM is 
degraded and replaced (i.e. remodeled), particularly during the resolution of inflammation, 
atypically expressed ECM molecules can modulate immune cell activation, differentiation, and 
persistence. These atypical ECM molecules, termed cryptic peptides, are bioactive peptides that 
are created or exposed by selective cleavage of ECM by proteases, particularly matrix 
metalloproteinases66. In a murine model of digit amputation, Agrawal and colleagues 
demonstrated that a C-terminal telopeptide of collagen IIIα present at the site of amputation 
recruited progenitor cells, increased calcium deposition, enchanced alkaline phosphatase activity, 
and amplified osteogenesis73.In a mouse model of lung inflammation, MMP8 or MMP9 cleavage 
of type I collagen resulted in an acetylated Pro-Gly-Pro peptide that activated CXCR receptors 
and attracted neutrophils74. Recently, matrix-bound nano-vesicles (MBVs) have been identified 
as an integral and functional component of bioscaffolds composed of extracellular matrix75. 
These vesicles have the ability to act as vehicles to transfer RNA, proteins, and other signaling 
molecules between cells, and can regulate physiologic and/or pathologic processes. These MBVs 
have been shown to induce a phenotypic change in macrophage activation state in vitro; a 
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phenomenon now recognized as a mechanism by which ECM bioscaffolds mediate their 
functional remodeling outcomes in vivo.  
Altogether, these examples point to an active role of the native ECM in tissue and organ 
development, homeostasis, inflammation, and healing. Analogous to these physiological roles for 
native tissue ECM, biologic scaffold materials composed of ECM activate many of these same 
endogenous signals76-79. Stated differently, biologic scaffolds composed of ECM serve as 
immunomodulatory biomaterials. 
The present manuscript reviews the advantages and limitations of the use of synthetic 
biomaterials, especially in the context of tissue engineering applications, and suggests a rationale 
for the relative effectiveness of ECM-based scaffold materials. In addition, the critical role of the 
immune system in tissue engineering approaches is described and thus, the increasingly 
important contribution of immunomodulatory biomaterials.   
2.3 IMMUNOSUPPRESSION: THE IMPACT UPON ORGAN TRANSPLANTATION 
An understanding of the host response to biomaterials benefits from knowledge of the 
earliest attempts at tissue and organ replacement. The concept of replacing damaged or diseased 
tissues and organs has not been the exclusive pursuit of the tissue engineering community, but 
rather, has been a part of medical practice for millennia. One of the earliest documented cases of 
tissue and organ transplant, skin grating, occurred in approximately 3000 BC as revealed in 
Sanskrit texts of ancient India80. Documentation of tissue transplant and grafting that spans the 
18th and 19th century includes the use of skin flaps to repair missing nose tissue after sword 
fights80, teeth transplants, and the use of cadaveric tissues. It was not until the realization that 
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transplant failure was largely attributed to immunologic events81 that the concept of 
immunosuppression was extensively investigated. The development of effective 
immunosuppression techniques allowed for organ transplantation to become commonplace. 
Immunosuppression progressed from a cell-centric approach that non-specifically targeted 
rapidly dividing cells by irradiation, to steroid therapy, to lymphocyte depletion, and eventually 
to inhibition of selected cytokines82. These immunosuppression strategies are associated with 
variable success rates, immune disorders, susceptibility to infections, and significant morbidity. 
Nonetheless, the discovery of major histocompatibility complexes (MHC) and the importance of 
human leukocyte antigen (HLA) matching led to improved success of immunosuppression 
compared to prior transplant methods, and has allowed for an exponential increase in the number 
of successfully transplanted organs and tissue grafts during the past 50 years.  
2.4 DEVELOPMENT OF “INERT” BIOMATERIALS 
As exhaustive studies were being conducted in the context of tissue and organ transplantation, 
the biomaterials community was identifying “inert” materials as desirable83-85. Biomaterials such 
as silicone that were isolated from the surrounding tissue by a defined fibrous capsule were 
grouped with materials identified as inert. In hindsight, the very formation of the capsule and the 
associated foreign body response was a manifestation of the host immune reaction toward the 
biomaterial. Attempts to mitigate fibrous tissue capsule thickness included steroid coatings or 
coating with cytotoxic agents83,86. Modifications of surface topology, functionalization with 
various ligands, and design changes that eventually included large (>75µm) pores were gradually 
added to biomaterials in attempts to control the local tissue response. 
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Arguably, there is no such thing as an “inert biomaterial.” Upon implantation, such 
biomaterials, usually of synthetic composition, are subjected to a series of well-defined processes 
characterized as the foreign body reaction (FBR) that ultimately leads to fibrous encapsulation of 
the implant87. Implanted medical devices are often isolated from the body by a dense, 
collagenous capsule, which has long been an acceptable form of “biocompatibility” both by 
regulatory and historical standards. However, the inability to interface with normal host tissue as 
a result of intervening fibrous tissue eventually leads to diminished function for devices that 
require close contact with parenchymal cells or neurovascular structures. Metals and alloys have 
long been used for orthopedic implants and dental implants but are typically subject to corrosion, 
leaching, and adverse immune responses to wear debris. Silicone rubber and natural rubber have 
been used for breast implant and ocular lens applications, among others, but are associated with 
oil adhesions and other complications associated with the FBR including capsular contraction 
that may eventually necessitate explant88-92. Drug-eluting and other porous materials and sensor-
based strategies to direct tissue repair are eventually ineffective if they fail to address the FBR, 
as the fibrous capsule that will inevitably surround the material will inhibit diffusion or 
controlled release of drug or sensor-related signals. It should be recognized that the inevitable 
inflammatory response that occurs to all biomaterials is virtually the same as the innate immune 
response, thus setting the stage for the concept of immunomodulatory biomaterials. The biologic 
processes of vascularization, cell response, fibrous tissue deposition, and the foreign body 
response have not changed; these events are now simply recognized as part of the host immune 
response. It is logical therefore, that modulation or redirection of the immune response rather 
than suppression of the immune response is important for long term biomaterial functionality.  
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2.5 BIOLOGIC SCAFFOLDS AS IMMUNE MODULATING BIOMATERIALS 
Within the last decade, the essential and necessary role of an intact and fully functional immune 
system in normal development93, regeneration94, and tissue homeostasis13,95-97, and in the 
constructive remodeling properties of ECM bioscaffolds98-100 has been recognized. Biomaterials 
composed of extracellular matrix (ECM), typically derived from xenogeneic tissues have shown 
notable success in promoting constructive and functional tissue remodeling in multiple anatomic 
sites in both pre-clinical and clinical studies including hernia repair applications, esophageal 
mucosa replacement following cancer resection, volumetric muscle loss treatment, cardiac 
repair, and mitral valve replacement, among others89,101-107. It is important to note that ECM 
scaffolds prepared by methods that remove essentially all cellular remnants (i.e. xenogeneic 
antigens that would normally elicit a pro-inflammatory response), serve as an inductive niche to 
influence cell behavior and the downstream tissue remodeling response. Though xenogeneic in 
tissue origin, there has never been any clinical or histologic evidence of hyperacute or delayed 
rejection of efficiently decellularized ECM-derived bioscaffolds. Although, no 
immunosuppressive agents are used with these bioscaffold materials, this does not imply 
immune-privilege. In fact, there is a distinct immune response as described below. 
Much is known about the mechanisms by which ECM bioscaffolds promote constructive 
tissue remodeling, including the fact that upon implantation, these bioscaffolds degrade, release 
chemoattractant108-110, antimicrobial111, and mitogenic peptides109,110,112,113, growth factors113,114, 
and extracellular vesicles75 that contribute to endogenous stem cell recruitment among other 
bioactive effects. Perhaps most importantly, these scaffolds have been associated with a robust, 
but favorable host immune response that precedes constructive remodeling outcomes76. ECM 
bioscaffolds modulate the behavior of responding immune cells towards a regulatory, anti-
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inflammatory phenotype. In 2001, a seminal study conducted by Allman et al showed that 
xenogeneic-derived ECM bioscaffolds promote a transition in the host innate immune response 
toward a Th2-restricted response. The study showed that there is indeed a robust host immune 
response to porcine-derived ECM bioscaffolds when implanted in a murine host, but the cytokine 
and antibody isotype profile is associated with production of anti-inflammatory cytokines 
including IL-4 and IL-10 and noncomplement fixing antibodies, indicators of biomaterial 
acceptance115. Stated differently, ECM bioscaffold materials are not inert, but rather, 
immunomodulatory.  
The immunomodulatory effects of ECM bioscaffolds have since been extensively 
examined. The thoroughness of decellularization of the source tissue is a critical determinant of 
the ability of these materials to elicit an anti-inflammatory macrophage / T cell (M2-like/Th2-
like) host response116,117. In addition, the use of chemical crosslinking76,100, the anatomic origin 
of the source tissue from which ECM is derived118, the source animal age119, the terminal 
sterilization method utilized120, and the supplementary use of NSAIDs121, all can markedly affect 
the host response to ECM bioscaffolds. For example, compounds such as non-steroidal anti-
inflammatory drugs (NSAID) that inhibit COX1/2 have been shown to reduce the constructive 
remodeling response driven by biologic scaffolds. Dearth et al. demonstrated that COX1/2 
inhibition by aspirin led to less myogenesis and collagen deposition in an animal model of 
skeletal muscle injury121. In vitro, macrophages exposed to aspiring caused a reduction in ECM-
driven prostaglandin secretion. Aspirin treatment also reduced the expression of CD206, a 
marker of M2-like macrophages. Thus, in clinical practice, the use of NSAIDs in conjunction 
with ECM scaffolds may dampen the healing process stimulated by the implant. In addition to 
the biomaterial properties, host-related factors can likewise contribute to the immune response to 
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biomaterials including age122,123, nutritional status124,125, anatomic site of implantation62,126, and 
the presence of co-morbidities127,128.  
In 2009, Valentin et al showed that not only do ECM bioscaffolds elicit a favorable host 
innate immune response, specifically the macrophage response, but that this response is required 
for constructive ECM-mediated tissue remodeling100. Macrophages have recently been 
recognized as a critical determinant of regeneration in species such as the adult salamander 
129and in mammals during acute regenerative responses such as following skeletal muscle 
injury13. Brown et al further showed that the early phenotype profile of macrophages during the 
first weeks following ECM implantation can predict downstream remodeling outcomes76. It has 
since been shown that macrophages exposed to degradation products of ECM have a unique 
phenotype that is associated with suppression of inflammation and high antigen-presenting 
capabilities130, even in the presence of a harsh pro-inflammatory microenvironment as in 
ulcerative colitis131 or volumetric muscle loss132. Furthermore, the immunomodulatory properties 
of ECM bioscaffolds act not only by directly influencing macrophage phenotype78,79, but also 
through paracrine effects, mediating macrophage cross-talk with endogenous stem / progenitor 
cells78.   
The immunomodulatory effects of ECM biomaterials include adaptive immune cells as 
well as cells of the innate immune system. Sadtler et al have expanded upon the early work of 
Allman by showing that, in a model of volumetric muscle loss, the remodeling response that 
follows implantation of an ECM bioscaffold critically relies upon T helper 2 pathways that 
guides macrophage polarization. It now appears likely that the cross talk between macrophages 
and T-regulatory cells initiated by ECM degradation products is a critical determinant of 
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downstream remodeling outcomes associated with not only the use of ECM bioscaffolds130,133, 
but also during the native tissue response to disease and injury134,135. 
Sicari et al has shown that degradation products of extracellular matrix bioscaffolds can 
directly activate macrophages towards an iNOS-/Fizz1+ macrophage phenotype79. Further, 
Huleihel et al (in press) conducted an exhaustive analysis of macrophage phenotype following 
exposure to ECM degradation products showing that ECM is consistently associated with down-
regulation of pro-inflammatory genes and proteins. As discussed above, the ability of ECM 
bioscaffolds to activate macrophages is well established. The specific macrophage surface 
receptors and associated intracellular pathways involved in bioscaffold-mediated immune 
activation have only been partially elucidated. Future work would benefit from identification of 
the specific components within ECM materials that contribute to macrophage activation 
including cryptic peptides, topical cues, and miRNA among other components.  
Recent work has reinforced the need for caution in drawing broad conclusions regarding 
the immunomodulatory effects of biomaterials, specifically the effects attributed to macrophage 
phenotype16. Although it is clear that macrophage phenotype is a major determinant of the host 
response, use of a single cell marker or even several markers, may be inadequate to accurately 
characterize the functional and paracrine effects of these cells. Though desirable, it is often 
impractical to evaluate an exhaustive panel of markers to define macrophage phenotype. 
Recognizing this limitation, it is recommended that investigators select markers most relevant to 
the physiologic or pathologic condition being studied. When subsequently reporting the data, 
investigators should provide a justification for the selected markers. 
A separate, but equally important consideration is the type of macrophage used for in 
vitro studies as this variable can markedly affect results and conclusions. A recent study 
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evaluated the use of primary mouse bone marrow derived macrophages (BMDM) versus a 
human monocyte cell line (ThP1) for in vitro activation studies. Drastically different gene 
expression profiles between BMDM and ThP1 after stimulation with LPS+IFNγ, IL-4, or ECM 
degradation products were reported. Phenotype nomenclature can also be misleading (i.e., M1 vs 
M2) can contribute to misinformation regarding cause-effect relationships between biomaterials 
and the host immune response. The terminology “M1” and “M2” has been widely used to 
describe pro-inflammatory and anti-inflammatory macrophage phenotypes, respectively. 
However, this dichotomy is an over-simplification that can contribute to misleading results. 
Macrophage phenotype exists as a spectrum from pro-inflammatory to anti-inflammatory cell 
types. A recent consensus report suggests nomenclature for macrophage phenotype that should 
minimize such problems16. In their review, Murray et al. recommended that key parameters be 
reported when describing in vitro experiments. These parameters should include cell source 
(mouse strain, tissue/organ, pathological condition, etc. as relevant), starting cell number, media 
and supplements utilized, tissue culture conditions, time in culture, source and concentration of 
cytokines, macrophage yield, activation conditions, and processing/analysis protocols. Reporting 
these parameters will then permit investigators to directly compare the results of different 
experiments. Moreover, Murray et al. propose that macrophages be described by the activator 
utilized, e.g. M(IL4) instead of M2.   
2.6 DEVELOPMENT OF IMMUNORESPONSIVE MATERIALS 
Many of the available immunosuppression strategies arose prior to an understanding of the 
normal immune response following tissue injury. The development of ECM-based biologic 
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scaffold materials, the relatively recent elucidation of macrophage plasticity and their 
derivatives, and a more in-depth understanding of the role of the immune response during 
development, normal wound healing, tissue homeostasis, and tissue/organ regeneration have 
sparked renewed interest in biomaterials as facilitators of functional tissue repair. For example, 
the use of ECM-coated synthetic polymers has been investigated as a method to promote a 
regulatory/anti-inflammatory host response as opposed to an otherwise pro-inflammatory 
response. Specifically, ECM hydrogel coatings have been shown to mitigate the chornic 
inflammatory response and associated downstream scar tissue formation after implantation of 
polyprolyene mesh, the most commonly used synthetic material used to manufacture surgical 
mesh devices136. Faulk et al. reported that the addition of an ECM hydrogel coating decreased 
the number of pro-inflammatory CD86+/CD68+ macrophages in the vicinity of the 
polypropylene fibers 2 weeks after implantation. Six months after implantation, the coated 
polypropylene was associated with less collagen deposition (i.e. fibrosis) than was associated 
with uncoated polypropylene. In similar work, the use of a porcine dermal ECM hydrogel to coat 
polypropylene mesh reduced macrophage accumulation and formation of foreign body giant 
cells137. At 35 days post-implantation, the ECM coating was fully degraded and replaced with a 
loose connective tissue. 
The use of biomimetic ECM components has also been investigated to limit inflammatory 
responses to synthetic materials (i.e. immunomodulation. For example, in an in vitro model of 
sterile inflammation, addition of high sulfated hyaluronan reduced macrophage secretion of 
Proinflammatory cytokines, IL-1β, IL-6, IL-8, IL-12, and TNFα and induced secretion of the 
immunoregulatory cytokine IL-10 and the expression of CD163138. Direct coating of surgical 
meshes with pro-remodeling cytokines such as IL-4 has been associated with improved implant-
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tissue integration139.  Implantation of IL-4 coated mesh in mice was associated with an increased 
M2-like (regulatory/anti-inflammatory) macrophage to M1-like (pro-inflammatory) macrophage 
raito leading to reduction in the formation of a fibrotic capsule around the implant. In addition to 
bioactive coatings, hybrid hydrogels have been evaluated for modulating the immune response. 
PEG hydrogels containing a peptide mimic of the TNFα recognition loop on the TNF-receptor 1 
were evaluated as a cell encapsulation material140. Because these hydrogels could sequester 
TNFα, encapsulated cells were protected from this pro-infalmmatory cytokine. Similarly, PEG 
hydorgels containing an inhibitory peptide for the IL-1 receptor was able to protect encapsulated 
islet cells141.  
Attempts to combine controlled-release technologies and biomaterials to alter the host 
immune microenvironment and promote better cell engraftment have also been investigated in 
preclinical animal studies with success142,143. Many of the successful cell-centric strategies for 
tissue engineered constructs have largely been due to the paracrine effects of such stem cells 
upon the responding immune cell infiltrate, particularly in the case of mesenchymal stem cell 
delivery (MSCs)144,145. MSC encapsulated in a poly(ethylene glycol) (PEG) hydrogel secreted 
PGE2, mediated immunoregulation of macrophages in vitro, and resolution of the foreign body 
response in vivo. Though the immune response to synthetic material is (or should be) a critical 
design consideration, the incorporation of a naturally occurring moiety places design constrains 
on polymer architecture, dynamics, and stabilization that can affect the long-term functionality of 
an implant146. It cannot be ruled out, however, that biomimetic strategies merely prolong the 
inevitable pro-inflammatory immune response (foreign body response) to a synthetic material. In 
short, immunomodulation is now recognized as an effective method for improving biomaterial 
performance.  
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2.7 CONCLUSIONS 
Successful clinical translation of tissue engineering and biomaterial-based approaches for 
functional tissue replacement is critically dependent upon a compatible host response. 
Immunomodulatory strategies for limiting the foreign body reaction and resolving the 
inflammasome following material implantation / cell transplant are at the center of efforts to 
influence the host-biomaterial interface. The native extracellular matrix and ECM-based 
biomaterials possess signaling molecules that promote such events. Future studies will logically 
be aimed at investigation of specific components (both structural and soluble) within clinically 
used scaffold materials that activate the immune response. The reason(s) for mitigation of an 
adverse immune response to ECM bioscaffolds, even though they are largely xenogeneic in 
nature, represents an additional area of future investigation. In a broader context, it appears clear 
that a better understanding of the role of both the innate and adaptive immune systems in the host 
response to biomaterials, tissue remodeling, and regeneration will help shape the next generation 
of biomaterials and will be required to overcome current bottlenecks in the clinical translation 
pathway for tissue engineering and biomaterial-based technologies. 
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3.0  MECHANISMS BY WHICH ACELLULAR BIOLOGIC SCAFFOLDS 
PROMOTE FUNCTIONAL SKELETAL MUSCLE RESTORATION2 
3.1 ABSTRACT 
Acellular biologic scaffolds derived from extracellular matrix have been investigated in 
preclinical and clinical studies as a regenerative medicine approach for volumetric muscle loss 
treatment. The present chapter provides a review of previous studies supporting the use of 
extracellular matrix derived biologic scaffolds for the promotion of functional skeletal muscle 
tissue formation that is contractile and innervated. The chapter also identifies key mechanisms 
that have been associated with ECM-mediated skeletal muscle repair, and provides hypotheses as 
to why there have been variable outcomes, ranging from successful to unsatisfactory, associated 
with ECM bioscaffold implantation in the skeletal muscle injury microenvironment.  
                                                 
2 Portions of this chapter were adapted from the following publication: 
Badylak SF, Dziki JL, et al. Mechanisms by which acellular biologic scaffolds promote functional skeletal muscle 
restoration. Biomaterials. June 2016. DOI:10.1016/j.bioamterials.2016.06.047 
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3.2 INTRODUCTION 
Select tissues in the adult mammal, including liver, epidermis, bone marrow, and the mucosal 
epithelium of the intestines147-150 have robust regenerative capacity. Similarly, skeletal muscle 
has a remarkable ability to regenerate following injury: a process that partially recapitulates 
development. However, this regenerative response fails in skeletal muscle when a large volume 
of tissue is lost, a scenario referred to as volumetric muscle loss (VML)1. There are limited 
treatment options for VML including physical therapy debridement of scar tissue and/or muscle 
transposition, which are associated with morbidity and less-than-optimal outcomes1,3-5,28. Most 
attempts to induce or facilitate new functional skeletal muscle formation have been cell-
centric29,37,39,40,151 and have either been unsuccessful36,152-156 or resulted in marginal 
improvement34,157,158.  
 An acellular approach with bioscaffolds composed of extracellular matrix (ECM) has 
been used to promote functional tissue restoration in a variety of soft tissue locations, including 
skeletal muscle, a process identified as “constructive remodeling” (i.e., not regeneration)159. The 
physiologic events associated with ECM-induced constructive remodeling are remarkably 
similar to those which occur naturally in injured muscle that is capable of full recovery. 
Specifically, a robust cellular infiltrate is followed by a temporal sequence of myogenesis, 
remodeling, and maturation/functional repair160. These processes include the participation of 
muscle progenitor cells and macrophages, restoration of innervation and vascularization, and 
site-appropriate spatial reorganization of myocytes and stroma in response to mechanical loading 
(physical therapy) (Figure 1). For these reasons, ECM bioscaffolds have been investigated in 
both preclinical models of VML161-164 and in patients with VML107. Outcomes have shown 
partial restoration of both structure and function. In vitro studies, preclinical and human clinical 
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studies, and the role of physical therapy, all of which support the translational aspects of these 
ECM-induced mechanisms will be described in the context of ECM bioscaffolds as an acellular 
therapeutic option for volumetric muscle loss. 
 
Figure 1. Mechanisms of ECM-mediated skeletal muscle repair. Following implantation, ECM 
bioscaffolds degrade, releasing bioactive constituents that promote macrophage infiltration and activation as well as 
myogenic stem / progenitor cell recruitment, proliferation, and differentiation. In the presence of concomitant 
mechanical load, clinical results have shown that the resulting formation of skeletal muscle tissue is innervated and 
fully contractile. 
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Table 2. Overview of the ECM mediated repair process 
Skeletal muscle remodeling event Report(s) Summarized results 
1. ECM bioscaffold degradation Carey L et al. Biomaterials. 2014. 
Sep; 35(29):8297-304 
Valentin et al. Tissue Eng Part A. 
2009. Jul;15(7):1687-94 
Gilbert et al. Biomaterials. 
2007;28:147-50 
Non-crosslinked ECM bioscaffolds degrade in vivo  reaching 
0% scaffold remaining by 24 weeks after implantation 
Macrophages are necessary for in vivo degradation of ECM 
bioscaffolds 
ECM bioscaffolds are populated and degraded by the host 
producing proteolytic enzymes that facilitate the degradation of 
the matrix and generating bioactive cryptic peptides. 
2. Protein adsorption Slack S et al. Ann N Y Acad Sci. 
1987;516:223-43 
Upon implantation, blood and plasma proteins adsorb to the 
biomaterial surface, a process determined by competitive 
protein exchange (the Vroman effect).  
3.M1-like macrophage infiltration Tidball JG et al. Am J Physiol Regul 
Integr Comp Physiol. 2010. 
May;298(5):R1173-87 
Ruffell et al. PNAS. 2009;106:17475-
80 
M1-like macrophages are among the first responders to skeletal 
muscle injury, infiltrating within hours 
Inhibition of either M1 or M2 macrophages associated with 
lack of myogenic differentiation, chronic active inflammation, 
and necrosis.  
4. Muscle stem cell proliferation St Pierre B et al. J Appl Physiol. 
1994. Jul;77(1):290-7 
Crisan et al. J Cell Mol Med. 2012; 
16:2851-60 
Dellavalle et al. Nat Cell Biol. 
2007;9:255-67 
Macrophage subpopulations are associated with distinct phases 
of skeletal muscle regeneration.  
Perivascular stem cells are highly myogenic  and participate in 
the adult mammalian response to skeletal muscle injury 
5. Muscle loading Kadi F et al. Histochem Cell Biol. 
2000 Feb;113(2):99-103 
Ambrosio F et al. Arch Phys Med 
Rehabil 
Exercise and muscle loading can induce activation and 
proliferation of satellite cells  
Functional overloading enhances MSC contribution to muscle 
contraction. 
6.M2-like macrophage infiltration Deng B et al. J Immunol. 2012 Oct 
1;189(7):3669-80 
Sicari et al. Biomaterials. 2014. 
Oct;35(30):8605-12 
A phenotypic switch from M1-like to M2-like macrophages are 
required for efficient muscle regeneration and normal muscle 
growth following injury  
ECM bioscaffolds promote an M2-like macrophage phenotype 
and these macrophages, in turn, promote skeletal muscle 
progenitor cell chemotaxis and myogenesis 
7. Angiogenesis Tidball JG et al. Development. 2014 
Mar;141(6):1184-96 
Li F et al. Endothelium. 2004 May-
Aug;11(3-4):199-206 
Immune cells play regulatory roles in muscle regeneration 
through permissive mechanisms that act to influence 
regeneration by modulating angiogenesis  
Bioactive peptides released as a result of ECM bioscaffold 
degradation recruit endothelial cells in vivo 
8. Myoblast differentiation and 
fusion 
Piccoli M et al. Biomaterials. 2016 
Jan; 74:245-55 
Sicari et al. Sci Transl 
Med. 2014 Apr30;(234)234ra58 
ECM implantation in the diaphragm supported a regenerative 
environment and myogenesis 
ECM bioscaffold implantation results in de novo muscle 
formation in mice and humans with volumetric muscle loss 
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Table 2 (continued)   
9. Reinnervation Han N et al. Phys Ther. 2015 Nov 12 Clinical improvements in muscle strength and function 
following ECM implantation for VML treatment concomitant 
with the presence of electrical activity within the scaffold 
remodeling site 
10.Myofiber formation Sicari et al. Tissue Eng Part A. 2012 
Oct;18(19-20);1941-8 
Targeted placement of SIS-ECM scaffolds within mouse 
volumetric muscle loss resulted in the formation of site-
appropriate skeletal muscle tissue  
11. Contractile tissue development Valentine et al. Biomaterials. 2010. 
Oct;31(29):7475-84 
Turner et al. J Surg Res. 2012. 
Aug;176(2):490-502 
Machingal et al. Tissue Eng Part A. 
2011 Sep:17(17-18):2291-303 
Mase et al. Orthopedics. 2010 Jul 
13;33(7):511 
Chen et al. JPRAS. 2013;66:1750-8 
Aurora et al. Biomaterials. 2015 
Oct:67-393-407  
SIS-ECM implanted into the rat abdominal wall resulted in 
skeletal muscle formation with the same maximal contractile 
force as that of native tissue 
ECM bioscaffolds implanted in a gastrocnemius 
musculotendinous junction defect resulted in vascularized, 
innervated, contractile muscle tissue after 6 months.  
Latttissimus dorsi (LD) muscles in mice repaired with UBM 
roduced 50% of  native muscle LD force at 2 months following 
implantation 
SIS ECM bioscaffold implantation in a 19 year old marine with 
ML resulted in marked gains In isokinetic performance, new 
tissue formation at the implant site, and no complications. 
Repair of VML with muscle ECM bioscaffolds in a rat resulted 
in significant improvements in LD muscle function. 
Repair of tibialis anterior VML by UBM ECM bioscaffolds 
reduced the functional deficit by 29% as determined by 
isometric torque measurement.  
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3.3 SKELETAL MUSCLE REGENERATION 
A brief review of the natural response of skeletal muscle following recoverable injury165,166 will 
facilitate an understanding and appreciation of ECM bioscaffold mediated muscle restoration. 
The inherent regenerative response of skeletal muscle involves three phases: the degeneration 
phase, the repair phase, and the remodeling phase9,167,168. The degeneration phase consists of 
myocyte and stromal (i.e. ECM) disruption and the influx of inflammatory cells10,168. The repair 
phase is characterized by the activation of quiescent myogenic stem cells that are stimulated to 
enter the cell cycle and migrate toward the site of injury169,170. These activated progenitor cells 
then receive signals to exit the cell cycle, differentiate, and fuse to form multinucleated 
myofibers9,171. During the remodeling phase the newly regenerated myofibers spatially organize, 
mature, and develop the ability to contract.  
Skeletal muscle regeneration is contingent upon a population of cells defined anatomically 
as satellite cells. Satellite cells represent the putative skeletal muscle stem cell and, when 
quiescent, are located between the plasma and basal membrane of skeletal muscle 
myofibers172,173. Satellite cells divide asymmetrically and, following injury and in response to the 
associated microenvironmental cues, give rise to skeletal muscle myoblasts9, which then 
proliferation, differentiate, and fuse to form multinucleated and functional contractile skeletal 
muscle myofibers9,174. Several primitive progenitor and/or stem cells, including perivascular 
stem cells, bone-marrow-derived cells, and other mesenchymal stromal cells, have also been 
shown to possess myogenic potential and/or occupy the satellite cell niche and give rise to 
skeletal muscle myoblasts43,175.  
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3.3.1 Mediators of skeletal muscle regeneration 
Regardless of the origin of myogenic progenitor cells, the microenvironmental cues that 
orchestrate their activity are provided, at least in part, by the host innate immune response, 
specifically macrophages13,176,177. Immediately following skeletal muscle injury, cytokines 
released by damaged myocytes and acute responder cells such as neutrophils activate the later-
arriving host macrophages towards a pro-inflammatory (M1-like) phenotype. These pro-
inflammatory macrophages exert paracrine effects which stimulate the proliferation and 
mobilization of resident satellite stem cells13. A shift in macrophage activation then occurs, and 
is characterized by a transition to a predominant anti-inflammatory, regulatory, and pro-
remodeling (M2-like) phenotype98. In contrast to the pro-inflammatory phenotype, the paracrine 
effects of the remodeling macrophage promote cell-cycle exit and differentiation of the expanded 
myogenic satellite cells into functional contractile skeletal muscle13. Inhibition of either the pro-
inflammatory or pro-remodeling phenotype is associated with lack of myogenic differentiation, 
chronic active inflammation, necrosis, and scar tissue formation178. Therefore, the secreted 
products of macrophages represent at least some of the mediators of skeletal muscle 
regeneration. However, questions remain regarding the biologic cues that promote the transition 
of pro-inflammatory macrophages to an anti-inflammatory, pro-remodeling phenotype, and the 
relationship of this phenotype transition to ECM bioscaffold-mediated muscle repair, especially 
in the context of VML. Studies have shown that ECM can directly influence macrophage 
phenotype78, which in turn suggests that factors present within ECM bioscaffolds themselves 
have the ability to foster this phenotypic switch. It is likely, however, that a combination of 
direct and indirect (i.e. paracrine / cell-mediated) effects of ECM bioscaffolds contribute to 
macrophage modulation.   
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3.3.2 Biologic scaffolds composed of extracellular matrix (ECM) 
Mammalian extracellular matrix (ECM) is composed of the secreted structural and functional 
molecules from resident cells of tissues or organs.  The composition of native tissue ECM is 
dependent upon factors that affect the resident cell phenotype, such as microenvironmental 
mechanical forces, biochemical milieu, and innate and adaptive patterns of gene expression, 
among others. The ECM, in turn, influences the phenotype, chemotaxis, mitogenesis, and 
differentiation of resident cells, and facilitates cell-cell communication73,108-110,113,179-184. It is 
plausible, therefore, that ECM-derived signals are involved in phenomena such as macrophage 
phenotype transition during times of need; e.g., in response to muscle injury.  
Native skeletal muscle ECM plays a critical role in the acute regeneration and normal 
developmental process. ECM molecules including collagens and proteoglycans have key roles in 
orchestrating skeletal muscle myoblast chemotaxis, proliferation, and fusion to form 
myotubes185. Following injury, degradation of the matrix releases growth factors and other 
biomolecules that trigger satellite cell activation and their associated contribution to the myoblast 
pool. These events in turn, facilitate myofiber differentiation and, ultimately, regeneration of 
functional skeletal muscle9,186,187. Furthermore, cell-matrix interactions are important in 
regulating satellite cell adhesion and translocation as well as promotion of re-innervation through 
activation of Schwann cells188,189. The appropriate regulation of ECM degradation and synthesis 
through synergy of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases 
(TIMPs), and myogenic cells results in the regenerative capacity for which skeletal muscle is 
known. State differently, ECM provides a crucial and complex microenvironmental niche to 
facilitate natural skeletal muscle regeneration.  
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3.3.3 Composition of ECM bioscaffolds 
Biologic scaffold materials are prepared by removal of cells from source tissue such as dermis190-
192, small intestinal submucosa (SIS)193-195, and urinary bladder matrix (UBM)194,195. ECM 
bioscaffolds, therefore are logically a rich source of effector molecules that influence cell 
behavior including the transition of macrophages to anti-inflammatory, regulatory 
phenotypes76,78,98,116,196.  
 The molecular composition of ECM includes collagen, fibronectin, laminin, elastin, 
glycosaminoglycans (GAGs), growth factors, and cryptic peptides, among others182,197. Collagen 
is the most abundant molecule within mammalian ECM and comprises nearly 90% of its dry 
weight198. In addition to maintaining the structure of each tissue, GAGs, and low molecular 
weight cryptic oligopeptides released or exposed by the degradation of structural ECM such as 
collagen and fibronectin are known to possess significant biologic activity73,108,180,199-201. Type I 
collagen is the predominant isoform in skeletal muscle tissue202. Following injury, fibroblasts 
respond by producing type III collagen. Preclinical studies suggest that an increased collagen I: 
collagen III ratio may contribute to the return of strength in skeletal muscle tissue, and changes 
in collagen I and collagen III amounts have been evaluated in the initial phases of skeletal 
muscle injury repair. The balance of collagen isoforms may represent an important criterion for 
efficient skeletal muscle remodeling and a potential ECM-related therapeutic target203.  
Functional molecules within ECM include growth factors such as vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), stromal derived growth factor (SDF-1), 
epidermal growth factor (EGF), transforming growth factor beta (TGF-B), keratinocyte growth 
factor (KGF), hepatocyte growth factor (HGF), platelet derived growth factor (PDGF), and bone 
morphogenic protein (BMP), among others114,204-207. Stated differently, the ECM is a complex 
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mixture of structural and functional molecules that collectively represent the microenvironmental 
niche of its resident cells. However, it should be noted that variables such as source animal 
age119, source tissue of ECM208, extent of decellularization117, use of chemical crosslinking 
agents100, presence of residual detergents following decellularization209, methods of terminal 
sterilization120, and other processing parameters can influence the remodeling outcomes 
following ECM implantation.  
3.4 CONSTRUCTIVE REMODELING OUTCOMES 
When properly prepared and placed at sites of tissue injury in a variety of anatomic locations, 
ECM bioscaffolds have repeatedly shown constructive and functional remodeling in contrast to 
the default response to injury, which consists of inflammation and scar tissue 
formation76,101,102,104,107,210,211. Some of the cellular and subcellular events associated with ECM 
bioscaffold-mediated constructive remodeling are described below; the relevance and similarity 
of these events to naturally occurring skeletal muscle regeneration are noteworthy. 
3.4.1 Degradation of extracellular matrix bioscaffolds and production of effector 
molecules 
ECM bioscaffold degradation is mediated primarily by macrophages100. In vivo degradation 
occurs quickly and is important for several reasons. First, the mechanical properties of the 
bioscaffold show an initial decrease in strength, followed by a gradual increase as host tissue 
replaces the scaffold and responds to mechanical loading (i.e. physical therapy)212.  This gradual 
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load transfer stimulates site-appropriate organization and orientation of new load bearing cells 
and connective tissue. 14C labeling studies have shown 60% degradation of ECM bioscaffolds by 
30 days post implantation and complete degradation after 90 days213. Dense ECM scaffolds such 
as those composed of human or porcine dermal ECM, degrade more slowly and can persist for 
12-24 months214. Secondly, the temporary presence of the material avoids the foreign body 
reaction that occurs in response to non-degradable biomaterials. The third, and perhaps most 
important reason that degradation is desirable, is that the degradation products are 
bioactive73,108,200,201. Matricryptic peptides produced by cleavage of parent molecules such as 
collagen show antimicrobial activity194,200, are chemotactic for stem / progenitor 
cells108,180,181,199,201,215, and have marked influence on the host innate immune response76,98-
100,116,200. Inhibition of degradation, as occurs with chemical crosslinking, prevents the 
participation of these bioactive molecules in the remodeling process76.  
3.4.2 Recruitment of stem / progenitor cells by extracellular matrix bioscaffolds 
One of the hallmarks of ECM bioscaffold remodeling is a rapid and robust infiltration of host 
cells, which is mediated in a part by the ECM degradation products mentioned above. 
Constructive remodeling of an acellular scaffold obviously requires the involvement of a variety 
of site-appropriate cell types. For skeletal muscle applications, the new tissue would ideally have 
all the cell types of native muscle tissue including satellite cells, myocytes, endothelial cells, 
nerve cells, and fibroblasts, among others. Since an ECM bioscaffold is by definition acellular, 
all cells of the remodeling process must originate from the implanted host / patient.   
 ECM bioscaffolds and their degradation products have been associated with the in vitro 
and in vivo recruitment of endogenous stem / progenitor cells, including in vitro recruitment of 
 36 
myogenic stem and progenitor cells109, in vivo recruitment of Sox2+ cells181; in vitro  and in vivo 
recruitment of skeletal muscle myoblasts208, and in vitro and in vivo recruitment of multipotent 
perivascular stem cells (PVSCs)175,180,216,217. PVSCs are CD146+ , NG2+ cells found in the 
vascularized tissues of adult mammals and reside in a niche encircling microvessels and 
capillaries where they regulate vasoconstriction175. When mobilized from their typically 
quiescent niche, these cells are multipotent and give rise to cells with adipogenic, osteogenic, 
and chondrogenic cell lineages. PVSCs have been shown to be myogenic when transplanted into 
areas of injured muscle175,218, while endogenous PVSCs have been shown to give rise to skeletal 
muscle myoblasts and participate in the adult mammalian regenerative response to skeletal 
muscle injury42,43. Therefore, an ECM bioscaffold with its recruited stem / progenitor cells would 
logically be well suited for VML injuries.  
3.4.3 Modulation of the host immune response 
In addition to the recruitment of endogenous stem / progenitor cells, ECM-mediated modulation 
of the innate immune response plays a pivotal role in the normal healing response of all tissues, 
including injured or missing skeletal muscle100,219-222. In fact, macrophage depletion or 
pharmacologic inhibition prevents both normal wound healing and degradation of ECM biologic 
scaffolds100,223, thereby mitigating the formation and release of bioactive effector molecules (i.e. 
matricryptic peptides) that participate in normal wound healing and the constructive remodeling 
of ECM bioscaffolds. Recent studies have shown the robust ability of ECM degradation products 
to induce an anti-inflammatory, regulatory macrophage phenotype thus providing a logical and 
plausible explanation for ECM-mediated skeletal muscle reconstruction in the presence of such 
scaffolds78. In summary, although the mechanisms by which ECM scaffolds support functional 
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tissue reconstruction, including skeletal muscle restoration when used for VML, are only 
partially understood, there are well documented ECM-induced cellular events that clearly change 
the default host response to injury. These events include bioscaffold degradation and release of 
bioactive molecules that modulate macrophage phenotype and promote endogenous 
stem/progenitor cell recruitment, proliferation, and differentiation. The results of preclinical and 
clinical studies described below show the downstream morphologic and functional consequences 
of these ECM-mediated events (Figure 1, Table 3).  
One of the primary factors responsible for the disappointing results of cell-based 
therapies is the rapid death of delivered cells, in part because of the unfavorable 
microenvironment into which they are typically placed28,29,34,36,37,40,152,153,156,158. Since the ECM 
in native tissue essentially represents the normal pericellular environment, it may be useful to 
think of an ECM bioscaffold as a compatible, temporary microenviornmental niche that can 
facilitate and/or promote endogenous remodeling.  
 
Table 3. Pre-clinical studies to determine the efficacy of ECM bioscaffolds as a skeletal muscle repair 
material 
Animal Species Mouse 
Rat 
Rabbit 
Canine 
Muscle Groups Quadriceps 
Abdominal wall 
Gastrocnemius/Achilles tendon 
Diaphragm 
Injury Sizes (15-75% of tissue) 
Source Tissues Small intestinal submucosa (SIS) 
Urinary bladder matrix (UBM) 
Skeletal muscle ECM (mECM) 
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3.4.4 Preclinical evidence of ECM-mediated skeletal muscle remodeling 
In 2010 Valentin et al showed that implantation of an acellular ECM bioscaffold in a rat 
abdominal wall partial thickness defect model could promote the formation of site-appropriate 
skeletal muscle with maximal contractile force similar to that of native muscle164. Turner et al. 
showed that 6 months following ECM implantation in a canine musculotendinous 
(gastrocnemius) defect, alpha-bungarotoxin positive motor end plates were present within islands 
of skeletal muscle tissue that replaced the scaffold material. The strength of the repaired muscle-
tendon unit was approximately 40% of the strength of the contralateral gastrocnemius muscle224. 
In a separate study, islands of desmin positive skeletal muscle cells were present following 
ECM-bioscaffold implantation in a critically-sized quadriceps defect (i.e., VML) in the 
mouse107,208. A recent study showed that an ECM bioscaffold used for the repair of a 
diaphragmatic defect was replaced by islands of skeletal muscle, ultimately resulting in enhanced 
functional outcomes225. These preclinical studies by Valentine et al., Turner et al., Sicari et al., 
and Piccoli et al.163,164,224,225  showed similar morphologic changes within the ECM scaffold 
material during the remodeling process; specifically, scaffold degradation by host cells, 
vascularization, and recruitment of stem / progenitor cells to the ECM remodeling site that were 
associated with variably sized islands of skeletal muscle. These islands of skeletal muscle were 
surrounded by well-organized collagenous connective tissue at later time points (Figure 2). 
Although the new muscle tissue following ECM bioscaffold implantation was associated with 
vascularization and re-innervation, it did not approach the volume or organization of the missing 
native muscle61,163,224,225. However, the new muscle tissue was associated with partially restored 
muscle function164,224. In the mouse model, a robust accumulation of CD146+ NG2+ 
perivascular stem cells was present within 14 days. The dense cell accumulation that occurs 
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within an ECM bioscaffold during the first several weeks following implantation is difficult to 
distinguish from an intense inflammatory response unless special effort is made to characterize 
the phenotype of the cells.  
 
 
Figure 2. Skeletal muscle formation following ECM bioscaffold implantation 56 days after injury. 
ECM bioscaffold implantation results in the formation of islands of skeletal muscle at the margin (denoted by dotted 
line) at the center (inset) of the defect surrounded by well-organized connective tissue as shown by desmin staining 
and Masson’s trichrome (Scale bars = 50µm). 
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3.4.5 The role of mechanical loading / rehabilitation in ECM-induced skeletal muscle 
regeneration  
One of the necessary components of constructive, functional remodeling is the early onset of 
appropriate mechanical loading (i.e. physical therapy). Preclinical studies that have failed to 
delivery physical therapy within days of scaffold implantation, and in a consistent and 
progressive fashion, do not show the formation of site-appropriate skeletal muscle tissue and 
instead find the scaffold replaced by adipose tissue and fibrous tissue61,226.   
The microenvironmental niche is defined by all factors that influence the resident cells, 
including the mechanical / physical properties of the ECM, and the mechanical forces to which 
the cell / scaffold complex is subjected in vivo. There is robust evidence supporting biologic 
adaptations in response to both dynamic and static mechanical stimuli emanating from the 
cellular microenvironment227-230. This concept has served as a foundation for the application of 
clinical rehabilitation protocols for the treatment of diseased or injured tissues. 
In the context of ECM-bioscaffold treatment for VML, the fate of recruited stem / 
progenitor cells is influenced by mechanical cues that contribute to the microenvironmental 
niche (i.e. physical therapy). The application of mechanical stimulation protocols in combination 
with cell therapy enhances stem cell transplantation efficacy and improves functional 
outcomes227,231-233. Specifically, muscle contractile activity and mechanical stimulation is an 
effective method for promoting tissue angiogenesis (reviewed in Ref.50), the release of 
myogenically favorable growth factors, and cellular alignment along the line of muscle axis234, 
all variables that have been associated with favorable outcomes following ECM-bioscaffold 
implantation2. In fact, Grasman et al. suggest that, given the geometric architecture of myofibers, 
proper cellular alignment may be one of the most critical factors in muscle regeneration2. Taken 
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together, mechanical loading, delivered by exercise or neuromuscular electrical stimulation, is 
not only sufficient, but likely necessary for appropriate differentiation, alignment, and function 
of recruited stem/progenitor cells. Since the accumulation of these multipotential cells at the 
ECM-scaffold remodeling site occurs within a few days of scaffold implantation, application of a 
mechanical load (i.e. physical therapy) is required much earlier than typically provided in a 
clinical setting.  
The application and enforcement of physical therapy in pre-clinical (i.e. animal) models 
is difficult at best. As an example, voluntary wheel running has been used in pre-clinical models 
of “rehabilitation” following the application of an ECM scaffold for the treatment of VML 
injuries226. However, without monitoring and diligent recording of running activity (which is 
voluntary), the influence of this critical variable cannot be determined and results are left in 
question.  
3.4.6 ECM bioscaffolds can facilitate skeletal muscle restoration in the clinical setting 
The constructive remodeling outcomes, including the temporospatial pattern of cell infiltration, 
scaffold degradation, formation of islands of new skeletal muscle, and the functional 
improvement shown in preclinical animal studies faithfully translated to humans when ECM-
bioscaffolds were used to treat VML.  
ECM bioscaffolds were implanted in 13 patients with VML who had all failed standard 
of care in a recent cohort study107,235. ECM intervention was associated with increased 
mobilization of perivascular stem cells (PVSCs), and the formation of randomly distributed and 
variably sized islands of desmin positive skeletal muscle. CT and MRI imaging corroborated 
immunolabeling findings in biopsy speicmens showing increased post-operative skeletal muscle 
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tissue mass (Figure 3). Patients showed an average improvement of 37.3 + 12.4% in strength and 
27.1 + 10.5% in range of motion task performance, and 271.8 + 62.6 % in functional task 
performance.  
All subjects completed a rigorous pre-operative rehabilitation protocol that was 
customized to target the individual’s specific functional deficits thus ensuring that any post-
operative functional improvement could be attributed to ECM implantation and was not the 
result of an improved rehabilitation protocol or a loading induced hypertrophy of the existing 
muscle tissue.  
It has been argued that irregularly sized and randomly distributed islands of skeletal 
muscle could not contribute to functional improvement following ECM bioscaffold implantation, 
and that any functional gains are a result of a fibrotic bridge that allows for force transduction 
across the defect site161. However, in patients treated for VML, the loss of tissue typically 
involves irregularly shaped deficits, multiple muscles within a compartment, and there may be a 
total loss of either a muscle origin or insertion. The ECM bioscaffold is placed in contact with 
adjacent native tissue to facilitate cell infiltration, remodeling, and integration. If merely a 
mechanical bridge were sufficient to restore strength and function, synthetic scaffold materials 
which elicit fibrosis and no new muscle tissue such as poly(glycolic acid) (PGA)236, poly-e-
caprolactone (PCL)237, and polypropylene164, would logically produce similar functional 
outcomes instead. The ECM is typically provided in a sheet configuration and serves both an 
initial mechanotransduction function for infiltrating cells and an inductive function for skeletal 
muscle remodeling as shown in Figure 1. Although ECM-induced functional remodeling has 
been disputed226, these same manuscripts acknowledge the 25-52% improvement in function 
shown in preclinical studies57,226.  
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Figure 3. CT images of human hamstring VML after ECM bioscaffold implantation. ECM bioscaffold 
implantation resulted in bulk muscle formation in the human hamstring after 8 months as shown by CT imaging 
(yellow arrow, bulk muscle tissue formation outlined in red). 
 
3.5 CONCLUSIONS AND FUTURE DIRECTIONS 
It is evident that the effectiveness of ECM bioscaffolds for functional soft tissue reconstruction is 
dependent upon variables such as processing methods of bioscaffolds, patient age and 
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comorbidities, surgical technique, and the extent of surrounding viable muscle tissue, among 
other determinants. Further work is required to better define these factors. It should also be noted 
that the clinical study involved chronic VML injuries following repeated failure of all existing 
standard of care approaches. It is possible that there would be even greater success if an acellular 
bioscaffold approach was applied acutely after injury.  
This opinion manuscript provides the scientific underpinnings that, at least partially, 
explain the rationale for ECM bioscaffolds as a treatment option for VML. This success has been 
substantial, with histologic electrophysiologic and clinical evidence for the creation of new, 
functional tissue. While acellular bioscaffolds are not the ultimate solution for treatment of 
VML, they do represent a notable improvement over existing treatment options. It is likely that a 
combination of cell-based, scaffold-based, and pharmacologically based approaches will be more 
effective than ECM bioscaffolds or physical rehabilitation alone. Such approaches have not been 
evaluated to date, and clearly warrant further study.  
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4.0  OBJECTIVES  
Volumetric muscle loss as a result of trauma, tumor ablation, or degenerative disease remains a 
challenging clinical problem for which therapeutic options are limited. Current standards of care 
including muscle transposition or tendon transfer are associated with significant donor site 
morbidity and fail to restore strength or functional re-innervation of the host muscle tissue. 
Patients are therefore faced with a bleak prognosis: persistent strength and functional deficits that 
contribute to disability and a compromised quality of life. A regenerative medicine approach has 
shown promise for functional skeletal muscle reconstruction. Specifically, acellular bioscaffolds 
composed of extracellular matrix (ECM) have been shown to stimulate endogenous skeletal 
muscle repair via mechanisms that include modulation of the host innate immune response and 
recruitment of endogenous stem / progenitor cells. However, the specific role of these 
macrophages and progenitor cells, the influence of the ECM microenvironmental niche upon 
these cells, and the effect of concomitant physical rehabilitation (i.e. mechanical loading) are 
only partially understood. The proposed study will investigate the effect of ECM bioscaffolds 
upon macrophage phenotype and will evaluate potential bidirectional cross talk between skeletal 
muscle progenitor cells with and without mechanical loading and phenotypically activated (i.e. 
polarized) macrophages in the context of ECM-mediated skeletal muscle repair.  
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5.0  CENTRAL HYPOTHESIS AND SPECIFIC AIMS 
Central Hypothesis: ECM bioscaffolds can promote constructive remodeling of skeletal muscle 
via macrophage-mediated effects that are augmented by concomitant mechanical loading. 
Specific Aim 1: To determine the spatiotemporal patterns of macrophage and progenitor 
cell infiltration following ECM treatment of murine volumetric muscle loss  
Corollary Hypothesis:  ECM implantation will promote an early and sustained M1-like to 
M2-like macrophage transition, increased progenitor cell recruitment, and increased myogenesis  
Rationale: ECM has been shown to promote skeletal muscle remodeling in preclinical 
and clinical studies in which mobilization of perivascular stem cells (PVSCs) has been 
associated with the remodeling process. Furthermore, the prescence of macrophages and the 
transition from an M1-like to an M2-like phenotype is not just sufficient, but required for acute 
skeletal muscle repair. It is therefore expected that ECM implantation in a mouse model of VML 
will result in an appropriately timed transition to an M2-like macrophage phenotype, increased 
PVSC mobilization, and myogenesis.  
Specific Aim 2: To characterize the effects of ECM derived from small intestinal 
submucosa (SIS-ECM) upon macrophage phenotype as defined by surface marker expression, 
protein expression, phagocytic capacity, and antimicrobial effects. 
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Subaim 2.1: To compare SIS-ECM treated macrophages to macrophages treated with 
ECM derived from urinary bladder (UBM), skeletal muscle (mECM), brain (bECM), esophagus 
(eECM), colon (coECM), dermis (dECM), and liver (LECM) 
Corollary Hypothesis: SIS-ECM will promte an alternative macrophage phenotype 
characterized by M2-like surface markers, protein expression, increased phagocytic capacity, and 
antimicrobial effects. Not all ECM types will promote the same effect upon macrophage 
phenotype.  
Rationale: Previous work has shown the effect of ECM in promoting a shift from a 
predominant M1-like to M2-like macrophage population and associated downstream 
constructive remodeling outcome. Since the ECM from ach tissue and organ differs in 
composition, at least to a small extent, it is hypothesized that ECM can directly affect 
macrophage phenotype, but that not all types (i.e. tissue sources of ECM) will affect phenotype 
identically.  
Specific Aim 3: To determine the effects of hind limb unloading upon ECM-mediated 
skeletal muscle remodeling in a mouse gastrocnemius/Achilles injury model 
Subaim 3.1 To determine the effects of mechanical loading upon macrophage-skeletal 
muscle progenitor cell crosstalk 
Corollary Hypothesis: Mechanical loading results in improved ECM-mediated skeletal 
muscle remodeling when compared to unloading  
Rationale: Concomitant physical rehabilitation during the ECM remodeling period is 
associated with favorable preclinical and clinical outcomes including an increased cellular 
infiltrate, more rapid and extensive neovascularization, and more organized connective tissue 
matrix. The cellular mediators of the improved outcome with mechanical loading are unknown. 
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Since macrophages play a critical role in tissue remodeling following injury, it is possible that 
absence of mechanical loading will result in a reduced macrophage infiltrate, a lower M2-
like/M1-like ratio, and decreased myogenesis and force production. 
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6.0  IMMUNOMODULATION AND MOBILIZATION OF PROGENITOR CELLS BY 
EXTRACELLULAR MATRIX BIOSCAFFOLDS FOR VOLUMETRIC MUSCLE LOSS 
TREATMENT3 
6.1 ABSTRACT 
Acellular bioscaffolds composed of extracellular matrix (ECM) have been effectively used to 
promote functional tissue remodeling in both preclinical and clinical studies of volumetric 
muscle loss, but the mechanisms that contribute to such outcomes are not fully understood. 
Thirty-two C57bl/6 mice were divided into eight groups of four animals each. A critical-sized 
defect was created in the quadriceps muscle and was repaired with a small intestinal submucosa 
ECM bioscaffold or left untreated. Animals were sacrificed at 3, 7, 14, or 56 days after surgery. 
The spatiotemporal cellular response in both treated and untreated groups was characterized by 
immunolabeling methods. Early time points showed a robust M2-like macrophage phenotype 
following ECM treatment in contrast to the predominant M1-like macrophage phenotype present 
in the untreated group. ECM implantation promoted perivascular stem cell mobilization, 
increased presence of neurogenic progenitor cells, and was associated with myotube formation. 
These cell types were present not only at the periphery of the defect near uninjured muscle, but 
                                                 
3 Portions of this chapter have been adapted from the following publication: 
Dziki JL, Sicari BM, Wolf MT, Cramer MC, Badylak SF. Immunomodulation and mobilization of progenitor cells 
by extracellular matrix bioscaffolds for volumetric muscle loss treatment. Tissue Engineering Part A. November 
2016. DOI:10.1089/ten.tea.2016.0340 
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also in the center of the ECM-filled defect. ECM bioscaffolds modify the default response to 
skeletal muscle injury and provide a microenvironment conducive to a constructive healing 
response.   
6.2 INTRODUCTION 
The well-recognized ability of adult skeletal muscle tissue to regenerate following acute injury is 
contingent upon activated resident myogenic progenitor or “satellite” cells. Activated satellite 
cells give rise to proliferative committed skeletal muscle myoblasts, which subsequently undergo 
regulated stages of expansion and differentiation42,43,172,175,238,239. Other multipotent myogenic 
stem / progenitor cells including multipotent perivascular stem cells (PVSCs) and mesenchymal 
stem cells participate in myogenesis via direct and indirect mechanisms. The progression of 
myogenic progenitor cells through stages of proliferation and differentiation is dependent upon 
the host inflammatory response, including the number, phenotype, and temporal pattern of 
infiltrating macrophages and T-helper lymphocytes10,13,133,240-242. A transition in the 
activation/polarization state of macrophages and lymphocytes at the injury site from a 
predominant classically activated and Proinflammatory M1/Th1 phenotype, to a predominant 
alternatively activated and constructive M2/Th2 phentoype not only facilitates, but also is 
required for downstream functional remodeling by regulating the stages of myogenic progenitor 
cell activity following muscle injury13,15,133,241. Specifically, paracrine factors secreted by M1 
macrophages prompt local progenitor cells to enter the cell cycle and proliferate, thus facilitating 
an expansion of readily available cells with myogenic potential present at the site of injury. In 
contrast, paracrine factors produced by M2 macrophages induce the expanded progenitor cell 
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population to exit the cell cycle, which promotes the differentiation of these cells into functional 
skeletal muscle cells15,178,243,244. The source and temporal pattern of molecular signals that initiate 
and sustain the M1 to M2 transition in vivo remain unknown.  
Sever skeletal muscle injury resulting from trauma, tumor ablation, or degenerative disease 
may cause a massive or overt loss of skeletal muscle tissue known as volumetric muscle loss 
(VML). VML injuries overwhelm the inherent regenerative ability of skeletal muscle tissue and 
are associated with robust scar tissue deposition, loss of function, and serious morbidity1,163. 
Current therapeutic options for VML include scar tissue debridement, muscle transposition, 
and/or the use of cell-centric regenerative medicine strategies. Cell-based approaches remain 
generally ineffective as they typically fail to thrive in the unfavorable tissue injury 
microenvironment31-33,245. An approach that facilitates the necessary macrophage phenotype 
transition and simultaneously provides a supportive microenvironmental niche for progenitor cell 
proliferation and differentiation would be desirable107,163.  
 The surgical placement of acellular extracellular matrix (ECM) bioscaffolds has been 
shown to promote a microenvironment that supports constructive and functional tissue 
remodeling in both preclinical models and human patients with VML107,133,163,179,246,247. Other 
studies with ECM bioscaffolds in the context of skeletal muscle injury have not shown similar 
results, but differences in study design, including postoperative rehabilitation protocols, may 
have contributed to the disparate results61,226. In vitro and in vivo studies have shown that 
degradation products from ECM bioscaffolds promote a pro-healing, M2-like macrophage 
phenotype and are chemotactic for stem/progenitor cells78,199,248,249. Paracrine factors from these 
ECM-treated macrophages, in turn, promote chemotaxis and myogenesis of skeletal muscle 
progenitor cells78. However, the spatial and temporal pattern of such events in vivo remains only 
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partially understood in the context of VML. Likewise, although the presence of neurogenic cells 
at early time points following ECM bioscaffold treatment for various soft tissue applications has 
been associated with favorable outcomes, the presence of these cells in skeletal muscle 
applications has not been investigated108,179,250. The objective of this study was to quantitatively 
analyze the spatiotemporal pattern of myogenic and neurogenic progenitor cells and the pattern 
of macrophage activation following ECM bioscaffold treatment in a mouse model of VML.  
6.3 MATERIALS AND METHODS 
6.3.1 Overview of experimental design 
Thirty-two C57bl/6 mice were randomly divided equally into four treated or four untreated 
groups. Surgically created volumetric muscle loss was treated with an ECM bioscaffold or left 
untreated163.  Animals were sacrificed at 3, 7, 14, and 56 days post implant (4 animals per group 
per time point). Explants were fixed in 10% neutral buffered formalin (NBF) and immunolabeled 
for M1 and M2 macrophage phenotype markers iNOS and Fizz1251,252, strong indicators of the 
pro-inflammatory vs pro-remodeling macrophage phenotype, respectively. F4/80 was used as a 
pan-macrophage marker. Perivascular stem cells (CD146+), differentiated myotubes (myosin 
heavy chain, MHC+), and cells with markers of neurogenesis (β-III tubulin and nestin+) were 
also identified by immunolabeling. Positively labeled cells were quantified and results compared 
between groups. All animal studies were approved by the Institutional Animal Care and Use 
Committee at the University of Pittsburgh. Animal care complied with the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. 
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6.3.2 SIS-ECM bioscaffold preparation 
The jejunum was harvested from market weight (approximately 240 lbs) pigs and was 
decellularized via mechanical and chemical methods as previously described to prepare small 
intestinal submucosa (SIS) ECM253-255. Decellularized material was lyophilized and milled to 
form a comminuted form of SIS-ECM with dimensions of approximately 850 and 250 µm2 
which were combined at a ratio of 2:1, respectively and lyophilized to form a 25 x 12.5 x 3 mm 
powder pillow construct. The pillow was subdivided into smaller pillows with 4 x 4 x 3 mm 
dimensions at approximately 27.6 + 4.5 mg.  
6.3.3 Surgical procedure 
A 3 x 4 mm defect was made in the mouse quadriceps as previously described163. Briefly, female 
C57bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were anesthetized with 1.5-2.5% 
isoflurane in oxygen and positioned in dorsal recumbency. A 1.5 cm incision was made 
unilaterally and longitudinally in the epidermis, dermis, and fascia to expose the underlying 
quadriceps muscle. A 4 x 4 x 3 mm thickness segment was resected from the tensor fasciae latae 
and the underlying rectus femoris. Marker sutures (7-0 prolene, Ethicon Inc.) were placed to 
identify the injury site at the time of tissue harvest. Defects were treated with size-matched SIS-
ECM powder pillows. Lyophilized single SIS-sheets were positioned over the pillow implant and 
sutured to native muscle to secure the implant within the defect. The pillow was hydrated using 
normal saline before dermal closure with 7-0 prolene. All animals survived the surgical 
procedure and study period without complications.  
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6.3.4 Explant harvest 
Animals were sacrificed at 3, 7, 14, and 56 days via CO2 inhalation and cervical dislocation. The 
defect site and adjacent native quadriceps muscle was harvested and fixed in 10% neutral 
buffered formalin (NBF). Tissue was then embedded in paraffin and cut into 5 um-thick sagittal 
sections and mounted onto glass slides for Masson’s Trichrome staining or for immunolabeling.  
6.3.5 Immunolabeling 
Tissue sections were deparaffinized with xylene and rehydrated with a graded ethanol series 
followed by enzymatic antigen retrieval with 0.1% (v/v) trypsin/0.1% (w/v) calcium chloride 
digestion at 37ₒ C followed by heat-mediated antigen retrieval with citrate buffer (10 mM, pH 6) 
for 20 minutes at 95-100ₒ C. Tissue sections were exposed to blocking buffer (0.1% Triton X-
100, 0.1% Tween-20, 2% bovine serum albumin, 4% goat serum) to reduce nonspecific antibody 
binding for 1 hour at room temperature. Tissue sections were then incubated in the following 
primary antibodies diluted in blocking buffer at 4ₒ C for 18 h: (1) rat monoclonal F4/80 (abcam, 
Cambridge, MA), (2) rabbit polyclonal iNOS (abcam) at 1:200, (3) rabbit polyclonal Fizz1 
(Peprotech, Rocky Hill, NJ) at 1:200, (4) mouse monoclonal CD146 (abcam) at 1:350, (5) rabbit 
polyclonal CD31 (abcam) at 1:200, (6) mouse monoclonal sarcomeric myosin (MF-20, 
Developmental Studies Hybridoma Bank, University of Iowa) at 1:200, (7) mouse monoclonal 
beta-3-tubulin (TU-20, Pierce, Rockford, IL) at 1:100, or (8) monoclonal anti-Nestin (EMD 
Millipore, Darmstadt, Germany) at 1:200. Following primary antibody incubation, tissue was 
washed with PBS and incubated in secondary antibody at 1:200 dilution: (1) AlexaFluor 488 
anti-rat (Invitrogen), (2) AlexaFluor 594 anti-rabbit (Invitrogen), (3) AlexaFluor 488 anti-rabbit 
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(Invitrogen), or (4) AlexaFluor 594 anti-mouse (Invitrogen) for 1 hour at room temperature. 
Tissue sections were then washed with PBS and incubated for 5 minutes at room temperature 
with 4’,6-diamidino-2-phenylindole (DAPI) nuclear stain. Following PBS washing, mounting 
media was applied to each tissue section and slides were cover slipped.  
6.3.6 Image analysis  
Tissue sections were imaged using a Nikon E600 microscope with a Nuance multispectral 
imaging system (CRI Inc.) with appropriate fluorescent filter sets. Six images were taken from 
each biopsy using exposure times that were normalized using isotype and positive controls. 
These exposure times were maintained for all images taken with the same immunolabel marker 
and positive controls. Nuance unmixing software was used to remove auto-fluorescence using a 
high-throughput tunable filter distinctly matched to the bandwidths of the markers. Three 20X 
fields of view were taken at the interface with native underlying muscle marked by sutures, and 
three 20X fields of view were taken within the center of the defect, defined as 50% of the 
distance between the proximal and distal edge of the defect, 50% of the distance between the 
medial and lateral edges of the defect, and 50% of the distance between the base of the defect 
and surface of the ECM bioscaffold as measured by Nuance software. CellProfiler image 
analysis software was used to count positively-labeled cells per field of view.  
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6.3.7 Statistical analysis  
 
A one-way ANOVA was used for all comparisons between groups with an LSD post-hoc 
analysis. All statistical analysis used SPSS Statistical Analysis Software (SPSS, IBM, Chicago, 
IL, USA). 
6.4 RESULTS 
6.4.1 ECM bioscaffold treatment of VML results in cellular infiltration, neomatrix 
deposition, and skeletal muscle formation 
Masson’s trichrome staining shows a change in default mammalian wound healing response 
following ECM bioscaffold treatment of VML when compared to the untreated group. ECM 
treatment is characterized by increased cellular infiltration and neomatrix deposition compared to 
the untreated control (Figure 4). 
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Figure 4. Masson's trichrome staining of VML. (A) Masson's trichrome staining of untreated VML 
(100X magnification) shows deposition of collagenous tissue, consistent with a critical size defect with no resultant 
muscle formation. 
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Figure 5 (continued on next page) 
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Figure 5. Macrophage polarization (A, B, E, F) When compared to the untreated control which is 
characterized by a predominant iNOS+ M1-like macrophage population at all time points (C,D,G,H), ECM 
treatment alters the default response to critical size injury of skeletal muscle from one of a predominant pro-
inflammatory, M1-like macrophage activation to the constructive M2-like macrophage phenotype. Spatial 
quantification shows few differences between the margin and center of the defect within groups, but highlights the 
contrasting iNOS+ versus Fizz1+ macrophage phenotypes when left untreated or treated with ECM, respectively. 
Temporal quantification shows that a high number of Fizz1+ cells are present at all time points following ECM 
treatment, with the highest number occurring at 7 days following injury. Untreated defects are associated with a 
lower number of infiltrating macrophages with those present being predominantly iNOS+ (Scale bars = 50µm, error 
bars represent standard deviation, *p<0.05). 
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6.4.2 Surgically placed SIS-ECM bioscaffolds are associated with a predominant 
constructive cellular infiltrate 
The ECM-treated group shows an early transition from a predominant iNOS+ macrophage 
activation profile to the Fizz1+ macrophage phenotype. Specifically, after 3 days, both treated 
and untreated groups show a high percentage of iNOS+ macrophages, characterized by F4/80 
and iNOS expression, within the defect site (Figure 5A,C). However, ECM treated injury sites 
show a large population of Fizz1+ macrophages, characterized by F4/80 and Fizz1 expression, as 
early as 3 days after implantation (Figure 5C,D). By 7 and 14 days, the total number of 
macrophages present in ECM injury sites is increased and shows a predominant Fizz1+ 
macrophage phenotype with low numbers of iNOS+ macrophages (Figure 5). This response is 
present at both the interface with underlying native muscle and throughout the expanse of the 
defect site (Figure 5). In contrast, untreated VML sites show a predominant iNOS+ population at 
all time-points.  
6.4.3 ECM bioscaffolds promote PVSC mobilization 
Perivascular stem cells are multipotent progenitor cells that are typically found encircling 
microvessels and capillaries; however, they have the potential to mobilize away from their 
normal perivascular niche and contribute to remodeling of acute skeletal muscle injury and 
contribute to the satellite cell pool43. In the present study, untreated VML sites show CD146+ 
perivascular stem cells present at all time-points localized around CD31+ microvessels (Figure 
6A). These PVSCs are identified mostly along the margin of the defect site near the native 
underlying muscle. These cells are absent in the granulation tissue and scar tissue within the 
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center of the untreated defects. In contrast, ECM treatment shows a significant increase in the 
number of migratory PVSCs, at both the margin and center of the defect (Figure 6B). The 
number of PVSCs dissociated from the normal perivascular location peaks at 7 days, which 
coincides with an increase in Fizz1+ macrophages and is sustained through 56 days after 
implantation (Figure 6D). 
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Figure 6. Perivascular stem cell migration. (A-D) CD146+ PVSCs are found in their normal anatomic 
location adjacent to vessels (CD31+) in both untreated and ECM treated defects. (A,B) Without ECM intervention, 
PVSCs remain vessel associated. (C,D) In contrast, ECM-treated defects are populated with PVSCs outside their 
normal anatomic location, a response that continues at 14 and 56 day time points. These PVSCs are shown to be 
localized at both the center and margin of the defect. (Scale bars = 50µm, error bars represent standard deviation *p 
<0.05, PVSC, perivascular stem cell). 
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6.4.4 ECM bioscaffolds are associated with the presence of neurogenic precursor cells 
ECM-treated VML defects show an increase in β-III-tubulin positive cells both along the 
periphery and within the center of the implantation site (Figure 7B), in contrast with minimal 
presence of such cells in untreated defects (Figure 7A). Nestin+ cells are also present in 
increased numbers following ECM treatment when compared to the untreated control at early 
time points of 3, 7, and 14 days (Figure 8B,C). The number of nestin expressing cells diminishes 
by 56 days however, while β-III-tubulin expressing cells persisted through 56 days after ECM 
treatment.  
 
6.4.5 Skeletal muscle presence following ECM treatment 
Occasional cells showing myotube formation were present in untreated VML sites near the edge 
of the defect as determined by myosin heavy chain immunolabeling (Figure 9A). In contrast, 
ECM treatment shows skeletal muscle myotube formation at both the interface with native 
underlying muscle and within the center of the defect (Figure 9B). Quantification by CellProfiler 
shows increased MHC+ nuclei in the ECM treated defects when compared to untreated defects 
and persistence of MHC+ nuclei until the 56-day time point, suggesting ongoing remodeling 
(Figure 9C, D).  
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Figure 7. β-III tubulin positive mononuclear cells are present within ECM treated VML defects. (A-
D) Cross-sections of β-III tubulin+ nerve fibers are present at the margin of the defect in both treated and untreated 
VML at early time points. (C,D) β-III tubulin+ mononuclear cells are shown at the periphery and also at the center 
of the defect at 7, 14, and 56 days following ECM treatment, while these cells were absent in untreated defects. This 
finding may suggest that de novo innervation following ECM treatment contributes to functional remodeling 
outcomes. (Scale bar = 50µm, error bars represent standard deviation, *p <0.05). 
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Figure 8. ECM treatment increases numbers of Nestin+ cells (A,B). Untreated VML defects were 
associated with diminished numbers of nestin+ nuclei when compared to (C,D) ECM treated VML. Nestin+ cells 
were localized at both the interface with native muscle and at the center of the defect following ECM treatment 
whereas untreated groups showed nestin+ cells mainly confined to the interface. Quantification shows that this result 
is consistent across all time points from 3 to 56 days post implantation. (Scale bars = 50µm, error bars represent 
standard deviation, *p <0.05). 
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Figure 9. Site appropriate skeletal muscle remodeling by ECM bioscaffolds (A,B) Few signs of MHC+ 
nuclei resulted after VML was left untreated. (C,D) ECM treatment resulted in increased numbers of MHC+ nuclei. 
Interestingly, these muscle fibers were also located in the center of the defect, suggesting de novo myogenesis. 
Temporal averages show increased numbers of MHC+ nuclei at 7, 14, and 56 day time points indicating ongoing 
remodeling. (Scale bars = 50µm, error bars represent standard deviation, *p <0.05). 
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6.4.6 The temporal host cellular response of ECM-treated versus untreated VML  
Global averages of immunolabeled cells at both the margin and center of treated and untreated 
defects show that ECM treatment corresponds with an early and robust transition to a Fizz1+ 
macrophage phenotype which coincides with increased PVSC mobilization and skeletal muscle 
formation when compared to the predominant iNOS+ macrophage response and diminished 
progenitor cell populations which occurred when VML was left untreated (Figure 10). 
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Figure 10. Temporal host macrophage and progenitor cell response following VML. (A) ECM 
treatment corresponds with an early and robust transition to an M2 macrophage phenotype which coincides with 
increased PVSC mobilization and skeletal muscle formation when compared to the (B) predominant M1 
macrophage response which occurs when VML is left untreated. Untreated groups were characterized by lower 
macrophage numbers overall and lower numbers of PVSCs, neurogenic cell types, and skeletal muscle. 
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6.5 DISCUSSION 
This study advances the findings of previous in vitro and in vivo studies that ECM treatment 
facilitates a robust and rapid transition to an M2 macrophage phenotype and an attenuated M1 
macrophage phenotype. This phenomenon has not been previously shown to be a part of the 
response to VML when treated with ECM bioscaffolds. Such a mechanism likely contributes to 
downstream functional skeletal muscle remodeling, as it has been shown that failure of the 
phenotypic switch of macrophages results in impaired muscle regeneration13. Recent in vitro 
work has shown that macrophages activated by exposure to ECM degradation products are able 
to induce myogenic progenitor cell chemotaxis and differentiation78. Although the ability of 
macrophages to exert paracrine effects upon resident stem/progenitor cells in vivo has previously 
been shown, and the resulting feedback from macrophage-progenitor cell crosstalk may 
contribute to a sustained M2 macrophage response and differentiation of such stem cells27, the 
source of signals that promote these events has not been identified. Results of this study suggest 
that ECM-derived signals may contribute to such events. 
One progenitor cell population known to contribute to skeletal muscle remodeling and 
myogenesis is the PVSC. PVSCs, typically found encircling microvessels and capillaries, are 
multipotent stem cells that have myogenic potential. ECM implantation in this study was 
characterized by a robust accumulation of CD146+ PVSCs away from their normal vessel-
associated location, implicating their participating in remodeling. Importantly, these cells were 
evident both at the interface of the ECM bioscaffold with native uninjured muscle and at the 
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center of the ECM bioscaffold. In contrast, untreated defects showed very few PVSCs migrating 
away from vessels, the majority of which remained encircling CD31+ vasculature. ECM alone 
has been shown to be conducive to PVSC growth in vitro175,256,257, and these cells have also been 
shown to be responsive to ECM-polarized macrophages with enhanced chemotactic and 
myogenic potential43,256. PVSCs have been implicated as key contributors to constructive and 
functional remodeling following VML107. Whether such cells are instructed by ECM itself or 
through permissive ECM-macrophage signaling, or both, warrants further investigation.  
Innervation is an essential component of tissue development and also a requirement of 
functional muscle recovery. Innervation is obviously required for voluntary contractility and 
motor coordination. VML often results in denervation atrophy of the associated muscle, which 
leads to functional impairment258-260. Previous work has shown the functional innervation via 
needle electromyography in remodeled ECM when used for VML treatment107, though the 
mechanisms responsible for this response have not been investigated. This study corroborates 
and extends these findings, and shows an early presence and a persistence of β-III-tubulin-
positive cells as a part of ECM-mediated remodeling in the skeletal muscle location. A 
population of β-III tubulin positive mononuclear cells was present in both the center of the ECM-
treated defect and at the interface with native muscle. ECM treatment was also characterized by 
an increase in nestin positive cells at both the interface and center of the defect. The currently 
accepted innervation paradigm of skeletal muscle following minor muscle injury involves 
outgrowth of neurons from existing tissue. Whether or not the population of mononuclear β-III 
tubulin positive cells or nestin positive cells within the center of the defect contributes to de novo 
innervation in this model of VML warrants further investigation. Nestin positive cells have been 
shown to retain differentiation potential to become motor neurons261. It should be noted, 
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however, that developing myofibers have also been shown to transiently express nestin during 
development of myotendinous and neuromuscular junctions262,263.  
Analysis of the spatial and temporal distribution pattern of specialized progenitor cell 
types following ECM treatment, while not conclusive, contributes to an understanding of the 
pattern of ECM-mediated skeletal muscle remodeling. Temporally, macrophages dominate the 
cellular infiltrate at 3-, 7-, and 14-day time points in both ECM treated and untreated defects 
though their phenotype was clearly different between groups. In the ECM-treated groups, there 
was little difference in the number of PVSCs and myoblasts present at the interface versus the 
center of the defect, which was notably different from the pattern of PVSC presence in the 
untreated groups at any time point. Whether or not the response seen in the ECM-treated site is 
the same or similar to classical muscle fiber regeneration has not been determined. Regardless, 
the ability of ECM to promote site-appropriate tissue formation (i.e. the formation of myoblasts 
throughout the defect site) is promising, and is reflected in the functional and 
electromyographical improvements observed in clinical ECM-mediated remodeling107,246,264.  
There are several limitations to this study. Although macrophages are known to be a 
plastic cell population capable of phenotypic heterogeneity, the analysis described herein utilizes 
only two markers to characterize the extremes of the macrophage phenotypic spectrum (iNOS 
and Fizz1). Utilization of multiple markers and functional assays could allow for a more 
comprehensive analysis of macrophage phenotype. Additionally, while cells expressing neuron-
associated markers were evident by immunolabeling techniques, functional improvement was 
not determined at each time point. It would be interesting to assess functional innervation at the 
studied time points to determine whether there is a correlation between function and histologic 
presence of neurogenic cell types in the VML remodeling site. Finally, while islands of skeletal 
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muscle were evident in later time points, scaffold degradation was not complete at 56 days. This 
study utilized a powder pillow construct to entirely fill the VML defect. Clinical studies, in 
contrast, have utilized a sheet form of ECM bioscaffolds. It is likely that the higher surface area 
of the powder pillow construct resulted in a slower degradation rate in this model, compared to 
the relatively rapid degradation rate seen in the clinical use for VML102,104,246. A longer duration 
study will help to determine whether ECM-associated myogenesis seen in this study can 
contribute to formation of functional contractile skeletal muscle tissue deposition.  
6.6 CONCLUSIONS 
This study shows that when implanted in a mouse model of VML, ECM bioscaffolds change the 
default response to injury and facilitate a constructive remodeling outcome. This response is 
characterized by a rapid and predominant M2 macrophage activation profile, increased 
mobilization of endogenous PVSCs, the presence of cells showing neural differentiation 
markers, and the presence of skeletal muscle myoblast differentiation and site-appropriate tissue 
deposition. The ability of an ECM bioscaffold to influence the local skeletal muscle injury 
microenvironment allows for synergy and cross-talk among key immune regulators and skeletal 
muscle progenitor cells, the spatiotemporal distribution of which is associated with de novo 
skeletal muscle formation and site-appropriate remodeling.  
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7.0  SOLUBILIZED EXTRACELLULAR MATRIX BIOSCAFFOLDS DERIVED 
FROM DIVERSE SOURCE TISSUES DIFFERENTIALLY INFLUENCE 
MACROPHAGE PHENOTYPE4 
7.1 ABSTRACT 
The host response to biomaterials is a critical determinant of their success or failure in tissue-
repair applications. Macrophages are among the first responders in the host response to 
biomaterials and have been shown to be predictors of downstream tissue remodeling events. 
Biomaterials composed of mammalian extracellular matrix (ECM) in particular have been shown 
to promote distinctive and constructive remodeling outcomes when compared to their synthetic 
counterparts, a property that has been largely attributed to their ability to modulate the host 
macrophage response. ECM bioscaffolds are prepared by decellularizing source tissues such as 
dermis and small intestinal submucosa. The differential ability of such scaffolds to influence 
macrophage behavior has not been determined. The present study determines the effects of ECM 
bioscaffolds derived from eight different source tissues upon macrophage surface marker 
expression, protein content, phagocytic capability, metabolism, and antimicrobial activity. The 
results show that macrophages exposed to small intestinal submucosa (SIS), urinary bladder 
                                                 
4 Portions of this chapter were adapted from the following publication:  
Dziki JL, Wang DS, Pineda C, Sicari BM, Rausch T, Badylak SF. Solubilized extracellular matrix bioscaffolds 
derived from diverse source tissues differentially influence macrophage phenotype. Journal for Biomedical 
Materials Research Part A. July 2016. DOI:10.1002/jbm.b.35894 
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matrix (UBM), brain ECM (bECM), esophageal ECM (eECM), and colonic ECM (coECM) 
expresses a predominant M2-like macrophage phenotype, which is pro-remodeling and anti-
inflammatory (iNOS-/Fizz1+/CD206+). In contrast, macrophage exposure to dermal ECM 
resulted in a predominant M1-like pro-inflammatory phenotype (iNOS+/Fizz1-/CD206-), 
whereas liver ECM (LECM) and skeletal muscle ECM (mECM), did not significantly change the 
expression of these markers. All solubilized ECM bioscaffold treatments resulted in an increased 
macrophage antimicrobial activity, but no differences were evident in macrophage phacoytic 
capabilities and macrophage metabolism was decreased following exposure to UBM, bECM, 
mECM, coECM, and dECM. The present work could have imporatn implications when 
considering the macrophage response following ECM implantation for site-appropriate tissue 
remodeling.  
7.2 INTRODUCTION 
The use of biomaterials for the repair or reconstruction of damaged or diseased tissues is 
commonplace across a wide range of clinical applications. The success (i.e., safety and efficacy) 
or failure of these biomaterials is dependent, in large part, upon the host tissue response 
following implantation. The host innate immune response, especially the macrophage response, 
is a critical determinant of downstream tissue remodeling outcomes. Macrophages represent a 
cell population with heterogenous phenotypes that are involved in a variety of biologic processes 
including tissue homeostasis, inflammation, disease progression, and functional tissue 
reconstruction. Macrophages are among the first responders to pathogens, tissue injury, and also, 
implanted biomaterials76,100,265,266. Macrophage phenotypes have been classified along a 
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spectrum ranging from M1 or pro-inflammatory cells to M2 or pro-healing and regulatory cells. 
These various phenotypes can be distinguished by cell surface markers, associated cytokines and 
effector molecules, and functional activity including nitric oxide (NO) production or orthinine 
synthesis, respectively267,268, among others.  
Biomaterials have been manufactured from both synthetic and biologic substrates and each 
has their associated advantages and disadvantages62. Of relevance to the present study, biologic 
scaffolds composed of mammalian extracellular matrix (ECM) are associated with a constructive 
remodeling outcome following injury, as opposed to fibrosis or the classic foreign body reaction, 
and have been used in many clinical applications including dermal269-271, cardiac272, 
musculoskeletal107,273-275, and gastrointestinal repair102. The host macrophage phenotypic 
response was shown to be a determining factor in ECM bioscaffold-mediated remodeling 
outcomes78. In turn, scaffold preparation and processing methods were shown to have a profound 
influence upon macrophage phenotype in a study utilizing small intestinal submucosa (SIS) 
ECM as a body wall repair device98. Subsequent studies have confirmed and expanded the 
importance of macrophage phenotype in biomaterial-mediated tissue remodeling196,276-280. 
Specifically, it has been shown that the process of ECM-mediated tissue remodeling relies upon 
the infiltration and activation of host macrophages toward an immunomodulatory, M2-like 
phenotype76,100 and that a higher M2/M1 ratio at early time points is indicative of a favorable, 
constructive remodeling outcome at later time points. Although it has been shown that pepsin-
solubilized SIS-ECM bioscaffolds activate macrophages toward an M2-like phenotype, with 
increased Fizz1 and CD206 expression78, the mechanisms by which ECM bioscaffolds directly 
affect macrophage phenotype remain poorly understood.  
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 ECM bioscaffolds have been prepared from many source tissues including small 
intestine212, urinary bladder194, brain184,281, esophagus257, liver282, skeletal muscle208, and 
dermis192, among others, but the differential effects of these bioscaffolds upon macrophage 
phenotype have not been characterized. The objective of the present study is to characterize the 
phenotype of macrophages exposed to a variety of ECM scaffold materials, each of which is 
derived from a different source tissue. Phenotypic analysis includes surface marker profile, 
protein expression, viability, metabolic activity, phagocytic capacity, and antimicrobial activity. 
The findings of this study may influence the choice of ECM bioscaffolds for clinical use.  
7.3 MATERIALS AND METHODS 
7.3.1 Overview of experimental design 
ECM bioscaffolds were prepared from porcine tissues utilizing established protocols in 
accordance with previously established decellularization guidelines283. Murine bone-marrow 
derived macrophages were treated with pepsin-solubilized ECM bioscaffolds, and then harvested 
to analyze surface marker expression via immunolabeling, protein expression via western 
blotting, cell integrity by trypan blue exclusion, MTT metabolism, phagocytic capability, and 
antimicrobial activity.  
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7.3.2 Preparation of solubilized ECM bioscaffolds 
Biologic scaffolds composed of porcine small-intestinal submucosa (SIS), urinary bladder matrix 
(UBM), skeletal muscle ECM (mECM), brain ECM (bECM), esophageal ECM (eECM), dermal 
ECM (dECM) liver ECM (LECM), and colon ECM (coECM), were prepared following 
previously established decellularization protocols (Table 4). All scaffold materials met stringent 
requirements for sufficient decellularization; specifically, no visible intact nuclei by DAPI and 
hematoxylin and eosin (H&E) staining, remnant DNA concentration less than 50 ng/mg total 
scaffold dry weight, and DNA fragment length less than 200 base pairs. Scaffolds were 
lyophilized and milled to form a particulate powder. The powder was then solubilized with 
pepsin as previously described for the preparation of an ECM hydrogel to yield a 10 mg/ml 
solution of solubilized ECM. The solubilized ECM was then neutralized by addition of one-tenth 
digest volume of 0.1 N NaOH and one-ninth digest volume of 10X PBS to bring pH to 7.4, 
phosphate buffer to 0.01 M, and sodium chloride concentration to 0.15M. 
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Table 4. Overview of decellularization protocols 
ECM 
Bioscaffold 
Decellularization Method Reference 
Small intestinal 
submucosa (SIS) 
Mechanical removal of muscular layers followed by 0.1% peracetic acid 
and water washes 
Badylak SF. Tissue Eng. 
1993.. 
Urinary bladder 
matrix (UBM) 
Mechanical removal of surrounding muscular layers followed by 0.1% 
peracetic acid and water washes.  
Freytes DO et al. J Biomed 
Mater Res B Appl 
Biomater. 2006.  
Skeletal muscle 
ECM (mECM) 
Mechanical removal of fat and connective tissue, washes with 2:1 (v/v) 
chloroform:methanol, graded ethanol series, 0.02% trypsin/0.05% EDTA, 
2% deoxycholate, 1% Triton X-100, 0.1% peracetic acid, and water 
Wolf et al. Biomaterials. 
2012.  
Brain ECM 
(bECM) 
Mechanical removal of dura matter, water wash, washes with 0.02% 
trypsin/0.05% EDTA, 3.0% Triton X-100, 1.0 M sucrose, 4.0% 
deoxycholate, and 0.1% peracetic acid  
Crapo et al. Biomaterials. 
2012.  
Esophageal ECM 
(eECM) 
Mechanical removal of mucsularis layer,, washes with 1% trypsin/0.05% 
EDTA, 1.0 M sucrose, 3% Triton X-100, 10% deoxycholate, 0..1% 
peracetic acid, 4% ethanol, 100 U/ml DNAse, water, and PBS 
Keane et al. Biomaterials. 
2013.  
Dermal ECM 
(dECM) 
Mechanical removal of fat, connective tissue, and epidermis, washes with 
0.25% trypsin, 70% ethanol, 3% H2O2 1% Triton X-100, 0.26% 
EDTA/0.69% Tris, water, 0.1% peracitic acid/0.4% ethanol, and PBS 
Reing et al. Biomaterials. 
2013.  
Liver ECM 
(LECM) 
Mechanical slicing / massage to aid cell lysis followed by washes with 
0.02% trypsin/0.05% EDTA, 3% Triton X-100, 4% deoxycholate, and water 
Sellaro et al. Tissue Eng. 
2007.  
Colonic ECM 
(coECM) 
Mechanical isolation of submucosa, washes with 2:1 (v/v) 
chloroform:methanol, graded ethanol series, 0.02% Trypsin/0.05% EDTA, 
4% deoxycholate, 0.1% peracetic acid/4% ethanol, and water 
Keane et al. J Biomed 
Mater Res B Appl 
Biomater. 2015. 
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7.3.3 SDS PAGE analysis 
Protein composition of each of the solubilized ECM from the various tissues was compared 
qualitatively using SDS PAGE and a See Blue Pre-stained Molecular Weight Marker 
(Invitrogen). Five (5) ug of each ECM was added to a 4-20% polyacrylamide gel and run at 
120V for two hours. The gels were stored in fixing buffer overnight and then stained with a 
Pierce Silver Stain for Mass Spectrometry Kit (Life Technologies) following the manufacturer’s 
instructions. 
7.3.4 Macrophage isolation and polarization  
Mouse bone marrow was harvested as previously described78,284. Briefly, female 6 to 8 week old 
C57bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were euthanized via CO2 inhalation and 
cervical dislocation. Aseptically, the skin from the proximal hind limb to the foot was removed, 
the tarsus and stifle disarticulated, and the tibia isolated. The coxafemoral joint was 
disarticulated for isolation of the femur. After removal of excess tissue, bones were kept on ice 
and rinsed in a sterile dish containing macrophage complete medium consisting of DMEM 
(Gibco, Grand Island, NY), 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 10% 
L929 supernatant, 50 uM beta-mercaptoethanol (Gibco), 100 U/ml penicillin, 100 ug/ml 
streptomycin, 10 mM non-essential amino acids (Gibco) and 10 mM hepes buffer. The ends of 
the bones were transected and the marrow cavity was flushed with complete medium to collect 
bone marrow. Cells were washed, plated at 2 x 106 cells/ml, and allowed to differentiate into 
macrophages for 7 days at 37°C, 5% CO2 with complete medium changes every 48 hours as 
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previously described285. After 7 days, resulting naïve macrophages were treated with basal 
medium consisting of 10% FBS, 100 ug/ml streptomyocin, 100 U/ml penicillin in DMEM and 
one of the following conditions as previously described: (1) 20 ng/ml IFNγ and 100 ng/ml of 
LPS to promote an M1-like phenotype, (2) 20 ng/ml IL-4 to promote an M2-like phenotype, (3) 
200 ug/ml of pepsin control buffer, or (4) 200 ug/ml of ECM for 18 hours at 37°C, 5% CO2.  
7.3.5 Immunolabeling  
After 18 hours, macrophages were washed and fixed with 2% paraformaldehyde. Following PBS 
washes, cells were incubated in blocking solution consisting of 0.1% Triton-X 100, 0.1% Tween 
20, 4% normal goat serum, and 2% bovine serum albumin (BSA) for 1 hour at room temperature 
to prevent non-specific antibody binding. The following primary antibodies were diluted in 
blocking solution: (1) monoclonal anti-F4/80 (Abcam, Cambridge, MA) at 1:200 dilution for a 
pan-macrophage marker, (2) polyclonal anti-iNOS (Abcam, Cambridge, MA) at 1:100 dilution 
for an M2 marker, and (3) polyclonal anti-Fizz1 (Peprotech, Rocky Hill, NJ) for an M2 
marker287-289. Cells were incubated in primary antibodies for 16 h at 4°C. After PBS washes, 
cells were incubated in fluorophore-conjugated secondary antibodies (Alexa Fluor donkey anti-
rat 488 or donkey anti-rabbit 488, Invitrogen) for 1 hour at room temperature. After PBS washes, 
nuclei were counterstained with 4’6’diamidino-2-phenylindole (DAPI) prior to imaging three 
200X fields containing on average 900 cells each, using a live-cell microscopes. Light exposure 
times were standardized to a negative isotype control and kept constant across images. Images 
were quantified utilizing CellProfiler Image Analysis software to obtain positive F4/80, iNOS, 
and Fizz1 percentages.  
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7.3.6 Western blotting 
After treatment with cytokines or ECM, macrophages were lysed for western blot analysis. Cell 
lysates were diluted 1:1 in 2x Laemmili sample buffer with 5% beta-mercaptoethanol. Twenty 
(20) ug of protein was loaded per well in 4-20% Bio-Rad Mini-PROTEAN TGX Stain-Free 
polyacrylamide gels. Gels were run at 100 V for 15 minutes and then 150 V in 1X running buffer 
(30.3 g Tris, 144 g glycine, 10 mL 10% SDS solution in water). Separated proteins were 
transferred to Immobilon-P polyvinylidene difluoride (PVDF) membranes for 3 hours at 150 mA 
in transfer buffer (10% 10X running buffer, 20% methanol, 70% water). The membranes were 
then incubated in blocking buffer (5% BSA and 0.1% Tween-20 in TBS) for one hour to prevent 
non-specific antibody biding. Membranes were incubated in primary antibodies for 16 hours at 
4°C at a 1:500 dilution for M1-like iNOS (abcam, Cambridge, MA) and M2-like CD206 (abcam) 
in 0.5% BSA and 0.1% Tween-20 in TBS. Membranes were washed 0.1% Tween-20 in TBS and 
incubated with horseradish peroxidase secondary antibodies applied at 1:5000 in 0.5% BSA and 
0.1% Tween-20 in TBS. Five (5) mL Bio-Rad Western ECL solution (Bio-Rad, Hercules, MA) 
was applied to each membrane for five minutes before imaging. Densitometry was calculated 
with ImageJ software. 
7.3.7 Cell viability  
Macrophage viability following treatment with ECM was evaluated using the trypan blue 
exclusion assay290. Exposed macrophages were washed with PBS and harvested with Accutase® 
(Stem Cell Technologies, Vancouver, CA) solution for 10 minutes, followed by inactivation with 
medium containing 10% FBS. Trypan blue solution (0.4% w/v) was mixed in a proportion 1:1 
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with the cell suspension. The number of viable cells (trypan blue excluded) and non-viable cells 
(trypan blue included) were determined using a hemocytometer. The percentage of cells showing 
trypan blue exclusion was determined dividing the amount of trypan blue excluding cells by the 
total number of cells. 
7.3.8 Macrophage metabolism  
Metabolism of exposed macrophages to the tissue-specific ECM was measured using the MTT 
assay (Vibrant®MTT Cell Proliferation Assay Kit, V-13154, Molecular Probes, Eugene, OR) 
following the manufacturer instructions with slight modifications. Briefly, 1*105 bone marrow 
derived cells were plated and differentiated into macrophages as previously described. 
Macrophages were treated with 200 ug/ml of ECM or cytokine controls for 18 hours at 37°C, 5% 
CO2. After treatment, macrophages were washed with PBS and incubated with 1.2 mM MTT (3-
(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution for 2 hours. The straight-
line equation from the standard curve was used to interpolate the concentration of cells reducing 
the MTT after the exposure to the ECM digests. As 1*105 cells were initially seeded, the value is 
presented as the percentage of reducing cells relative to the initial value (1*105 cells).  
The formazan produced by reduction of the MTT was diluted with 50 ul of dimethyl 
sulfoxide (DMSO) and its concentration determined by optical density at 540 nm. The metabolic 
activity of macrophages was calculated from a standard curve. Results were presented relative to 
untreated (MCSF only) macrophages. 
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7.3.9 Phagocytosis  
The ability of macrophages to phagocytose fluorescent latex microspheres was evaluated as 
previously described with some modifications. After treatment of 1*106 bone marrow-derived 
macrophages with 200 ug/ml of ECM or cytokine controls for 18 hours, macrophages were 
rinsed with PBS and incubated with 4.55*107 particles/ml of Fluoresbrite YG Microspheres 1.00 
um (Polysciences, Warrington, PA) in complete medium for 15 minutes at 37°C, 5% CO2. After 
incubation with microparticles, macrophages were washed with PBS and harvested with 
Accutase® solution. Cells were centrifuged and rinsed with PBS followed by a counterstain with 
viability dye eFluor 780 (eBioscience, San Diego, CA) at a dilution of 1:1000. A non-phagocytic 
cell line, C2C12 mouse myoblasts, was used as a negative control. The percentage of phagocytic 
macrophages was determined by flow cytometry. 
7.3.10 Antimicrobial activity  
ECM bioscaffolds from each tissue-type were exposed to proliferating Staphylococcus aureus (S. 
aureus) bacteria for evaluation of antimicrobial activity as previously described200. Briefly, an 
isolated colony of Staphylococcus aureus (American Type Culture Collection 29213, clinical 
isolate) grown on tryptic soy agar was used to inoculate 10 m of tryptic soy broth. The bacteria 
were expanded in suspension overnight on a rotary shaker at 37oC. The bacteria were then 
diluted to 5 x 105 CFU/ml, and 150 ml of bacterial suspension were added to each well of a 96-
well microplate; ECM was added at a concentration of 200 ug/ml to the bacterial suspension. 
Secreted products of ECM-treated macrophages were derived using the following method: 
macrophages were treated for 18 hours with solubilized ECM or cytokine controls as described. 
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After 18 hours, cells were washed with PBS and medium was replaced with serum free, 
antibiotic free, ECM-free medium for 5 hours, after which time the medium was collected and 
was diluted at a 1:1 ratio with broth. Samples tested included solubilized ECM from each tissue 
type, a negative control of medium alone, and pepsin as a carrier control. Each sample was tested 
in triplicate. The bacterial growth in each well was monitored over the course of 24 h using 
absorbance readings at 570 nm with a BioRad 680 microplate reader. 
7.3.11 Statistical analysis  
A one-way ANOVA was used for all comparisons between groups with an LSD post hoc 
analysis. All statistical analysis used SPSS Statistical Analysis Software (SPSS, IBM, Chicago, 
IL, USA). Error bars represent standard deviation. 
7.4 RESULTS 
7.4.1 ECM bioscaffolds derived from different source tissues have distinct compositions 
SDS PAGE gel analysis of solubilized ECM bioscaffolds show distinct banding patterns 
following silver stain, indicating that ECM bioscaffolds derived from different source tissues 
have distinct compositions (Figure 11).  
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7.4.2 ECM differentially affects macrophage surface marker expression  
Immunolabeling for indicators of the M1 or M2 phenotype using iNOS and Fizz1, respectively 
shows that ECM bioscaffolds derived from different source tissues promote different expression 
patterns (Figure 12A). Specifically, SIS-ECM, UBM, bECM, eECM, and coECM promote a 
predominant Fizz1+ (M2-like) macrophage phenotype with minimal iNOS expression (Figure 
12B). Conversely, dECM shows a predominant iNOS+ (M1-like) phenotype (Figure 12B). 
mECM and LECM do not show significant increases in iNOS or Fizz1 expression when 
compared with untreated controls (Figure 12B). 
 
Figure 11. SDS PAGE gel analysis of ECM degradation products. Degradation products of ECM 
bioscaffolds derived from different source tissues were separated using SDS PAGE gel electrophoresis and show 
distinct banding patterns. (SIS=small intestinal submucosa, UBM=urinary bladder matrix, mECM=skeletal muscle 
ECM, bECM= brain ECM, eECM = esophageal ECM, dECM= dermal ECM, LECM= liver ECM, coECM = colonic 
ECM). 
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Figure 12. Immunolabeling of ECM treated macrophages (A) Macrophages were fixed with 2% 
paraformaldehyde following 18 h of treatment with cytokines or ECM degradation products and 
immunolabeled for indicators of the M1 or M2 phenotypes (iNOS, Fizz1, respectively). F4/80 was used 
as a pan macrophage marker. (B) Results were quantified using CellProfiler Image Analysis software and 
show that SIS, bECM, eECM, and coECM promote a predominant M2-like macrophage phenotype, 
whereas dECM promotes a predominant M1-like macrophage phenotype. (MCSF = macrophage colony 
stimulating factor, SIS= small intestinal submucosa, UBM= urinary bladder matrix, mECM= skeletal 
muscle ECM, bECM= brain ECM, eECM= esophageal ECM, dECM= dermal ECM, LECM= liver ECM, 
coECM=colonic ECM) (* and # indicate p < 0.05 when compared to MCSF group for iNOS and Fizz1 
quantification, respectively. n=8, error bars represent standard error of the mean. Light exposure times 
were standardized to a negative isotype control and kept constant across images). 
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7.4.3 ECM differentially increases M1-like and M2-like macrophage protein expression  
Western blotting shows that SIS, UBM, eECM, and coECM treated macrophages significantly 
increased CD206 expression similarly to the IL-4 treated control (Figure 13B). IFNy/LPS 
treatment as well as mECM, bECM, dECM, and LECM are characterized by decreased CD206 
expression (Figure 13). SIS, bECM, and eECM are characterized by a significant decrease of 
macrophage iNOS expression when compared to the IFNy/LPS treated control; where as UBM, 
mECM, dECM, LECM, and coECM do not decrease macrophage iNOS expression (Figure 
13D). 
 
Figure 13. Western blotting of ECM-treated macrophages. . (A) Macrophage lysates were collected 
and probed for the presence of iNOS and (C) CD206 as M1 and M2-like protein markers, respectively. 
(B) Treatment with SIS, UBM, bECM, and coECM promotes a significant decrease in iNOS expression 
when compared to the vehicle (pepsin) control treatment. (D) Treatment with SIS, UBM, eECM, and 
coECM promotes a increase in CD206 expression, similarly to IL-4 treated macrophages when compared 
to the pesin treated macrophages. (MCSF= macrophage colony stimulating factor, SIS=small intestinal 
submucosa, UBM = urinary bladder matrix, mECM = skeletal muscle ECM, bECM = brain ECM, eECM 
= esophageal ECM, dECM = dermal ECM, LECM = liver ECM, coECM= colonic ECM). (* indicates p < 
0.05 when compared to vehicle control. n=6. Error bars represent standard error of the mean) 
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7.4.4 Exposure to ECM differentially affects macrophage viability 
 
ECM bioscaffolds differentially affect macrophage viability. At the evaluated concentration, 
none of the tissue-type ECMs cause a decrease in cell viability of more than 20%. Macrophages 
exposed to eECM (84.14%), LECM (83.34%), and bECM (83.28%) showed the lowest cell 
viability with significant differences when compared with non-activated M0 macrophages 
(93.74%) (Figure 14). 
 
Figure 14. Macrophage viability analysis. The viability of macrophages following treatment with 
cytokines or ECM degradation products was analyzed using trypan blue. Macrophage viability significantly 
decreases with eECM, LECM, and bECM treatment. (MCSF= macrophage colony stimulating factor, SIS=small 
intestinal submucosa, UBM = urinary bladder matrix, mECM = skeletal muscle ECM, bECM = brain ECM, eECM 
= esophageal ECM, dECM = dermal ECM, LECM = liver ECM, coECM= colonic ECM). (* indicates p < 0.05 
when compared to MCSF group. n=3. Error bars represent standard deviation) 
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7.4.5 Exposure to ECM differentially affects macrophage metabolism  
Exposure of macrophages to tissue-specific ECM differentially modified the macrophage 
metabolic activity. SIS-ECM, eECM, and LECM maintain cell metabolism activity when 
compared to untreated macrophages and cytokine-treated macrophages. In contrast, mECM, 
dECM, coECM, and bECM decrease macrophage MTT metabolism by more than 50%. UBM 
treatment also resulted in a significant decrease in MTT metabolic activity when compared to the 
untreated control (Figure 15). 
 
Figure 15. MTT metabolism of macrophages. MTT analysis shows treatment with mECM, dECM, 
cECM, or bECM reduces metabolic activity of macrophages when compared to the untreated control. UBM 
significantly increases MTT metabolism when compared to untreated macrophages, whereas mECM, bECM, 
dECM, and coECM result in a significant decrease. (MCSF= macrophage colony stimulating factor, SIS=small 
intestinal submucosa, UBM = urinary bladder matrix, mECM = skeletal muscle ECM, bECM = brain ECM, eECM 
= esophageal ECM, dECM = dermal ECM, LECM = liver ECM, coECM= colonic ECM). (* indicates p < 0.05 
when compared to MCSF group. Error bars represent standard deviation) 
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7.4.6 Phagocytic capability of macrophages does not significantly differ with phenotype  
Phagocytic capability of macrophages was unaffected by treatment with ECM and/or cytokine 
controls (Figure 16).  
7.4.7 ECM treated macrophages exert antimicrobial effects 
Secreted products from cytokine-treated and ECM-treated macrophages show an increased 
antimicrobial affect when compared to pepsin-treated and untreated controls. ECM activates 
macrophages similarly to cytokine-treated macrophages with respect to antimicrobial activity 
(Figure 17).  
 
Figure 16. Phagocytic capacity of macrophages. Fluorophore-conjugated bioparticle uptake was used as 
a measure of phagocytic activity of macrophages. Treatment with cytokines or ECM degradation products did not 
significantly change phagocytosis. (MCSF= macrophage colony stimulating factor, SIS=small intestinal submucosa, 
UBM = urinary bladder matrix, mECM = skeletal muscle ECM, bECM = brain ECM, eECM = esophageal ECM, 
dECM = dermal ECM, LECM = liver ECM, coECM= colonic ECM). (* indicates p < 0.05 when compared to 
MCSF group. n=3. Error bars represent standard deviation) 
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Figure 17. Indirect antimicrobial activity of ECM degradation products. S. aureus growth was used to 
determine the antimicrobial effects of macrophages exposed to ECM degradation products. After 18 hours, secreted 
products from ECM-treated macrophages significantly inhibit S. aureus growth, similarly to cytokine-treated 
macrophages, when compared to untreated macrophages and the negative control (broth). (MCSF= macrophage 
colony stimulating factor, SIS=small intestinal submucosa, UBM = urinary bladder matrix, mECM = skeletal 
muscle ECM, bECM = brain ECM, eECM = esophageal ECM, dECM = dermal ECM, LECM = liver ECM, 
coECM= colonic ECM). (* indicates p < 0.05 when compared to MCSF group. n=4. Error bars represent standard 
error of the mean) 
 
 
7.5 DISCUSSION 
Biologic scaffold materials composed of mammalian extracellular matrix (ECM) have been 
associated with favorable preclinical and clinical remodeling outcomes when used as a 
therapeutic approach following tissue damage or disease102,107,163,291,292. Xenogeneic ECM 
bioscaffolds that are thoroughly decellularized and relatively free of cell remnants are typically 
associated with robust biologic activity including the ability to recruit endogenous 
stem/progenitor cells and modulate the host innate immune response to injury117. It has 
previously been established that ECM is able to promote a shift from the default wound healing 
response to injury (i.e., fibrous scar tissue formation) toward constructive (i.e., functional and 
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site-appropriate) tissue remodeling246. Though the mechanisms responsible for this response are 
only partially understood, one important and necessary event is an early transition in responding 
macrophage phenotype; specifically, from an M1-like, pro-inflammatory phenotype to an M2-
like, regulatory and pro-remodeling phenotype following scaffold implantation and subsequent 
degradation within host tissue76,100,196. 
The extent of ECM mediated constructive remodeling can differ depending upon a 
number of variables involved in ECM bioscaffold preparation including source animal age119, 
use of chemical crosslinking agents100, storage conditions293, extent of decellularization117, 
terminal sterilization methods294 and the tissue from which the ECM was derived295,296, among 
others. ECM bioscaffolds have been shown to direct endogenous cell behavior and influence the 
local tissue microenvironment. The availability of these bioactive molecules to surrounding host 
tissue / cells is dependent upon the degradation of ECM bioscaffolds following implantation, 
subsequently releasing and/or exposing matricryptic peptide sites that have been shown to be 
chemotactic and mitogenic108,109 for progenitor cells and able to induce their differentiation78. It 
is logical to assume that ECM derived from homologous source tissue (i.e. from the same tissue 
that is to be replaced) would contain the inherent structural and biochemical milieu required for 
tissue-specific differentiation and would represent the optimal environment for such a tissue’s 
associated cells. Some studies have shown that homologous ECM is preferable and maintains 
tissue specific cell phenotypes295-300. However, other studies show that heterologous ECM is 
adequate in promoting site-appropriate tissue deposition102,208. Whether there are differences in 
the ability of ECM bioscaffolds derived from different source tissues to directly influence 
macrophage phenotype has not been previously evaluated. The present study shows that the 
source tissue from which an ECM bioscaffold is derived can indeed be a determining factor with 
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respect to the macrophage response. While most ECM bioscaffolds promote an M2-like 
phenotype in vitro, surface marker expression shows some exceptions including skeletal muscle 
ECM (mECM), dermal ECM (dECM), and liver ECM (LECM) treated macrophages which show 
lower M2-like Fizz1 and CD206 expression with higher levels of M1-like iNOS expression.  
It is plausible that these differences in phenotype could be a result of the preparation 
methods, specifically the method of decellularization utilized for different tissue types. In the 
present study, all ECMs were decellularized in accordance with previously established protocols 
designed to meet recognized minimum criteria for decellularization (i.e., no visible intact nuclei 
by hematoxylin and eosin staining, remnant DNA concentration less than 50 ng/mg dry weight, 
and DNA fragment length less than 200 base pairs) 283 283 283. For example, SIS-ECM and UBM 
are prepared with relatively mild decellularization methods whereas skeletal muscle ECM or 
esophageal ECM are exposed to a series of enzymatic, detergent, and chemical treatments. 
Variations of decellularization protocols likely contribute to the distinct protein profile for each 
tissue ECM as shown in the SDS PAGE gel analysis. A proteomic analysis has been conducted 
using solubilized urinary bladder matrix with hundreds of proteins identified within the 
solubilized scaffold301. However, it should be noted that proteomic analysis is a function of the 
particular solubilization process, which in itself generates even more proteins. The present study 
shows that while there are differences in protein content between each ECM bioscaffold type, it 
would be difficult to determine which of these differences contribute to any differences in 
bioactivity, let alone macrophage phenotype specifically due to the sheer number and overlap of 
proteins within the different scaffolds. Previous studies have shown that the macrophage 
response differs when exposed to fractions of structural and soluble components of the ECM249. 
It is likely that decellularization protocols also impact the relative constituents of solubilized 
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ECM utilized in the present study. However, whether a specific peptide or combinations of 
peptides is responsible for a phenotypic change in macrophages is unknown and warrants future 
study. The presence of residual detergent could also be a contributing factor in the differences in 
macrophage responses to different ECM bioscaffolds. Variation in detergents used for tissue 
decellularization has been shown to have an impact upon the basement membrane complex of 
urinary bladder matrix, specifically the extent of collagen denaturation, glycosaminoglycan 
(GAG) concentration, and cellular infiltration, growth, and differentiation209. It is likely that 
residual detergent remains within the pepsin-solubilized scaffolds used in the present study, and 
could have an impact upon the macrophage response. However, the objective of the present work 
was to compare the effects of ECM bioscaffolds and not decellualrization methods, though the 
question of the impact of specific detergents upon the macrophage response warrants 
investigation.  
A plausible rationale for selecting ECM bioscaffolds derived from one tissue source over 
another for a given application could include the ability to influence macrophage phenotype. 
Interestingly, gastrointestinal-derived ECM analyzed in the present study (SIS-ECM, eECM, 
coECM) promotes a heightened M2-like protein expression profile and diminished M1-like 
protein expression profile. Moreover, it has been shown that resident macrophages within the 
gastrointestinal tract retain a more immunotolerant (i.e. more M2-like) phenotype. Perhaps 
macrophage phenotype is partially determined by the native ECM within the gastrointestinal 
tract.  
In general, the present study shows that regardless of the source tissue from which it is 
derived, ECM stimulated macrophages show a distinct phenotype when compared to the 
canonically activated IFNγ/LPS and IL-4 treated macrophages. In general, ECM induces a shift 
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toward an M2-like phenotype. No significant differences were seen in macrophage phagocytosis. 
Metabolic activity of ECM treated macrophages, in the case of treatment with mECM, dECM, 
coECM, or bECM, is lowered. The results herein suggest that this decreased metabolic activity is 
not generated by loss of cell viability (i.e. apoptosis and necrosis), as corroborated by trypan blue 
exclusion assay results, but by changes in redox states. In this sense, it has been previously 
shown that cellular metabolism is differentially regulated in macrophage activation to meet the 
energetic needs of each phenotype in the local microenvironment302,303, with M1-like 
macrophages requiring greater amounts of NADH (increased redox potential) than its 
counterpart M2-like phenotype304,305. Since MTT assay, widely used to determine cell viability, 
incorporates the reduction of MTT to formazan in a NADH-dependent mechanism mainly 
outside the mitochondria304, this technique could be used as an indirect first approximation to 
determine the metabolic changes in macrophages. However, additional studies are required to 
identify the mechanisms involved in the metabolic activation of the macrophages exposed to 
tissue-specific ECM.  
ECM treated macrophages show similar antimicrobial activity to both IFNγ/LPS and IL-4 
treated macrophages. When compared to untreated or pepsin-treated macrophages, cytokine or 
ECM activated macrophages promoted a more potent antimicrobial effect, though no significant 
differences were found when comparing the effects from macrophages treated with different 
ECM bioscaffolds. These results show that ECM can indirectly contribute to antimicrobial 
activity through macrophage activation. Such results also highlight the heterogeneity of 
macrophages and emphasize the need to evaluate these cells using multiple metrics for 
comprehensive characterization. 
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The present study has several limitations. Although macrophages are a key player in 
tissue-mediated remodeling across species, only mouse bone marrow derived macrophages were 
utilized for phenotypic characterization following ECM exposure. Whether these same trends 
will be corroborated utilizing human macrophages should be investigated. Additionally, the 
present study did not investigate the specific effects of individual decellularization methods upon 
an ECM’s ability to influence macrophage phenotype. It is likely that a different 
decellularization protocol, one that does not sufficiently lower DNA content as those used in the 
present study or otherwise modifies the molecular profile of the ECM, would influence 
macrophage phenotype.  
7.6 CONCLUSION 
The results herein show that ECM is able to induce changes in macrophage phenotype and 
function. Overall, ECM promotes a macrophage phenotype that is distinct from that of cytokine-
activated macrophages.  The direct effects of ECM bioscaffolds upon macrophage phenotype 
could have implications for the use of site-specific ECM in therapeutic applications. The findings 
reported show the heterogeneity of macrophages and the differences in bioactive molecules 
generated from ECM derived from diverse source tissues. 
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8.0  THE EFFECT OF MECHANICAL LOADING UPON EXTRACELLULAR 
MATRIX BIOSCAFFOLD-MEDIATED SKELETAL MUSCLE REMODELING5 
8.1 ABSTRACT 
Mounting evidence suggests that site-appropriate loading of implanted extracellular matrix 
(ECM) bioscaffolds and the surrounding microenvironment is an important tissue remodeling 
determinant, though the role at the cellular level in ECM-mediated skeletal muscle remodeling 
remains unknown. The present study evaluates cross-talk between progenitor cells and 
macrophages during mechanical loading in ECM-mediated skeletal muscle repair. Myoblasts 
were exposed to solubilized ECM bioscaffolds and were mechanically loaded at 10% strain, 1 
Hz for 5 hours. Conditioned media was collected and applied to bone-marrow-derived 
macrophages followed by immunolabeling for pro-inflammatory M1-like and pro-remodeling 
M2-like markers. Macrophages were subjected to the same loading protocol and their secreted 
products were collected for myoblast migration, proliferation, and differentiation analysis. A 
mouse hind limb unloading, volumetric muscle loss (VML) model was used to evaluate the 
effect of loading upon the skeletal muscle microenvironment after ECM implantation. Animals 
                                                 
5 Portions of this chapter were adapted from the following publication: 
Dziki JL, Giglio RM, Sicari BM, Wang DS, Gandhi R, Londono R, Dearth CL, Badylak SF. The effect of 
mechanical loading upon extracellular matrix bioscaffold-mediated skeletal muscle remodeling. Tissue 
Eng Part A. March 2017. DOI: 10.1089/ten.tea.2017.0011 
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were sacrificed at 14 or 180 days. Isometric torque production was tested and tissue sections 
were immunolabeled for macrophage phenotype and muscle fiber content. Results show that 
loading augments the ability of myoblasts to promote an M2-like macrophage phenotype 
following exposure to ECM bioscaffolds. Mechanically loaded macrophages promote myoblast 
chemotaxis and differentiation. Lack of weight-bearing impaired muscle remodeling as indicated 
by Masson’s trichrome stain. Isometric torque was significantly increased following ECM 
implantation when compared to controls, a response not present in the hind limb unloaded group. 
The present work provides important mechanistic insight of the effects of rehabilitation upon 
ECM-mediated remodeling and could have broader implications in clinical practice, advocating 
multidisciplinary approaches to regenerative medicine, emphasizing rehabilitation. 
8.2 INTRODUCTION 
Severe skeletal muscle injury, such as volumetric muscle loss (VML), as a result of trauma, 
tumor ablation, or prolonged denervation is a challenging problem in civilian and military 
medicine with significant clinical and economic consequences1,2,306. Treatment strategies include 
muscle grafts, orthotic devices, and/or physical rehabilitation and typically leave patients with a 
bleak prognosis of persistent strength and functional deficits3-5.  To address this unmet clinical 
need, extensive efforts within the field of tissue engineering / regenerative medicine have 
attempted to develop alternative approaches to VML therapy which can facilitate the restoration 
of functional skeletal muscle.  
     The use of acellular biologic scaffolds composed of mammalian extracellular matrix 
(ECM) as an inductive myogenic template has been investigated for more than two decades in 
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multiple animal models, a variety of tissues and types of injury, and with diverse bioscaffold 
source tissues. Outcomes have ranged from successful to unsatisfactory61,161-164,224-226,307,308. The 
findings from these preclinical studies served as the basis for the clinical use of ECM 
bioscaffolds for VML treatment in a pilot, 13 patient cohort study, with promising results 
including partial restoration of muscle strength, function, and range of motion107,246,247. Although 
the preliminary clinical outcome of ECM bioscaffold-based treatment for VML is encouraging, it 
is likely that the use of ECM bioscaffolds alone will not yield complete restoration of skeletal 
muscle function. 
     Evidence suggests that mechanical loading is not only beneficial but necessary for 
musculoskeletal development, strength and endurance gains, fatigue resistance, and even acute 
regeneration309-313. However, the role of mechanical loading in the context of ECM bioscaffold-
mediated repair following volumetric muscle loss is not fully understood.  The innate immune 
response is a required component of the response to injury and also plays a regulatory role in 
tissue development and homeostasis. Moreover, macrophage presence and phenotype have been 
shown to be a critical regulator of acute skeletal muscle regeneration and predictive of 
downstream ECM-mediated tissue repair. Since mechanical loading has been shown to have 
myogenic benefits, it is plausible that incorporation of early post-injury mechanical loading may 
foster a pro-regenerative cross-talk between macrophages and myogenic progenitor cells 
following ECM implantation for VML repair. The objective of the present study was to 
investigate the role of mechanical stimulation upon the macrophage and myoblast response in 
ECM bioscaffold-mediated VML repair, in well accepted in vitro and in vivo models.  
 102 
8.3 MATERIALS AND METHODS  
8.3.1 Overview of experimental design  
The role of mechanical stimulation upon cell processes known to be important in ECM 
bioscaffold-mediated skeletal muscle remodeling was evaluated in a two-part study (Figure 18). 
In vitro characterization of the macrophage and myoblast response to concurrent exposure to 
ECM degradation products and mechanical stimulation was conducted (FlexCell International, 
Burlington, NC). Conditioned media (containing secreted factors) from myoblasts and 
macrophages following exposure to ECM degradation products and/or mechanical strain were 
collected. The corresponding cell type was then exposed to these conditioned media to evaluate 
the effect on well-established functional outcome metrics (Figure 18A,B).  In a parallel study, 
the effect of mechanical stimulation on ECM bioscaffold mediated skeletal muscle 
reconstruction was evaluated using tail-suspension induced hind limb unloading in an established 
in vivo model of volumetric muscle loss (Figure 18C).  
8.3.2 Preparation of ECM bioscaffolds  
Small intestinal submucosa extracellular matrix (SIS-ECM) was prepared as previously 
described118,132,253. Briefly, porcine small intestine was obtained (Animal Biotech Industries, 
Danboro, PA) and the stratum compactum, muscularis mucosa, and tunica submucosa were 
isolated from the jejunum of animals weighing approximately 240-260 lbs. Peracetic acid, 
deionized H2O, and phosphate buffer saline washes were used to decellularize the tissue. SIS-
ECM sheets were lyophilized to form sheets or milled to form a powder. The powder was then 
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solubilized with 1.0% pepsin as previously described for the preparation of an ECM hydrogel to 
yield a 10 mg/ml solution of ECM degradation products194. 
8.3.3 Isolation and culture of murine bone marrow derived macrophages  
Murine bone marrow derived macrophages were isolated and cultured as previously described78. 
Briefly, bone marrow was isolated from the femurs and tibias of female C57BL/6 mice and was 
subsequently cultured in complete growth media including macrophage colony-stimulating 
factor (M-CSF) for 7 days with complete media changes every 48 hours until mature bone 
marrow derived macrophages were obtained, as confirmed by F4/80 immunolabeling.  
Macrophages were cultured on Uniflex culture plates (FlexCell International) for mechanical 
loading. 
8.3.4 Myoblast culture  
 
C2C12 myoblasts (ATCC) were cultured in accordance with ATCC guidelines.  The cells were 
grown in Dulbecco’s Modified Eagles Medium (DMEM)/High Glucose (4500 mg/L), 10% fetal 
bovine serum, and 1% penicillin-streptomycin. Cells were grown at 37°C, 5% CO2 and were 
assayed at approximately 80% confluence. 
8.3.5 ECM treatment and mechanical loading of myoblasts and macrophages  
Macrophages and myoblasts were treated with solubilized small intestinal submucosa (SIS-
ECM) at 200 ug/mL in media containing 10% fetal bovine serum and 1% penicillin/streptomycin 
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in DMEM/High Glucose for 18 hours or treated with canonical activation controls of IFNγ and 
LPS to derive a pro-inflammatory macrophage phenotype, or IL-4 to derive a pro-remodeling 
phenotype.   Cells designated for mechanical loading were plated on 35mm collagen I-coated 6-
well Uniflex culture plates (FlexCell International) and were subjected to 10% uniaxial strain at a 
cyclic rate of 1 Hz using the F-4000 FlexCell machine after being cultured to approximately 70% 
confluence.  Cells were kept in normal growth media with or without SIS-ECM to analyze the 
effect of mechanical loading upon cell phenotype, or were mechanically loaded in serum-free, 
ECM-free media for secreted product collection for cross-talk analyses.  
8.3.6 Immunolabeling analyses  
Macrophages and myoblasts were fixed following mechanical strain with 2% paraformaldehyde 
for 20 minutes and then washed with phosphate buffered saline (PBS). Cells were then 
immunolabeled for macrophage activation markers iNOS and Fizz1 or myogenic markers MyoD, 
desmin, and sarcomeric myosin. Prior to immunolabeling, cells were incubated for 1 hour in 
blocking solution consisting of 0.1% Triton-X 100, 0.1% Tween-20, 2% bovine serum albumin, 
and 4% normal goat serum. Cells were then incubated with the following primary antibodies 
diluted in blocking solution for 16 hours at 4˚C (1) monoclonal anti-F4/80 (abcam, Cambridge, 
MA) as a pan macrophage marker at 1:200, (2)polyclonal anti-iNOS (abcam) as an Mpro-
inflammatory macrophage marker at 1:100, (3) polyclonal anti-Fizz1 (Peprotech, Rocky Hil, NJ) as 
an Mpro-remodeling macrophage marker at 1:200, (4) monoclonal anti-MyoD (ThermoFisher, 
Pittsburgh, PA) at 1:500 as an early myogenic marker, (5) monoclonal anti-desmin (abcam), and 
(6) anti-sarcomeric myosin heavy chain (Developmental Studies Hybridoma Bank, University of 
Iowa) at 1:500. Cells were then washed with PBS and incubated in Alexa Fluor 488 goat anti-rat, 
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goat anti-rabbit, or goat anti-mouse diluted to 1:200 in blocking solution for 1 hour at room 
temperature and nuclei were counterstained with DAPI.  
8.3.7 Myoblast chemotaxis  
The effect of macrophage conditioned media upon C2C12 skeletal muscle myoblast chemotaxis 
was examined using a modified Boyden Chamber cell migration assay as previously 
described314314314. C2C12 myoblasts were cultured in starvation media (DMEM, 0.5% FBS, 1% 
penn/strep) for 18 hours prior to use. Cells were then trypsinized, re-suspended in growth-factor-
free DMEM, and transferred to a 15 ml conical tube for 1 hour incubation at 37 ˚C, 5% CO2. 
Polycarbonate chemotaxis membranes with 8µm pores were coated with 0.05 mg/ml collagen 
type I. Macrophage conditioned media (MIFNy+LPS, MIL-4, MECM, and their mechanically loaded 
counterparts) or positive (DMEM with 20% FBS) or negative (growth factor-free DMEM) 
controls were added to the lower wells of Neuro Probe 48-well micro chemotaxis chamber. 
Collagen-coated membranes were placed over the chemoattractants and 2 x 105 cells were added 
to each of the upper wells of the chamber. Cells were allowed to migrate across the chamber for 
3 hours at 37 ˚C, 5% CO2. Following the migration period, non-migrating cells were scraped 
from the upper side of the membrane using a rubber scraper. Migrated cells that attached to the 
bottom of the membrane were fixed with 95% methanol and stained with DAPI prior to imaging. 
Membranes were imaged using a Zeiss Axiovert microscope and the number of migrated cells 
was quantified using a CellProfiler pipeline.  
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8.3.8 Myoblast mitogenesis  
C2C12 myoblasts were seeded in normal growth media at 1 x 103 cells per well in a 96 well 
plate. Media was switched to starvation media (DMEM, 0.5% FBS, 1% pennicllin strep) for 18 
hours. Following the starvation period, cells were treated with one of the macrophage secreted 
product samples or positive (DMEM with 20% FBS) or negative (growth factor-free DMEM) 
control media for 18 hours. Treatments were supplemented with 10 µM 5-bromo-2’deoxyuridine 
(BrdU) for the final 4 hours. Cells were fixed with 95% methanol for 10 minutes and washed 
with PBS. Cells were then treated with 2 N HCl for 30 min at 37 ˚C. Following HCl treatment, 
cells were blocked using the previously described blocking solution for 1 h at room temperature. 
Following the blocking period, cells were incubated in G3G4 (Anti-BrdU) antibody 
(Developmental Studies Hybridoma Bank, University of Iowa) at a dilution of 1:1000 for 16 
hours at 4 ˚C. After primary antibody incubation, cells were washed 3 times with PBS and 
incubated in Alexa Fluor donkey anti-mouse 488 secondary at a dilution of 1:300 for 1 hour at 
room temperature before being subjected to DAPI nuclear stain. BrdU incorporation was imaged 
using a Zeiss Axiovert microscope and quantified using an ImageJ macro.  
8.3.9 Myoblast myogenesis  
High serum media (10% FBS) and low serum media (1% FBS, 1% horse serum) were used as 
negative and positive controls for C2C12 myotube formation as described previously315. These 
media will be referred to as proliferation and differentiation media, respectively. Myogenic 
differentiation potential following exposure to macrophage secreted products was determined by 
examining myotube formation. C2C12 myoblasts were cultured in proliferation media until they 
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reached approximately 70% confluence. Media was then changed to treatment media consisting 
of a 1:1 solution of macrophage supernatants and 20% FBS DMEM to yield a final serum 
concentration of 10% FBS, or controls of proliferation or differentiation media. Following 4-5 
days or when differentiation media controls showed myotube formation, cells were fixed for 
immunolabeling with 2% paraformaldehyde. Fixed cells were blocked according to the 
previously described protocol for 1 hour at room temperature and incubated with anti-sarcomeric 
myosin heavy chain as described previously. Images of five 20X fields were taken for each well 
using a Zeiss Axiovert microscope.  
8.3.10 Surgical procedure and hind limb unloading  
All animal studies were conducted in accordance with the University of Pittsburgh Institutional 
Animal Care and Use Committee (IACUC) guidelines. Seventy-two C57bl/6 mice (Jackson 
Laboratories, Bar Harbor ME) were randomly divided into six equal groups. All mice were 
subjected to tail-suspension to achieve hind limb unloading with full access to the cage floor for 
two weeks to acclimate prior to the surgical procedure.  A mouse model of volumetric muscle 
loss was used to evaluate the in vivo remodeling response to SIS-ECM in the presence or 
absence of mechanical load. A 5 mm segment including the distal third of the gastrocnemius and 
proximal half of the Achilles tendon was surgically excised, or left uninjured as a healthy 
control. In the VML groups, the segmental defect was repaired with an SIS-ECM sheet, 
autologous test sample, or was allowed to heal normally without intervention (i.e. no treatment). 
The device or autologous graft was placed over the proximal and distal stumps and fixed in place 
with interrupted 7-0 prolene sutures. The skin closure was subcuticular with absorbable sutures. 
Animals were then allocated into the tail suspended hind limb unloaded group or the normal 
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ambulation group. Animals were checked twice daily to assure slippage from the tail-suspension 
apparatus had not occurred, and were sacrificed at 14 or 180 days post-surgery.  
8.3.11 Tissue harvest and immunolabeling  
Animals were sacrificed at their predetermined time point and the gastrocnemius and Achilles 
tendon unit was excised from the surrounding tissue, fixed in neutral buffered formalin, and 
paraffin embedded. Sections were deparrafinized and rehydrated using a graded ethanol series 
and subjected to heat-mediated antigen retrieval with citrate buffer (pH=8). Following antigen 
retrieval tissue sections were incubated in blocking solution consisting of 0.1% Triton X-100, 
0.1% Tween-20, 2% bovine serum albumin, and 4% goat serum to prevent non-specific antibody 
binding. After the blocking step, tissue sections were incubated with the following primary 
antibodies diluted in blocking solution for 16 h at 4°C (1) anti-iNOS (abcam) and (2) anti-Fizz1 
(Peprotech). After incubation in primary antibody, tissue sections were washed with phosphate 
buffered saline (PBS) and incubated for 1 hour at room temperature with fluorescent secondary 
antibody diluted in blocking solution: (1) Alexa Fluor 488 goat anti rabbit at 1:200. Sections 
were washed again and counterstained with 4’,6-diamidino-2-phenylindole, dihydrochloride 
(DAPI) and cover-slipped for imaging using a Nuance multispectral microscope with appropriate 
fluorescent filter sets.  
8.3.12 Isometric torque measurement  
Functional analysis was performed by measuring isometric torque production of the 
gastrocnemius 180 days post-surgery using a protocol previously described316. This method 
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allows for determination of the contractile properties of the isolated gastrocnemius, while 
maintaining normal muscle orientation, innervation, and vascular supply. Animals were 
anesthetized while the hind limb was stabilized by platform supports with the foot in the flexed 
position. Needle electrodes were inserted into the belly of the muscle injury site approximately 
2-3 µm beneath the skin. Muscles were stimulated at nine different frequencies (1 Hz to 200 Hz) 
with a two-minute rest period between each frequency. Twitch contraction and tetanic 
contraction were analyzed using a Dynamic Muscle Analysis program (Aurora Scientific Inc., 
Canada) and data was normalized to the animals’ weight.  
8.3.13 Statistical analysis  
All statistical analysis was conducted using SPSS Statistical Analysis Software (IBM, Chicago, 
IL). Data was normally distributed and tested for homogeneity of variance. Data was compared 
between groups using a one-way independent ANOVA and Tukey’s post hoc analysis with an 
alpha value of 0.05. Error bars represent standard deviation.  A two-way ANOVA and LSD post-
hoc analysis was used to compare isometric torque between treatment groups at each frequency 
with an alpha value of 0.05. Error bars represent standard deviation.  
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8.4 RESULTS  
8.4.1 Cyclic mechanical strain promotes a Fizz1+ macrophage phenotype  
After 18 hours, degradation products derived from SIS-ECM promote a predominant iNOS-
/Fizz1+ macrophage phenotype. When exposed to mechanical load, naïve macrophages begin to 
express the M2-like marker Fizz1 similarly to IL-4 and ECM-treated resting macrophages 
(Figure 19).  
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Figure 18. Overview of experimental design. The goal of the present study was to determine the ability of 
mechanical stimulation in the presence of ECM degradation products to promote skeletal muscle remodeling. The 
following questions were posed (A) How does mechanical loading affect macrophage phenotype in the presence of 
an ECM bioscaffold and how is the macrophage secretome altered in the context of promoting myoblast chemotaxis, 
proliferation, and differentiation? (B) How does mechanical loading affect myoblast differentiation in the presence 
of an ECM bioscaffold and how does the myoblast/myotube secretome change in the context of promoting a change 
in activation in macrophages? (C) What is the effect of absence of mechanical loading upon the ECM-mediated 
skeletal muscle repair microenvironment? 
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Figure 19. Cyclic mechanical strain of bone marrow derived macrophages. Macrophages were 
subjected to 10% mechanical strain for 5 hours using the FlexCell system. 5 hours of mechanical strain resulted in 
an F4/80+/iNOS-/Fizz1+ macrophage phenotype, suggesting that mechanical strain alone can promote macrophage 
activation towards a pro-remodeling phenotype. 
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8.4.2 Cyclic mechanical strain promotes a pro-remodeling macrophage phenotype that 
induces myoblast chemotaxis  
As previously shown, naive macrophages treated with SIS-ECM behave similarly to 
macrophages treated with IL-4. Specifically, both promote a significant increase in myoblast 
chemotaxis and myotube formation (Figure 20A,D,C,F). In contrast, macrophages treated with 
IFNy+LPS increase myoblast mitogenesis. Interestingly, when mechanically strained, all 
macrophage types (IFNy+LPS treated, IL-4 treated, or SIS-ECM treated) promote a significant 
increase in myoblast chemotaxis when compared to their resting, unstrained counterparts (Figure 
20D).  
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Figure 20. The effect of ECM and mechanical stimulation upon the macrophage secretome. 
Macrophages were treated with activating cytokines IFNγ + LPS or IL-4 or 200 ug/ml of ECM degradation products 
for 18 hours. After 18 hours, cells were washed and media was replaced with serum-free, ECM-free media. 
Macrophages were strained for 5 hours and their conditioned mediat was collected for C2C12 experiments. (A,D) 
IL-4 and ECM treated macrophages promote increased C2C12 migration. Mechanically loaded macrophages 
significantly increase C2C12 migration compared the unloaded macrophages and the low serum negative control. 
(B,E) IFNγ+LPS treated macrophages promote increased C2C12 mitogenesis. Mechanically loaded macrophages 
significantly decreased C2C12 migotenesis compared to the unloaded and proliferation media positive control. (C,F) 
IL-4 stimulated and ECM stimulated macrophages significantly increase C2C12 myogenesis Mechanically loaded 
macrophages significantly increase C2C12 myogenesis compared to the unloaded and proliferation media negative 
control. (* indicates p<0.05. n=5. Error bars represent standard error of the mean) 
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Figure 21. Cyclic mechanical strain of C2C12 myoblasts. (A,C) Myoblasts were cultured and either kept 
in their proliferation media or (B,D) allowed to differentiate to form myotubes. (C,D) Cells were treated with 
solubilized ECM bioscaffolds for 18 hours or were left in media and were then mechanically strained for 5 hours or 
(A,B) were left unstrained. (F) SIS-ECM treatment increased expresson of desmin, with an additional increase after 
myoblasts were mechanically strained. (G) Mechanical strain increased myotbue formation shown by myosin heavy 
chain (MHC) expression. (*indicates p < 0.05, n=5, error bars represent standard error of the mean) 
 
 
8.4.3 Cyclic mechanical strain promotes a pro-remodeling macrophage phenotype that 
reduces myoblast proliferation and promotes myoblast differentiation  
IFNγ+LPS stimulated macrophages promote a significant increase in the number of BrdU 
positive, proliferating, myoblasts (Figure 20B,E). However, if IFNγ+LPS stimulated 
 116 
macrophages are first subjected to mechanical strain, this response is significantly diminished 
and is similar to IL-4 or SIS-ECM treated macrophages (Figure 20B,E). Mechanical strain 
applied to IFNγ+LPS stimulated macrophages also increased the ability of their collective 
secretome to promote C2C12 myotube formation (Figure 20C,F). 
8.4.4 Cyclic mechanical strain combined with SIS-ECM treatment promotes myoblast 
differentiation  
Treatment of proliferating myoblasts with SIS-ECM coupled with mechanical strain resulted in a 
significant increase in desmin expression (Figure 21F). Consistent with previous findings, the 
application of mechanical strain alone resulted in sarcomeric myosin heavy chain positive 
myotube formation in the proliferating group, suggesting the ability of mechanical strain to 
promote myoblast differentiation as shown in Figure 21G317. This response was augmented by 
the addition of SIS-ECM treatment. Further, when subjected to both SIS-ECM treatment and 
mechanical strain, the number of differentiated myotubes expressing the terminal differentiation 
marker, sarcomeric myosin heavy chain, significantly increased compared to the resting, 
untreated myotubes (Figure 21F).  
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Figure 22. The effect of ECM and mechanical strain upon the myoblast secretome. C2C12 cells were 
cultured in proliferation media or allowed to form myotubes in differentiation media culture. Myoblasts or myotubes 
were treated with 200 ug/ml of ECM degradation products for 18 hours, after which the media was replaced with 
serum free, ECM free media and the cells were subjected to mechanical strain. Conditioned media was collected and 
added to bone marrow derived macrophages for 18 hours and the cells were fixed for immunolabeling.(B) The 
secretome of proliferating myoblasts promotes an iNOS-/Fizz1+ macrophge phenotype, (C) however, differentiated 
myotubes do not promote the same effect. Treating myotubes with ECM degradation products, however, alters their 
secretome allowing them to promote a Fizz1+ macrophage phenotype. E) This response is augmented when ECM-
treated myotubes are subjected to mechaniacl strain. F) Percentage of iNOS and Fizz1 piositive macrophages were 
quantified using CellProfiler (* indicaptes p <0.05, n=4, eror bars represent standard error of the mean) 
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8.4.5 Cyclic mechanical strain promotes myotube-mediated macrophage activation 
towards a pro-remodeling phenotype  
It is well established that the secretome of stem cells can promote a pro-remodeling macrophage 
phenotype144. The secretome of proliferating C2C12 myoblasts (i.e. those upstream of the 
terminal differentiation pathway) can shift macrophages towards an iNOS-/Fizz1+ phenotype 
regardless of whether the myoblasts are treated with SIS-ECM or mechanically strained (Figure 
22). However, when allowed to exit the cell cycle and fuse to form myotubes following serum 
withdrawal, the secretome of C2C12 myotubes does not alter macrophage phenotype towards an 
iNOS-/Fizz1+ phenotype. In contrast, when first treated with SIS-ECM the C2C12 myotube 
secretome is altered and promotes the iNOS-/Fizz1+ macrophage phenotype (Figure 22). A 
similar response is seen when myotubes are mechanically strained. Exposure to both SIS-ECM 
and mechanical strain augments this response; specifically, there is significant increase in the 
number of Fizz1+ macrophages after exposure to this secretome (Figure 22F).  
8.4.6 Lack of mechanical stimulation alters the macrophage activation response in ECM-
mediated skeletal muscle remodeling  
After 14 days, hind limb unloading results in a significant decrease in the Fizz1+:iNOS+ 
macrophage infiltrate within the defect site (Figure 24).  
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8.4.7 Lack of mechanical stimulation hinders ECM bioscaffold-mediated constructive and 
functional remodeling in a mouse model of musculotendinuos injury  
SIS-ECM treatment promotes site-appropriate tissue deposition following VML (i.e. 
gastrocnemius-Achilles muscuoltendinous unit) injury in the mouse hind limb (Figure 25) 
whereas fatty tissue deposition and disorganized connective tissue occurs in the autologous graft 
or untreated controls (Figure 25). When prevented from weight-bearing on their hind limbs, the 
SIS-ECM treatment results in more fatty tissue deposition and less muscle formation within the 
defect site (Figure 25).  Isometric torque production in the SIS-ECM treated group is 
significantly increased compared to the autologous graft treated and untreated control groups 
following after 6 months when animals were allowed to weight-bear normally (Figure 25). This 
functional gain is significantly diminished in the absence of mechanical loading upon the hind 
limbs (Figure 25). Peak isometric torque is reduced in both the SIS-ECM treated groups and the 
healthy control animals in the absence of hind limb weight bearing (Figure 25). In general, there 
is a positive correlation between histologically evident new skeletal muscle tissue formation and 
a regain of isometric torque following injury.  
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Figure 23. Overview of animal model of VML and hind limb unloading. C57bl/6 mice were subjected 
to tail-suspension to achieve hind limb unloading for 2 weeks prior to surgery. Surgical excision of the distal 
gastrocnemius and proximal Achilles was replaced with either an SIS-ECM bioscaffold, an autologous graft, or left 
untreated. Animals were either allowed to walk normally or subjected to hind limb unloading and sacrificed 
according to the indicated timeline. 
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Figure 24. Macrophage response to hind limb unloading following ECM-mediated VML remodeling. 
(A) Hind limb unloading results in increased infiltration of iNOS+ macrophages at 14 days following implantation 
and (B) decreased Fizz1+ macrophage infiltration in contrast to the (C,D) normal ambulation control. (E) 
Quantification of the Fizz1+:iNOS+ macrophage ratio across all animals showed a significant decrease following 14 
days of hind limb unloading (** indiates p < 0.01, error bars represent standard error of the mean). 
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Figure 25. The effect of mechanical stimulation upon constructive remodeling following ECM 
implantation in a mouse model of VML. (A) Masson's trichrome staining shows site appropriate tissue deposition 
following ECM bioscafold implantation in mouse VML after 6 months in contrast to fatty tissue deposition and 
disorganized connective tissue formation in the autologous graft and untreated groups. Hind limb unloading for 6 
months decreases the deposition of site appropriate tissue. (B) ECM treatment results in a significant improvement 
in gastrocnemius isometric torque production when compared to the untreated and autologous control groups. Hind 
limb unloading diminishes this increase in force production. (C) Hind limb unloading significantly decreases 
isometric torque production in the ECM treated animals and the healthy controls. (D) Peak isometric torque 
production is significantly decreased following hind limb unloading in the healthy control and ECM groups (HU= 
hind limb unloading, * indicaptes p < 0.05, n=4, error bars represent standard error of the mean). 
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8.5 DISCUSSION 
The results of the present study show that mechanical stimulation fosters a pro-remodeling 
macrophage and myoblast cross talk with both direct and indirect promotion of an M2-like 
macrophage phenotype and increased myoblast chemotaxis and differentiation after exposure to 
the macrophage secretome. Lack of mechanical stimulation mitigates ECM-mediated skeletal 
muscle remodeling and reduces restoration of function. This less robust functional response was 
associated with a reduced M2:M1 macrophage ratio at early time points, which has previously 
been shown to be a critical regulator of downstream skeletal muscle remodeling76.   
     The mechanisms by which ECM bioscaffolds promote restoration of innervated, 
vascularized, skeletal muscle tissue with associated increased strength and improvement in 
functional performance in VML patients have not been totally elucidated, but it is well-
established that ECM bioscaffolds modify the default wound healing response by promoting an 
early transition in macrophage phenotype and mobilization of progenitor cells132,246. The 
successful clinical use of ECM bioscaffolds for VML has been coupled with aggressive, early 
(i.e. immediate) physical rehabilitation. This regimen of post-operative physical therapy has been 
considered an important contributor to downstream functional remodeling when ECM 
bioscaffolds are used107,246,318. The present study supports this concept and provides evidence of 
the complex signaling and, to at least some extent, dependency between mechanical loading, the 
innate immune system, and stem/progenitor cell development and differentiation. The 
incorporation of structured mechanical loading (i.e physical therapy), supported by data such as 
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that provided in the present study, could narrow the gap between some of the disparate outcomes 
seen with studies of ECM-mediated skeletal muscle remodeling226,319,320.  
     While the benefits of muscle loading and exercise have long been recognized, the 
impact upon the innate immune response and the benefits of early mechanical loading (i.e. within 
24-48 hours after injury and ECM placement) in the presence of a biomaterial intervention have 
not been appreciated. Macrophages are key regulators of many complex physiologic processes 
not only in wound healing but also in tissue homeostasis and development, and these cells appear 
to have particular importance in regulating skeletal muscle regeneration. The importance of 
macrophages has also been investigated in the broader context of ECM bioscaffold-mediated 
tissue repair76,78,79,98-100,116,118,196,321. The results of the present study confirm earlier findings that 
ECM-based signaling molecules influence macrophage behavior both directly78,79,118 and through 
myogenic progenitor signaling mechanisms78. These findings also show that mechanical 
stimulation can accentuate this response. While sensitivity of myoblasts to cyclic loading has 
been extensively studied, the early macrophage response to mechanical cues has not been 
generally appreciated. Previous work has shown that cell elasticity and cyclic strain can regulate 
macrophage phenotype and can drive biomaterial design322,323. Though in-vitro cyclic loading of 
macrophages was shown to push macrophages towards a pro-remodeling phenotype, the present 
study also shows a similar in vivo macrophage response. These findings show that macrophage 
behavior can be influenced by not only changing surface topography of a bioscaffold substrate, 
but also by providing external cues in the form of mechanical loading following severe skeletal 
muscle injury. Seminal studies investigating the response of macrophages to substrates of 
varying elasticities and rigidities have shown that changes in the cytokine secretion profile and 
gene / surface marker expression patterns of macrophages occurs through mechanotransduction 
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pathways including actin-polymerization, activation of stretch-sensitive ion channels, and/or 
activation or denaturation of G-proteins311,323,324. Through these and other mechanisms, a link 
between mechanics and biologic processes can be established, allowing for another controllable 
factor to drive the design of biomaterials, and the proscription of rational physical therapy / 
rehabilitation regimens to facilitate functional skeletal muscle restoration.  
 Though attempts to directly relate in vitro strain regimens to the complexities of the in 
vivo response to injury are generally over-reaching, studies have shown that altering strain 
regimens can promote both beneficial and detrimental cell responses322,325,326. The present study 
did not investigate a range of straining protocols, but it is noteworthy that mechanical loading in 
general, and in combination with cues from ECM bioscaffold degradation products, can foster a 
constructive cross-talk between myoblasts and macrophages. The results of this cross-talk 
include immunomodulation, myoblast chemotaxis and differentiation, site-appropriate tissue 
deposition, and increased isometric torque production. Future work would logically be aimed at 
investigating strain-related changes to macrophages, skeletal muscle progenitor cells, myofiber 
alignment, angiogenesis, and innervation among other important components of functional 
skeletal muscle regeneration. Such strain related variables would include a range of strain 
magnitude, duration, and rate in both in vitro constructs and in rehabilitation medicine.   
     There are several limitations to the present study. Macrophage phenotype cannot be 
characterized by analysis of a single marker as this inevitably ignores other important aspects 
such as the metabolic state, gene expression pattern, the secretome, and functional capacity16,327. 
This limitation being recognized, iNOS and Fizz1 are frequently utilized as pro-inflammatory 
and immunomodulatory macrophage markers, respectively, and they have been shown to be 
regulated by mechanical loading and play important roles in ECM remodeling following acute 
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skeletal muscle injury23,328,329. Changes in arginine metabolism by iNOS have been widely 
investigated in skeletal muscle and can affect muscle health23,328, and therefore iNOS and Fizz1 
were chosen as macrophage markers in the present study.  
Another limitation of the present study is the use of only one cell type for analysis of the 
skeletal muscle response to injury. Skeletal muscle regeneration in vivo involves the 
coordination of many cell types, not only myoblasts but also satellite cells330, perivascular stem 
cells43,331, and other myogenic progenitor cells. The effect of mechanical stimulation has been 
investigated particularly in satellite cell involvement312,332,333 but likely will affect most if not all 
of the cell types involved in skeletal muscle regeneration. Finally, though the hind limb 
unloading model sufficiently reduced weight bearing in the remodeling gastrocnemius/Achilles, 
it did not allow for complete immobilization. It is noteworthy, though, that the lack of weight-
bearing alone was clearly detrimental to the remodeling process after ECM intervention. Future 
work should evaluate the effects of complete immobilization, and conversely – overloading of 
the gastrocnemius upon remodeling outcomes to better understand the mechanisms through 
which mechanical stimulation contributes to skeletal muscle repair.  
8.6 CONCLUSION 
The results of the present work substantiate the relevance and importance of incorporation of 
mechanical cues in conjunction with acellular biologic scaffold therapies to support skeletal 
muscle remodeling following volumetric muscle loss. Appropriate mechanical loading may 
narrow the gap between ECM bioscaffold-mediated constructive remodeling and complete 
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skeletal muscle regeneration and has important implications when utilizing biologic scaffold 
therapies for volumetric muscle loss in clinical practice.  
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9.0  AN ACELLULAR BIOLOGIC SCAFFOLD TREATMENT FOR VOLUMETRIC 
MUSCLE LOSS: RESULTS OFA 13-PATIENT COHORT STUDY6 
9.1 ABSTRACT 
Volumetric muscle loss (VML) is a severe and debilitating clinical problem. Current standard of 
care includes physical therapy or orthotics, which do not correct underlying strength deficits, and 
surgical tendon transfers or muscle transfers, which involve donor site morbidity and fall short of 
restoring function. The results of a 13-patient cohort study are described herein and involve a 
regenerative medicine approach for VML treatment. Acellular bioscaffolds composed of 
mammalian extracellular matrix (ECM) were implanted and combined with aggressive and early 
physical therapy following treatment. Immunolabeling of ultrasound-guided biopsies, and 
magnetic resonance imaging and computed tomography imaging were performed to analyze the 
presence of stem/progenitor cells and formation of new skeletal muscle. Force production, range-
of-motion, and functional task performance were analyzed by physical therapists. 
Electrodiagnostic evaluation was used to analyze presence of innervated skeletal muscle. This 
study is registered with ClinicalTrials.gov, numbers NCT01292876. In vivo remodeling of ECM 
                                                 
6 Portions of this chapter were adapted from the following publication:  
Dziki JL, Badylak SF, Yabroudi M, Sicari BM, Ambroiso F, Stearns K, Turner NJ, Wyse A, Boninger ML, 
Brown E, Rubin JP. An acellular biologic scaffold treatment for volumetric muscle loss: results of a 13-
patient cohort study. Nature Regenerative Medicine. July 2016. DOI: 10.1038/npjregenmed.2016.8 
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bioscaffolds was associated with mobilization of perivascular stem cells, formation of new, 
vascularized, innervated islands of skeletal muscle within the implantation site; increased force 
production; and improved functional task performance when compared with pre-operative 
performance. Compared with pre-operative performance, by 6 months after ECM implantation, 
patients showed an average improvement of 37.3% (p < 0.05) in strength and 27.1% 
improvement in range-of-motion tasks (p < 0.05). Implantation of acellular bioscaffolds derived 
from ECM can improve strength and function, and promotes site-appropriate remodeling of 
VML defects. These findings provide early evidence of bioscaffolding as a viable treatment of 
VML.  
9.2 INTRODUCTION  
Volumetric muscle loss (VML) as a result of tumor ablation, trauma, or disease remains a 
challenging clinical problem for which therapeutic options are limited. Current noninvasive 
treatment for VML includes maximizing strength of remaining muscle and bracing. 
Unfortunately, this approach cannot make up for the lost strength associated with VML. Muscle 
transposition or tendon transfer can replace muscle function, but have less than satisfactory 
success rates1,3-5. Such procedures typically involve significant donor site morbidity and fail to 
provide efficient reconstruction or functional re-innervation of the lost muscle tissue. These 
approaches often result in persistent strength and functional deficits, which contribute to 
disability, weakness, and compromised quality of life for patients with VML.  
Skeletal muscle retains a limited capacity to regenerate following a severe acute injury. 
The regenerative process is dependent on resident progenitor cell populations, including satellite 
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cells and myoblasts, which have the potential to proliferate and differentiate into functional 
myofibers. Cell-based regenerative medicine strategies have attempted to augment this 
regenerative process through the delivery of exogenous (typically autologous) stem / progenitor 
cells to the VML defect site. Utilization of enriched muscle-derived stem cells, capable of long-
term proliferation and myogenic potential, has been somewhat successful and has been shown to 
increase the regenerative index when injected into sites of skeletal muscle injury28,29,40. Such 
approaches are limited, however, by issues of low cell viability37, poor cell migration and 
engraftment, and the need for immunosuppressive therapy, among others34,35. In fact, 
immunosuppressive therapy can further contribute to myoblast apoptosis36. Even if an ideal cell 
source and an effective delivery method are utilized, transplanted cells are often associated with 
less-than-optimal proliferative and differentiation potential within the host injury site48. Cell-
centric strategies are also associated with high cost due to the need for ex vivo cell expansion and 
manipulation. While some cell-based approaches have shown promise in preclinical studies, 
regulatory challenges, and a lack of notable efficacy have prevented their widespread adoption of 
treatment for VML151.  
We recently described an acellular bioscaffold approach for treatment of VML in five 
patients that showed encouraging results107. This approach involved the use of extracellular 
matrix (ECM) derived from decellularized porcine urinary bladder to promote scaffold-
associated skeletal muscle tissue formation and partial restoration of function. ECM bioscaffold 
implantation was also associated with the recruitment of endogenous perivascular stem cells 
(PVSCs). While ECM bioscaffolds have been used in reconstructive surgery, they are typically 
employed only as a barrier or reinforcing layer of soft tissue. In our prior report107, we provided 
evidence for functional remodeling of the ECM scaffold with formation of new muscle tissue. 
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An aggressive early post-operative rehabilitation protocol was a component of this strategy to 
place dynamic strain on the ECM and contribute to site-appropriate differentiation of the 
recruited stem / progenitor cells. The mechanism(s) of action responsible for ECM bioscaffold 
mediated VML repair are partially understood and include host cell-mediated scaffold 
degradation and recruitment of endogenous progenitor cells100,107,163,224. The recruitment of 
neurogenic cells and modulation of the innate immune response are also considered as common 
features associated with ECM-mediated constructive remodeling in preclinical 
studies108,179,180,334. Overall, ECM bioscaffolds have been shown to stimulate endogenous 
repair334. 
The present manuscript describes the results from the first 13 patients treated using the 
acellular bioscaffold approach, including results from the first 5 patients previously reported107. 
The results reported herein advance the previously reported findings in several respects: first, it 
expands the number of patients and anatomic sites of VML subjected to treatment; second, it 
includes the use of three different source tissues of ECM bioscaffolds; third, it includes the 
investigation of neurogenic cells as a component of the functional remodeling process; and 
finally, it includes electrodiagnostic evaluation of the remodeled muscle tissue. 
9.3 MATERIALS AND METHODS 
9.3.1 Overview of study design  
A cohort study examining functional and histomorphologic outcomes following VML repair 
with acellular biologic scaffolds was conducted with informed consent and approvals from the 
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Institutional Review Board of the University of Pittsburgh and the US Department of Defense 
Human Research Protection Office (Clinicaltrials.gov, identifier NCT01292876). Subjects were 
screened for established exclusion criteria. A total of 13 subjects were enrolled and subjected to a 
custom designed physical therapy regiment both before and following implantation of one of 
three different xenogenic scaffold materials, all of which were composed of porcine ECM (Table 
5). Patients were enrolled in pre-operative physical therapy and required to reach a functional 
plateau before the surgical procedure so that post-operative improvements in function could not 
be attributed to therapy alone. Force production, functional task improvement, EMG analysis, 
CT or MRI imaging, and histology were used to evaluate return of strength, function, and 
bioscaffold remodeling characteristics at 6-8 weeks, 10-12 weeks, and 24-28 weeks post 
implantation.  
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Table 5. Patient information 
Subject Age  Sex Injury Site (Side) 
Cause of 
Injury 
Months 
Between 
Injury 
and 
Surgery 
Number 
of  
Previous 
Surgeries 
Tissue 
Deficit 
(estimate) 
Device 
Used 
1 34 M 
Anterior Tibial 
Compartment 
(Left) 
Exercise induced 13 5 58% Acell, Matristem® 
2 37 M 
Anterior Tibial 
Compartment 
(Left) 
Skiing accident 32 4 67% Acell, Matristem® 
3 28 M Quadriceps (Left) IED blast 18 14 68% 
Acell, 
Matristem® 
4 27 M Quadriceps (Right) IED blast 89 50 83% 
Acell, 
Matristem® 
5 32 M 
Anterior/Lateral 
Tibial 
Compartment 
(Left) 
Skiing accident 85 8 90% Acell, Matristem® 
6 31 M Brachialis (Left) 
Wakeboarding 
accident 25 0 90% 
Acell, 
Matristem® 
7 31 M Biceps (Right) IED Blast 86 8 33% 
Cook, 
BioDesign® 
8 66 F Quadriceps (Left) MVA 85 1 50.2% 
Cook 
BioDesign® 
9 35 M Quadriceps (Right) MVA 120 6 80% 
Cook 
Biodesign® 
10 44 F Rectus Femoris (Right) Tendon Rupture 7  2 48-56% 
Bard, 
XenMatrix
TM
 
11 31 M Biceps/Deltoid (Left) MVA 72  4 50% 
Cook 
BioDesign® 
12 39 M Sartorius (Left) Electrocution 12   11 25% 
Cook 
BioDesign® 
13 30 M Hamstring (Left) Sports Injury 72  0 27%* 
Bard, 
XenMatrix
TM
 
Average 35.8    55.07 10.0 66.2%  
SEM 10.2    10.5 4.0 6.3  
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9.3.2 Subject selection and screening  
Participants ranging from 18 to 70 years of age with a minimum 20% structural volume deficit as 
determined by MRI or CT, and/or 25% functional deficit of the muscle group mass when 
compared with the contralateral limb were eligible for inclusion in the study. All study subjects 
acquired VML at least 6 months prior to study inclusion. Exclusion criteria included poor 
nutrition, chronic disease, active infection, neoplasia, denervation or other medical comorbidities 
with the potential to impair wound healing.  
Prior to inclusion in the trial, all subjects were screened by a licensed physical therapist to 
establish strength and functional deficits related to the anatomic location of interest, with respect 
to the contralateral limb. A detailed subject history was taken and the subject’s goals for 
participation in the study were recorded. Active and passive range-of-motion measurements were 
obtained at the joints both proximal and distal to the affected area using a goniometer. Isometric 
strength of the affected muscles was quantified using a hand-held dynamometer. Specific 
functional outcome variables were selected and evaluated for each subjected based on their 
functional deficits and the objective measurements of strength and joint range-of-motion. 
Patient-reported outcomes, including the Disabilities of the Arm Shoulder and Hand (DASH) 
scale and Lower Extremity Functional Scale (LEFS) were administered, as appropriate. Subjects 
were also asked to provide a self-report of functional status at each of the tested time points. 
Outcome variables were established a priori for each subject through ha study team consensus 
based on findings from the clinical examination specific to each subject and their observe 
strength and functional deficits. When possible, outcome variables were selected that were 
previously established as valid, reliable, and aligned with the subject’s goals for the trial. Video 
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recordings were performed during evaluations when possible so as to ensure consistency in the 
testing positions across time points.  
 
9.3.3 Surgical procedure  
All procedures were performed in a tertiary care medical center under general anesthesia and 
tourniquet control of the extremity used. The injured muscle compartment was accessed, scar 
tissue was debrided, and selective tenolysis performed. One of the following three ECM 
bioscaffolds was implanted at the site of missing muscle: MatriStem (ACell, Columbia, MD, 
USA); BioDesign (Cook Medical, Bloomington IN, USA), or XenMatrix (C.R. Bard, Warwick 
RI, USA) which were derived from porcine urinary bladder (UBM), small intestinal submucosa 
(SIS), or dermis, respectively. All three scaffold materials were decellularized to meet 
established minimum criteria for DNA removal. MatriStem was used in the first six subjects, and 
the remaining seven subjects received either BioDesign or XenMatrix, randomly assigned. The 
ECM bioscaffold was cut to defect size-matched appropriate length width and implanted within 
the injury site with contact to adjacent native healthy tissue, and secured under tension with 
monofilament absorbable sutures. Care was taken to prevent folding or wrinkling and to ensure 
adequate soft tissue coverage. All empty space was closed before closure of the surgical site to 
ensure maximum scaffold-host tissue interaction, and a closed suction drain was placed.  
9.3.4 Physical therapy  
Subjects were required to participate in rigorous pre-operative physical therapy for 4-16 weeks 
prior to surgery. The goal of the pre-operative physical therapy program was to maximize 
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performance with respect to the strength and functional outcome deficits identified during the 
screening examination. Due to the unique clinical presentation of each subject, physical therapy 
programs were customized for each subject to address the specific strength and functional 
deficits identified during the screening visit. Subjects were evaluated weekly on their progress by 
the treating physical therapist. Subjects were cleared to proceed to surgery after they reached a 
plateau in performance on their involved side, defined as functional gains of < 2-3% over the 
course of any 2-week period, as determined by the treating physical therapist. The treating 
physical therapist was not a member of the investigative team. Outcome variables were tested by 
the same evaluating physical therapist who was a member of the investigative team at each time 
point.  
Post-surgical physical therapy was initiated between 24 and 48 hours following surgery. No 
limitations were placed on the exercises or functional movements within the limits of tolerable 
pain. As early as the first post-operative day, targeted exercises were performed with the goal of 
stimulating muscle contraction and load bearing across the scaffold implantation site. Pain level, 
range-of-motion, strength, and functional capacity were evaluated at each visit, and exercises 
were continued as tolerated. The post-operative physical therapy phase lasted 24 weeks.  
9.3.5 Isometric strength measurement  
Isometric strength testing of the affected limb was measured 1-2 days prior to ECM 
implantation, and again at 6-8 weeks, 10-12 weeks, and 24-28 weeks post-operatively. All tasks 
were performed on both the affected and contralateral limb. Each task was repeated three times, 
and the average of the three trials was calculated as representative of performance on the task.  
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9.3.6 Range-of-motion and functional task analysis 
Range-of-motion and functional task analysis was conducted pre-operatively and at 6-8 weeks, 
10-12 weeks, and 24-28 weeks post-operatively. All tasks were performed on both the affected 
and contralateral limb. Each task was repeated three times, and the average of three trials was 
calculated as representative of performance on the task.  
9.3.7 Pre- and post-surgical imaging  
Initial pre-operative CT imaging was performed on a 64-slice CT scanner (LightSpeed VCT, GE 
Healthcare, Chicago, IL, USA) at a slice thickness of 1.25 and 2.5 mm and a pitch of 1.375 in 
both bone and soft tissue algorithms. MRI protocols included a variety of sequences in sagittal, 
coronal, and axial planes using T1-weighted spin echo, T2-weighted fast spin echo with or 
without fat suppression, and STIR sequences. The KVp and mA were optimized with respect to 
the subject habitus and site imaged. Coronal and sagittal reformations were obtained. Three-
dimensional volumetric reformatted imaging was also performed using Vitrea (Vital Images, 
Minnetonka, MN, USA) with surface rendering, as well as emphasis on the underlying 
musculature and osseous structures. Pre-operative imaging was reviewed by a musculoskeletal 
trained radiologist (4 years’ experience). Initial CT imaging was assessed primarily for the 
presence of volumetric loss of bulk and/or fatty infiltration in the affected musculature. The 
overall percentage loss of muscle volume and severity of fatty infiltration was graded, where 
appropriate. Imaging was also evaluated for concomitant soft tissue (e.g. tendinous) and osseous 
injury. Post-operative imaging was performed at a ~ 7-month interval with similar imaging 
parameters. Post-operative imaging included characterization of the location and appearance of 
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the surrounding musculature. Overall percentage change in affected muscle volume was 
measured.  
9.3.8 Ultrasound-guided core biopsy of ECM  
Ultrasound-guided biopsy of the surgically-placed ECM was performed ~ 6 weeks and 26 weeks 
post-operatively. Pre-procedural grayscale and color/Power Doppler ultrasound of the operative 
site was performed to identify and characterize the surgically-placed ECM. After an appropriate 
needle trajectory was selected, the area was prepped and draped in sterile fashion. Local 
anesthesia with skin infiltration and deeper injection was achieved with 1% lidocaine. Under 
ultrasound guidance, biopsy samples of the ECM bioscaffold and surrounding soft tissue were 
obtained using an 18-gauge spring-loaded biopsy needle (Temno, CareFusion, McGaw Park, IL, 
USA). A total of eight core samples were obtained at two separate biopsy sites. Biopsies spanned 
the proximal to distal length and medial to lateral width of the implantation site. Specimens were 
snap-frozen in liquid nitrogen and stored at -80°C.  
9.3.9 Electrodiagnostic studies  
As previously reported, nerve conduction and electromyography studies were performed for 8 of the 13 
subjects using a Synergy EMG machine (Cardinal Health, Dublin, OH, USA). The specific nerve 
conduction studies completed and the specific muscles tested with needle examination were determined 
by location of the VML. Needle EMG analysis used concentric needle electrodes placed in the standard 
muscle belly and was performed at the proximal and distal site of the injured muscle if the standard 
muscle belly showed no evidence of electrical activity. Improvement in nerve conduction was defined as 
> 20% increase in motor nerve conduction amplitude. For EMG studies, improvement was defined as 
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either evidence of increased firing in volitional recruitment of muscles or a decrease in abnormal 
spontaneous activity compared with pre-operative results. Differences in amplitudes of CMAP were 
compared between pre-and post-ECM bioscaffold implant. 
9.3.10 Histology and immunolabeling  
Frozen tissue sections were fixed in an ice cold 50:50 solution of methanol/acetone for 5 min and 
washed in phosphate-buffered saline (PBS). Tissue sections were incubated in blocking buffer to 
prevent non-specific antibody binding composed of 1% (w/v) bovine serum albumin (BSA), 2% 
(v/v) normal horse serum, 0.05% (v/v) Tween-20, 0.05% (v/v) Triton X-100 in PBS for 1 h at 
room temperature. Tissue sections were then incubated with primary antibodies diluted in 
blocking buffer as follows: mouse monoclonal CD146 (Abcam, Cambridge, MA, USA) at 1:350 
and rabbit polyclonal Neurogenin-2 (NG2, Millipore, Billerica, MA, USA) at 1:200 as 
perivascular stem cell markers, monoclonal anti-desmin (Abcam) at 1:200 for a muscle cell 
marker, and β-III tubulin at 1:200 for a neurogenic marker. After 16 h of incubation at 4°C, 
tissue sections were washed with PBS and incubated with fluorphore-conjugated secondary 
antibodies (Alexa Fluor donkey anti-mouse 488 or 594 or donkey anti-rabbit 488, Invitrogen, 
Carlsbad, CA, USA) for 1 h at room temperature. After secondary incubation, nuclei were 
counterstained with 4’6-diamidino-2-phenylindole (DAPI) and slides were coated with anti-fade 
mounting media (Dako, Carpinteria, CA, USA). Tissue sections were imaged using a Zeiss 
Axio-observer Z1 microscope using a x20, 0.4 numerical aperture objective with a 1.6x optovar 
magnification changer (Carl Zeiss, Oberkochen, Germany). Three fields of view were taken from 
each biopsy sample.  
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9.4 RESULTS  
9.4.1 Biologic scaffold implantation for the treatment of VML is associated with increased 
skeletal muscle force production  
Thirteen subjects with VML were enrolled in this cohort study and the average tissue deficit for 
all patients was 66.2%, when compared with the contralateral limb (Table 5). All subjects met 
established inclusion criteria (Table 10) and had received standard of care options, including 
surgical intervention and/or physical therapy. Strength testing showed that 7 of 13 patients had 
improvement from their pre-surgical maximum strength as early as 6-8 weeks after surgery, by 
an average of 15.2% + 12.6 with a maximum of 127.9% and a minimum of -33.3% (Table 6). By 
10-12 weeks, patients showed an average change of 21.1% + 12.2 with a maximum of 149.2% 
and a minimum of -33.0%. At 24-28 weeks, patients showed an average force production 
changed of 37.3% + 12.4 with a significant improvement when compared with pre-operative 
measurements (P < 0.05), with a maximum of 136.1% and a minimum of -17.88%.  
9.4.2 Biologic scaffolds for VML treatment are associated with improved range-of-motion 
and functional outcomes 
Tasks to assess range-of-motion were performed and data is reported for all patients who showed 
range-of-motion deficits pre-operatively. At 6-8 weeks post-surgery, all tested subjects showed 
improvement in at least one range-of-motion task with an average change of 16.7% + 4.9. At 10-
12 weeks, average range-of-motion change compared with pre-operative measures was 
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significantly increased (P<0.05) at 24.0% + 6.8. By 24-28 weeks after surgery, this improvement 
increased to 27.1% + 10.5 (p<0.05) (Table 7). 
At 6-8 weeks post-surgery, 10 out of 13 patients showed > 20% improvement in 
performance of at least one functional task when compared with pre-surgical performance (range 
20-1980%). By 10-12 weeks, 12 of 13 patients showed a > 20% improvement (range 20-2460%), 
and by 24-28 weeks 9 of 13 patients showed a > 20% improvement (range 25-1820%). Patient 3 
showed particularly notable improvement in the single-leg hop test improving by 1980%, 
2460%, and 1820% at 6-8, 10-12, and 24-28 weeks after surgery, respectively (Table 11). Patient 
5 showed a dramatic increase in single-leg jump landing distance, improving by 400%, 783.3%, 
and 1050% at 6-8, 10-12, and 24-28 weeks after surgery, respectively (Table 11). Likewise, 
patient 8 showed improvements in the single-leg step down task of 200%, 900%, and 1600% 
(Figure 26). Twelve of thirteen patients showed improvement in at least 1 functional task by 24-
28 weeks after surgery.  
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Table 6. Force production 
Subject Injury Site (Side) Activity Baseline force 
measurement (lb) 
6-8 weeks post 
surgical (%) 
10-12 weeks post 
surgical (%) 
24-28 weeks post 
surgical (%) 
1 Anterior Tibial 
Compartment 
(Left) 
Dorsiflexion  0.0 0.0 0.0 
2 Anterior Tibial 
Compartment 
(Left) 
Dorsiflexion  0.0 0.0 0.0 0.0 
3 Quadriceps 
(Left) 
Knee extension  6.0 -10.0 18.3 20.0 
4 
Quadriceps 
(Right) 
Knee extension 6.1 127.9 149.2 136.1 
5 Anterior/Lateral  
Tibial Compartment 
(Left) 
Dorsiflexion  3.6 -33.3 16.7 33.3 
6 Brachialis 
(Left) 
Biceps Flexion 35.8 NT -19.5 -17.9 
7 
Biceps 
(Right) 
Wrist 
supination   
Biceps flexion 
42.0 
38.1 
66.7 
12.3 
102.4 
7.6 
126.2 
16.8 
8 Quadriceps 
(Left) 
Knee extension 10.3 15.0 12.0 64.1 
9 
Quadriceps 
(Right) 
Knee extension 33.3 19.0 27.0 61.9 
10 
Rectus Femoris 
(Right) 
Knee extension 6.6 11.0 30.0 86.4 
11 
Biceps/Deltoid 
(Left) 
Shoulder 
abduction 
Shoulder 
flexion 
Shoulder 
extension 
Elbow flexion 
Elbow 
extension 
69.2 
46.6 
51.3 
66.9 
49.0 
-4.6 
41.9 
13.3 
0.0 
-8.2 
-4.1 
42.5 
22.6 
-0.3 
31.0 
20.1 
104.1 
46.8 
-4.0 
1.6 
12 
Sartorius 
(Left) 
Hip flexion 
Knee extension 
68.1 
92 
NT -15.6 
-28.0 
-3.5 
-1.1 
13 
Hamstring 
(Left) 
Knee flexion 
Knee extension 
53.5 
99.2 
11.8 
-33.0 
11.0 
-33.0 
-3.4 
0.5 
   Average 15.2 21.1 37.3
#
 
   SEM 12.6 12.2 12.4 
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Table 7. Range of motion 
Subject Injury Site (Side) Activity Baseline force 
measurement (deg) 
6-8 weeks post 
surgical (%) 
10-12 weeks post 
surgical (%) 
24-28 weeks post 
surgical (%) 
1 Anterior Tibial 
Compartment 
(Left) 
  0.0 0.0 0.0 
2 Anterior Tibial 
Compartment 
(Left) 
Active dorsiflexion 
Passive dorsiflexion 
0 
8 
0.0 
50.0 
0.0 
88.0 
0.0 
88.0 
3 Quadriceps 
(Left) 
Active knee 
extension 
22 18.2 18.2 18.2 
4 Quadriceps 
(Right) 
Active knee 
extension 
40 25.0 38.0 NT 
5 Anterior/Lateral  
Tibial Compartment 
(Left) 
Active dorsiflexion 
Passive dorsiflexion 
0 
10 
0.0 
20.0 
0.0 
20.0 
0.0 
NT 
6 
Brachialis 
(Left) 
External rotation 
(elbow 90°) 
Internal rotation 
(elbow 90°) 
31 
29 
NT 
NT 
32.9 
33.5 
13.6 
43.5 
8 Quadriceps 
(Left) 
Active knee 
extension 
45 11.1 -11.1 0.0 
11 
Biceps/Deltoid 
(Left) 
Shoulder external 
rotation 
Shoulder internal 
rotation 
Shoulder flexion 
Shoulder extension 
35.2 
46.2 
46.6 
51.3 
-11.7 
33.6 
41.2 
13.3 
8.5 
42.4 
42.5 
22.6 
-30.4 
41.6 
104.1 
46.8 
   Average 16.7 24.0# 27.1# 
   SEM 4.9 6.8 10.5 
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Figure 26. Functional task performance. Functional measures as assessed by task / exercise completion 
from each patient. Data represent percent change from pre-surgical maximum. NT=not tested. 
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9.4.3 ECM bioscaffold implantation is associated with PVSC mobilization, 
electromyographic evidence of innervation, the presence of neurogenic cells at the 
remodeling site, and muscle formation 
Tissue biopsies of the remodeling implantation site were obtained at 6-8 weeks, 10-12 weeks, 
and 24-28 weeks post-surgery, and showed a robust mononuclear cellular infiltration into the 
bioscaffold site along with evidence of muscle formation into the bioscaffold site along with 
evidence of muscle formation as early as 6-8 weeks post-surgery (Figure 27A), which was 
increased at each subsequent biopsy time point. Immunolabeling studies showed CD146+NG2+ 
PVSCs localized around vWF+ vessels at all time points (Figure 27G-I). PVSCs were also found 
removed from their normal anatomic location, suggesting their potential contribution to skeletal 
muscle formation (Figure 27J-L). Desmin+ cells with central nuclei were present as early as 6-8 
weeks post-surgery (Figure 27D) with striated desin+ muscle fibers present in all biopsy samples 
at both 10-12 and 24-28 weeks after surgery (Figure 27E-F). These desmin+ muscle fibers were 
present at locations both near the interface with native uninjured muscle and within the center of 
the scaffold site with no evidence for continuity with adjacent native healthy muscle. Biopsies 
also showed an increase in the presence of β-III tubulin+ nerve bundles by 6 months after 
implantation throughout the scaffold implant site (Figure 27O) CellProfiler (Broad Institute, 
Cambridge, MA, USA) quantification showed no significant differences in the number of 
migrating PVSCs or vessels between time points (Figure 27M-N). 
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Figure 27. Site-appropriate tissue remodeling by ECM bioscaffolds (A-C) Masson's trichrome staining 
of human muscle biopsies shows islands of skeletal muscle present at 6-8 weeks, 10-12 weeks, and 24-28 weeks 
post surgery, respectively. (D-F) Human muscle biopsies are characterised by desmin expression at all time points, 
indicating new muscle formation within the site of implantation. (G-I) ECM bioscaffold implantation is associated 
with the presence of CD146+NG2+ perivascular stem cells. (J-L) PVSCs were shown to migrate away from their 
normal vessel associated anatomic location at all time points. Arrows indicate CD146+ PVSCs migrating away from 
vessels. (M,N) Migrating PVSCs and vasularity were quantified using CellProfiler Image Analysis software. (O) At 
24-28 weeks post surgery, ECM bioscaffold implantation was associated with the presence of β-III tubulin+ cells, 
implicating innervated skeletal muscle (Scale bars = 50µm) 
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9.4.4 ECM scaffolds degrade following implantation  
Representative ultrasound imaging at 1 month after surgery showed a sheet-like hyperechoic 
structure consistent with the ECM scaffold overlying and adjacent to the native uninjured muscle 
(Figure 28A). By 7 months, BioDesign (SIS-ECM) and Matristem (UBM-ECM) ECM scaffold 
materials were no longer identifiable (Figure 28B,D) whereas XenMatrix (dermis-ECM) ECM 
scaffold was still identifiable (Figure 28F). In addition, increased muscle tissue, identified by an 
imaging signal consistent with muscle, was present at the site of ECM scaffold placement 
(Figure 28).  
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Figure 28. Ultrasound imaging shows that ECM bioscaffolds degrade upon implantation. (A) 
Grayscale ultrasound image 1 month after surgery in the posterior shoulder demonstrates a thin, sheet-like 
hyperechoic structure, representing SIS-ECM (yellow arrows) overlying the posterior deltoid muscle. The posterior 
deltoid muscle is increased in echogenicity due to underlying fatty infiltration. (B) Ultrasound imaging 7 months 
after surgery shows that surgically-placed SIS-ECM is no longer identifiable superficial to the posterior deltoid. 
(C)Ultrasound image 1 month after surgery in the medial mid thigh demonstrates an ill-defined hypoechoic structure 
representing SIS-ECM (yellow arrows) adjacent to the sartorius muscle. (D) Ultrasound image 7 months after 
surgery shows that surgically-placed SIS-ECM is no longer identifiable and the sartorius muscle apears to have 
enlarged. (E) Ultrasound imaging 1 month after surgery in the posterior mid thigh demonstrates a shet-like 
echogenic structure representing dermal ECM (yellow arrows) with surrounding complex anechoic material 
(dashed-blue line) likely representing post-operative fluid collection. (F) Ultrasound imaging 7 months after surgery 
shows dermal ECM (yellow arrows) has decreased in echogenicity and now has a tubular or 'rolled-up' appearance 
as opposed to a sheet-like appearance. The previously identified post-operative fluid collection has essentially 
resolved 
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9.4.5 ECM treatment increases bulk muscle content  
Before surgery, the average percent of muscle loss ranged from 25-90% of contralateral limb 
tissue (Table 5). By 8 months, computed tomography (CT) or magnetic resonance imaging 
(MRI) showed an increase in dense tissue consistent with that of skeletal muscle within the 
implantation site. Post-operative muscle bulk was calculated by selecting a region-of-interest in 
CT or MRI images. Bulk muscle increased in all patients post-operatively with an average 
increase of 27.2% (Figure 29). Interestingly, patient 13 showed complete atrophy and absence of 
hamstrings due to rupture pre-operatively. Following ECM treatment, the implant site was 
replaced with tissue characterized by an imaging signal consistent with muscle at measurements 
of 5.45 cm2, 6.90 cm2, and 7.39 cm2, at the proximal, middle, and distal aspect of the defect in 
the posterior compartment, respectively (Figure 29).  
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Figure 29. Representative CT imaging shows ECM bioscaffold implantation increases post-operative 
bulk muscle content. Overall, the area of the treated muscle was measured at three representative sites (proximal, 
middle, and distal) both prior to surgery and 7 months after surgery in multiple anatomic locations 
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Table 8. Nerve conduction study of eight of thirteen patients  
 Latency/Amplitude 
(ms/mV) 
Subject Evaluation site Contralateral  Pre-op Post-op 
1 Peroneal motor 2.5/3.7 2.6/3.7 2.5/2.5 
2  Peroneal motor 2.7/6.8 2.8/2.5 2.5/2.5 
3  Femoral motor 3.0/9.7 2.7/3.9 3.6/4.8 
4  Femoral motor NT/NT 3.1/10.9 3.6/4.8 
5 Peroneal motor 3.7/10.0 2.3/1.7 2.1/1.5 
7  Musculocutaneous Motor 2.1/8.4 2.6/5.6 3.4/6.9 
8 Femoral motor 2.5/7.2 1.2/3.8 2.9/5.0 
9 Femoral motor NT/NT 2.6/9.7 4.6/5.4 
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9.4.6 ECM bioscaffold implantation improves electrophysiological function 
Electrodiagnostics studies were conducted on 8 of the 13 patients. At baseline, seven of the eight 
tested subjects presented with patterns of mononeuropathies, with three subjects with anterior 
compartment injures in the lower leg presenting with deep peroneal mononeuropathy and three 
of the four subjects quadriceps injury presenting with femoral mononeuropathy and one 
individual presented no abnormal finding. The abnormalities were limited to the injury site and 
did not extend distally along the nerve. Two tested subjects showed severe atrophy with 
undetectable compound motor action potentials (CMAPs). Post-operatively, four subjects 
increased CMAP amplitude: one in the tibialis anterior, two in the vastus medialis, and one in the 
biceps brachii (Table 8). The remaining subjects showed no appreciable change in nerve 
conduction. Electromyography (EMG) analysis showed disappearance in abnormal spontaneous 
activity and improved recruitment patterning following ECM bioscaffold implantation (Table 9).  
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Table 9. Needle electromyography 
Subject Evaluation site Pre-op Post-op 
1 Tibialis anterior ASA - - 
Recruitment No unit No unit 
2 Tibialis anterior ASA - - 
Recruitment No unit No unit 
3 Vastus medialis ASA ++++ +++ 
Recruitment No unit No unit 
Vastus intermedius ASA ++++ +++ 
Recruitment MD GD 
Vastus lateralis ASA +++ +++ 
Recruitment GD No unit 
4 Vastus medialis ASA +++ +++ 
Recruitment No unit No unit 
Vastus intermedius ASA ++ - 
Recruitment No unit No unit 
Vastus lateralis ASA - + 
Recruitment Normal Normal 
5 Tibialis anterior ASA ++ - 
Recruitment GD SD 
Extensor digitorum longus ASA ++ - 
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Recruitment Single unit SD 
7 Biceps 
(proximal) 
ASA - - 
Recruitment Normal Normal 
Biceps 
(distal) 
ASA NT ++ 
Recruitment NT poly 
8 Vastus medialis ASA + - 
Recruitment Normal Normal 
Vastus intermedius ASA - - 
Recruitment Normal Normal 
Vastus lateralis ASA - - 
Recruitment Normal Normal 
9 Vastus medialis ASA - - 
Recruitment Normal Normal 
Vastus lateralis ASA - - 
Recruitment Normal Normal 
Rectus femoris ASA - - 
Recruitment Normal Normal 
 
 
 
 
Table 9 (continued) 
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Table 10. Inclusion and exclusion criteria 
Exclusion criteria Inclusion criteria 
Inability to provide informed 
consent 
18 to 70 years of age 
Poor nutrition (demonstrated by 
abnormal lab range for serum 
albumin) 
Civilian and current or former military personnel are eligible 
Cancer diagnosis within the last 12 
months 
Minimum structural deficit of 20% of muscle group mass 
Complete muscle/tendon gaps 
greater than 5 cm 
Minimum functional deficit of 25% when compared to 
contralateral limb 
Infection Injury may encompass a single muscle belly or compartment  
Known coagulopathy Injury suffered within the last 18 months; subjects may be enrolled 
with injury outside this range if PI determines there is viable 
muscle in the injured compartment by clinical exam and imaging 
analysis 
Diagnosis of schizophrenia or 
bipolar disorder 
Eligible for study procedures 3 months post injury 
Chronic disease (i.e. congestive 
heart failure, liver disease, renal 
disease, diabetes) 
Willing and able to comply with follow up examinations 
radiographic studies, physical therapy, muscle biopsy, and 
laboratory tests 
Active and unstable disease state 
or infection per doctor’s evaluation 
 
Pregnancy  
Hypersensitivity to bovine serum 
or porcine products 
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Table 11. Functional task raw data 
Subject Activity Baseline measurement 
(pre-op) 
6-8 weeks post 
surgical (%) 
10-12 weeks post 
surgical (%)  
24-28 weeks post 
surgical (%)  
1 Single leg stance 
(eyes closed) 
Get up and go 
13.3 s 
5.0 s 
50.0 
4.0 
-81.2 
2.0 
-7.0 
14.0 
2 Single leg stance 
(eyes open) 
Single leg stance 
(eyes closed) 
Forward reach (in) 
Backward reach (in) 
Stork balance test (s) 
Single limb jump 
landing (in) 
Triple hop test (in) 
>15 s 
> 30 s 
8.33 in 
4.67 in 
30 s 
66.4 in 
220 in 
0.0 
-1.0 
12.0 
91.0 
33.0 
15.0 
5.0 
0.0 
89.0 
32.0 
109.0 
41.0 
18.0 
8.0 
0.0 
120.0 
56.0 
114.0 
27.0 
8.0 
6.0 
3 Single leg squats 
(reps) 
Single hop (in) 
Triple hop (in) 
LEFS 
unable 
1.25 in 
unable 
45/80 
unable 
1980.0 
24.2 (compared to 
contralateral) 
22.2 
4.0 (compared to 
contralateral) 
2460 
29.3 (compared to 
contralateral) 
22.20 
13.3 (compared to 
contralateral) 
1820 
29.5 (compared to 
contralateral) 
35.56 
4 Single leg squats 
(reps) 
Single hop for 
distance (in) 
Triple hop (in) 
LEFS 
Chair lift test (reps) 
6 reps 
16 in 
52 in 
61 
38 reps 
NT 
NT 
NT 
NT 
NT 
100 
-38 
-21 
6.56 
84 
317 
25 
-9 
3 
274 
5 Single leg stance 
(eyes open) 
Single leg stance 
(eyes closed) 
Forward reach (in) 
Backward reach (in) 
Stork balance test (s) 
27.1 s 
10.0 s 
12.5 in 
6 in 
Unable 
3 in 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
232 
0 
12 
33 
Unable 
400 
232 
20 
24 
67 
Unable 
783 
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Single limb jump 
landing (in) 
Triple hop (in) 
LEFS 
 
45.5 in 
44 
 
NT 
 
49 
9 
 
115 
2 
6 Box and blocks test 
(s) 
Pull ups (reps) 
76 s 
4 reps 
NT 
NT 
-5.3 
25.0 
-7.9 
-25.0 
7 Push ups (reps) 
Pull ups (reps) 
Elbow flexion 
endurance (s) 
43 reps 
5 reps 
43 s 
2.3 
-25 
120.93 
14.0 
0 
116.28 
9.0 
-20.0 
272.09 
8 Single leg squats 
(reps) 
Single leg hop for 
distance (in) 
Triple hop (in) 
Single leg wall sit (s) 
Single leg step down  
(reps) 
4 reps 
Unable 
Unable 
30 s 
1 rep 
125.0 
unable 
unable 
-26.7 
200.0 
50.0 
unable 
unable 
-30.0 
900.0 
500.0 
unable 
unable 
10.0 
1600 
9 Single leg squats 
(reps) 
Single leg hop (in) 
Triple hop test (in) 
Single leg wall sit (s) 
Single leg step down 
(reps) 
Single leg step up 
(reps) 
11 reps 
15 in 
42 in 
23 s 
1 rep 
10 reps 
45.0 
-13.0 
unable 
78.3 
600.0 
130.0 
100.0 
20.0 
unable 
117.0 
1200.0 
360.0 
127.3 
33.0 
42.9 
143.0 
2200.0 
630.0 
Table 11 (continued) 
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10 Single leg squats 
(reps) 
Single leg step up 
(reps) 
Single leg hop (in) 
Triple hop test (in) 
Single leg wall sit (s) 
Single leg step down 
(reps) 
0 reps 
0 reps 
0 in 
0 in 
0 s 
0 reps 
0 
100 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
100 
0 
0 
1900 
0 
11 Push ups (reps) 
Pull ups (reps) 
23 reps 
2 reps 
-11.7 
0 
8.6 
0 
-30.4 
0 
12 Single leg hop (in) 
Triple hop test (in) 
Single leg wall sit (s) 
Single leg step down 
(reps) 
14.5 in 
67 in 
18 s 
4 reps 
NT 
NT 
NT 
NT 
59.0 
22.0 
106.0 
425.0 
88.3 
82.1 
67.0 
700.0 
13 Single leg squats 
(reps) 
Single leg step up 
(reps) 
Single leg hop (in) 
Triple hop test (in) 
Single leg wall sit (s) 
Single leg step down 
(reps) 
Single leg bridge 
(reps) 
Single leg bridge (s) 
15 reps 
77 reps 
39.5 in 
141 in 
69 s 
14 reps 
11 reps 
25 s 
67.0 
134.0 
20.0 
16.0 
1.5 
36.0 
136.4 
100.0 
87.0 
147.0 
16.0 
19.0 
43.0 
93.0 
182.0 
108.0 
106.7 
30.0 
24.0 
32.0 
52.0 
164.0 
309.0 
300.0 
 
Table 11 (continued) 
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Figure 30. Overview of study design. Patients underwent 6-8 weeks of pre-operative physical therapy 
followed up to 28 weeks of post-operative physical therapy. Tissue biopsies and functional assessments were 
evaluated 6-8, 10-12, and 24-28 weeks after ECM implantation. 
 
 
Figure 31. Representative gross changes of quadriceps following ECM implantation. Gross 
appearance of injury site of patient 3 pre-operatively and 28 weeks post-ECM implantation 
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Figure 32. ECM promotes muscle formation (A,C,E) ) Before surgery, at this level of the proximal 
aspect in the posterior compartment, patient 13 shows complete absence or atrophy of hamstrings. ECM 
imlpantation is associated with an increase in post-operative bulk muscle with areas measuring 5.4, 6.9, and 7.3 cm2 
at the proximal, distal, and middle aspect of the posterior compartment, respectively (B,D,F). 
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9.5 DISCUSSION 
The present study provides a comprehensive analysis of the structural remodeling, strength, and 
functional outcomes after VML defects were treated with extracellular matrix (ECM) 
bioscaffolds in thirteen human subjects. The study corroborates and extends the findings of 
previous work by not only increasing the number of patients, but also utilizing three different 
forms of ECM bioscaffolds, identifying neurogenic cell types in the remodeling site, and 
documenting electrophysiologic evidence of innervation and its association with functional 
remodeling outcomes.  
Acellular bioscaffolds for VML treatment represent an “off-the-shelf” approach to 
muscle repair. As opposed to cell-based strategies, a bioscaffold approach obviates the 
requirements of cell isolation, manipulation, expansion, storage, and delivery strategies. In the 
present study, ECM bioscaffolds derived from three different xenogeneic (porcine) source tissues 
– small intestinal submucosa (SIS), urinary bladder matrix (UBM), and dermal ECM were 
utilized. The first five patients were treated with UBM as previously reported, and the 
subsequent eight patients were treated with a randomly assigned scaffold derived from UBM, 
SIS or dermal ECM. To conclusively discriminate between the abilities of each scaffold type to 
promote muscle remodeling would require a much larger study. Although our study was not 
powered to detect variation based on ECM, no differences in outcomes were seen based upon 
bioscaffold used. These findings suggest that though the mechanical and physical properties vary 
between the three scaffold types, the signaling mechanisms associated with each type of scaffold 
seem to be similar and a spectrum of commercially available products can be used for this 
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therapeutic approach. A comparative analysis of the differences between ECM source tissues and 
their effects upon skeletal muscle reconstruction could only be reliably performed in a very large 
sample due to the variety of anatomic sites at which they need to be placed. Each of the 
bioscaffolds used differ in their preparation methods including method of decellularization and 
terminal sterilization. Such differences will logically confer differences in their mechanical and 
biochemical properties. Further investigation could provide insight into the preparation 
parameters that are associated with positive tissue remodeling outcomes and could implicate the 
specific bioscaffold constituents and/or properties that contribute to ECM-mediated skeletal 
muscle remodeling. 
While the exact mechanism(s) by which ECM bioscaffolds promote constructive tissue 
remodeling are only partially understood, previous work has shown that their degradation upon 
implantation generates low molecular weight matricryptic oligopeptides with the ability to 
recruit and influence endogenous progenitor cells78,109. It has been shown that perivascular stem 
cells (PVSCs) play a role in ECM-mediated skeletal muscle repair107. The present study shows 
CD146+NG2+ PVSCs are not only localized around their typical microvascular niche, but, 
following ECM implantation, mobilize away from this traditional anatomic site. All muscle 
biopsies showed this phenomenon as well as evidence for neovascularization and the presence of 
site-appropriate desmin+ striated muscle as early as six weeks after bioscaffold implantation. 
The ability of ECM bioscaffolds to influence the local skeletal muscle injury microenvironment 
may allow for synergy and cross-talk between PVSCs, myoblasts, neuronal progenitors, and 
other responding cell types which contribute to skeletal muscle formation at the implant site. The 
presence of PVSCs and myoblasts within this site strongly suggests their participation in the 
remodeling process. Whether or not the behavior of PVSCs and myoblasts is mediated directly 
 163 
by signaling from the ECM or via paracrine mechanisms is unknown; however, it is plausible 
and logical that other stem and progenitor cell populations also play a role in this constructive 
and functional remodeling process. Many progenitor cell populations have been shown to 
contribute to myogenesis following injury. PVSCs are among the most primitive source of stem 
cells that have been shown to give rise to myogeneic cells. In fact, such cells have been shown to 
give rise to satellite cells, the putative skeletal muscle precursor.  
Desmin+ skeletal muscle fibers were found not only at the interface of the bioscaffold 
with native, adjacent, uninjured muscle, but also within the center of the scaffold implantation 
site. The spatial distribution of skeletal muscle fibers clearly separated from the interface with 
adjacent uninjured native muscle suggests de novo skeletal muscle generation rather than simple 
integration of native muscle with the scaffold-filled defect site. In vitro studies have shown the 
ability of ECM signaling molecules to promote mitogenesis and myogenesis of skeletal muscle 
progenitor cells78. The presence of β-III tubulin+ cells in association with these new islands of 
skeletal muscle, combined with positive EMG recordings, further supports the conclusion that 
functional islands of new skeletal muscle have been formed.  
The degradation rate of biologic scaffolds has been investigated and studies have shown 
that this degradation is rapid – with the ECM being completely replaced by host tissue by 90 
days. There is evidence of islands of new skeletal muscle formation present throughout the 
collagenous tissue. However, we cannot determine with certainty whether this collagen is from 
the implanted ECM bioscaffold or is newly deposited host tissue ECM within the implant site. 
However, the accurate real time imaging enabled precise retrieval of tissue from the zone of 
regeneration. Moreover, the histologic findings are consistent with new muscle formation, and 
not mature native muscle or scar tissue. 
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CT or MRI imaging corroborated the histologic findings showing an increase in post-
operative soft tissue formation consistent with bulk skeletal muscle tissue in all thirteen patients. 
Whether or not this increase was due to an increase in the size or the number of muscle fibers 
requires further investigation. However, the needle EMG findings of decreased ASA and 
improved recruitment would seem to indicate new muscle fiber formation.   
The histomorphologic and imaging studies were accompanied by clear and clinically 
relevant functional improvement. Two of the thirteen patients showed an unappreciable change 
in force production compared to pre-operative outcomes, but eleven of thirteen patients increased 
their pre-operative force production measured via dynamometer by 20% to 140% at six months 
after surgery. Twelve out of thirteen patients showed improvement in functional task 
performance. It is important to note that all patients had previously undergone standard of care 
treatments, and custom designed, aggressive physical therapy regimens prior to ECM 
implantation and showed a plateau in force production or functional task performance. The 
improvements in performance following ECM bioscaffold implantation are thus likely due to 
ECM intervention. The importance of a rigorous physical therapy program following ECM 
implantation and its association with successful outcomes should not be underestimated. The 
application of a physiologic mechanical load (i.e., concomitant physical rehabilitation) during the 
entirety of the remodeling period following ECM implantation has been shown to promote 
favorable outcomes60,61,258,322. It has been suggested that ECM bioscaffolds contribute to force 
improvement by simple force transduction based upon results of a rodent model in which post-
operative physical therapy could not be controlled226. While the scar release of the procedure and 
the mechanical transduction effect of the ECM layer may both be contributing factors to the 
improved function, the histologic imaging and electrophysiologic evidence of vascularized, 
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innervated skeletal muscle within the defect site in the present cohort of human patients suggests 
a positive and contributing role for new skeletal muscle in the functional outcomes. Taken 
together, the data from this study shows that ECM implants for soft tissue reconstruction, while 
long regarded as a passive reinforcing layer, can undergo important functional remodeling during 
the healing process.  
Electrodiagnostic studies conducted on eight of the thirteen patients showed concomitant 
nerve and muscle remodeling following ECM treatment. Specifically, seven subjects presented 
with a pre-operative electrodiagnosis of incomplete mononeuropathy in the area of the VML 
defect. After treatment with ECM, five of the eight patients showed improvements in nerve 
conduction or needle electromyography parameters including compound motor action potential 
(CMAP). These results indicate electrically active, functionally innervated muscle. Electrical 
activity present within the ECM implant site is consistent with a concomitant strength 
improvement. Histologic outcomes further corroborate these results showing presence of β-III 
tubulin+ cells within the remodeling site by six months after surgery. 
The present study has several limitations. It was not possible to include an untreated 
control to determine the effects of scar tissue debridement and tenolysis alone. However, twelve 
of thirteen patients had been subjected to extensive standard of care therapy (i.e. average of ten 
previous surgeries across all patients) and failed to improve. Placebo effects (i.e. patients having 
more confidence after treatment which could translate to improved functional outcomes) were 
uncontrolled. Although histologic outcomes show the presence of perivascular stem cells and 
desmin+ muscle fibers within the ECM implantation site, and these findings were associated 
with improved functional and strength outcomes, the present study does not provide conclusive 
evidence that there is a causal relationship between the presence of these cells and the 
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downstream functional improvements. The diverse nature of anatomic implant sites and physical 
therapy activities performed by the subjects made determination of an “average” functional 
improvement following bioscaffold implantation impossible. No two patients had the same 
injury or comorbidities, and thus each had a personalized physical therapy regimen composed of 
specific exercises depending on the site of injury and other comorbidities.   
The results of this thirteen patient cohort study show that an acellular biologic scaffold 
approach can facilitate constructive and functional tissue remodeling following volumetric 
muscle loss. The mechanisms by which such materials mediate remodeling effects appear to 
include recruitment of myogenic progenitor cells, improved innervation, and functional skeletal 
muscle formation. The findings reported herein support the use of ECM bioscaffolds as a viable 
treatment option for VML treatment. 
9.6 ACKNOWLEDGEMENTS 
The US Department of Defense’s Limb Salvage and Regenerative Medicine Initiative and the 
Muscle Tendon Tissue Unit Repair and Reinforcement Reconstructive Surgery research study is 
collaboratively managed by the Office of the Secretary of Defense. The Initiative is focused on 
rapidly and safely transitioning advanced medical technology in commercially viable capabilities 
to provide our wounded warriors the safest and most advanced care possible today. We would 
like to gratefully acknowledge the work of Ally Lacovey, Debra Smith, Douglas Weber, Tyler 
Simpson, Lee Fisher, and Spencer Brown, as well as the surgical expertise of Ernest Manders, 
Jeffery Gusenoff, and Oguz Acarturk. This study is supported by research grants to S.B., J.P.R., 
by the U.S. Department of the Interior, the National Buisness Center, Acquisition Services 
 167 
Directorate, Sierra Vista Branch (award no. D11AC00006). A. Russell was instrumental in the 
acquisition of this funding. J.D. was supported by the National Science Foundation Graduate 
Student Research Fellowship.  
 168 
10.0  SUMMARY OF MILESTONES AND FUTURE DIRECTIONS  
The central hypothesis addressed in this thesis is that ECM bioscaffolds support constructive 
remodeling of skeletal muscle tissue by modulation of the microenvironment; specifically, 
macrophages and stem / progenitor cells, and that this response is augmented by concomitant 
mechanical loading. The following milestones were achieved: 
 
Milestone 1: The spatiotemporal cell response to ECM treatment of volumetric muscle 
loss was determined. 
Summary Milestone 1: Acute skeletal muscle regeneration relies upon the responding 
host innate immune response, specifically the transition in macrophage phenotype from pro-
inflammatory to pro-remodeling macrophages to drive myogenesis. This transition, however, is 
absent in cases of a critically-sized injury like volumetric muscle loss. Utilizing an acellular 
biologic scaffold approach, ECM treatment of VML promotes a phenotypic switch in 
macrophages, and this switch is subsequently followed by an increase in myogenic and 
neurogenic progenitor cells, contributing to constructive remodeling outcomes. Spatiotemporal 
quantification shows that these cells appear at both the margin of the defect near native uninjured 
muscle, but also at the center of the remodeling site.  
Future Directions Milestone 1:  Future experiments should focus on determining if there 
is a cause-effect relationship between the macrophage transition and the stem / progenitor cell 
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response in ECM-mediated VML remodeling. By preventing a macrophage transition, does 
constructive tissue remodeling still occur with ECM treatment? Additionally, while it was shown 
that some cells express neural progenitor markers by immunolabeling, temporal functional 
innervation should be tested to determine whether there is a correlation between function and the 
histologic presence of neurogenic cell types in the VML remodeling site.  
 
Milestone 2: The effect of ECM derived from diverse source tissues on the phenotype of 
macrophages was characterized. 
Summary Milestone 2: ECM-mediated constructive tissue remodeling has been 
associated with a modulation of macrophage phenotype at early time points. Macrophage 
activation has been established as a critical determinant of acute skeletal muscle regeneration, 
and is likely a key player in promoting remodeling in the case of volumetric muscle defects. 
Chapter 7 shows that ECM (1) directly affects macrophage phenotype, (2) the macrophage 
response to ECM is unique depending upon the source tissue from which the ECM is derived, (3) 
in general, ECM treatment prompts a pro-remodeling, M2-like macrophage phenotype and 
suppression of pro-inflammatory markers as evidenced through gene expression (Appendix), 
surface marker and protein expression (Chapter 7), and functional activity. However, an “MECM” 
macrophage is distinct from macrophages activated with canonical stimuli such as IFNγ and LPS 
and IL-4.  
Future Directions Milestone 2: Future experiments should focus on determining what 
component(s) of ECM elicit the macrophage response to determine the cause of the differential 
responses to diverse source tissues. In addition, while the present thesis shows that the ECM 
materials promote a shift in innate immune cell phenotype, future experiments should aim to 
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determine the effect of these materials on the adaptive immune response that also contributes to 
remodeling outcomes. An in vivo comparison of the macrophage response of ECM derived from 
diverse source tissues would provide valuable information regarding the impact of the 
macrophage response on constructive remodeling outcomes. 
Milestone 3: The impact of mechanical load on macrophage-progenitor cell crosstalk and 
ECM-mediated skeletal muscle remodeling as determined and the clinical efficacy of ECM 
bioscaffolds for VML treatment was evaluated.  
Summary Milestone 3: Mechanical loading has been associated with proper 
musculoskeletal strength and endurance maintenance, fatigue resistance, development, and acute 
regeneration. Chapter 8 shows that mechanical loading (1) activates macrophages towards a pro-
remodeling phenotype, (2) alters the secretome of macrophages to promote increased myoblast 
chemotaxis and differentiation, (3) promotes myogenesis, and (4) alters the secretome of 
myotubes to promote a pro-remodeling macrophage phenotype. The effect of mechanical loading 
augments the response of macrophages and myogenic progenitor cells to ECM bioscaffolds. The 
lack of concomitant mechanical load during ECM-mediated skeletal muscle remodeling impacts 
the local responding macrophage phenotypic ratio (decreases the M2-like to M1-like ratio), and 
hinders site-appropriate tissue deposition and negatively impacts strength restoration.  Clinically, 
the use of ECM bioscaffolds can promote strength, range-of-motion, and functional 
improvements in a diverse set of patients who had exhausted all previous standard-of-care 
therapies for VML as shown in Chapter 9. Early targeted physical rehabilitation seems to be a 
key determinant of this outcome. Patients were also shown to have an electromyographic and 
histologic improvement in nerve conduction, muscle formation, and mobilization of progenitor 
cells, respectively. Together these results could create a paradigm shift in the approach to VML 
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treatment away from the less-than-satisfactory methods currently used and towards incorporation 
of targeted, early physical therapy to stimulate the responding macrophages / progenitor cells and 
promote ECM-mediated constructive remodeling. Clinical translation of ECM bioscaffolds for 
VML repair is an efficient method to promote partial strength and functional gains and improve 
patient quality of life after suffering from volumetric muscle loss. 
Future Directions Milestone 3:  Future experiments should focus on a multi-center 
clinical trial to shift the standard-of-care for VML patients. Determining the mechanisms by 
which mechanical load stimulates a pro-regenerative microenvironment could guide clinical 
practice and physical therapy regimens for VML patients and other myogenic injuries / diseases. 
Further study is also necessary to determine whether the time between injury and treatment can 
improve outcomes, and if different forms of ECM (i.e. ECM hydrogels) can be used acutely to 
treat injured tissue noninvasively. Synergy between biomaterials, stem cell biology, 
pharmacology, and physical rehabilitation should be the focus for development of optimal 
therapies for VML. 
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APPENDIX A 
MACROPHAGE PHENOTYPE IN RESPONSE TO ECM BIOSCAFFOLDS7 
 
A.1 ABSTRACT   
Macrophage presence and phenotype are critical determinants of the healing response 
following injury. Downregulation of the pro-inflammatory macrophage phenotype has been 
associated with the therapeutic use of bioscaffolds composed of extracellular matrix (ECM), but 
phenotypic characterization of macrophages has typically been limited to a small number of non-
specific cell surface markers or expressed proteins. The present study determined the response of 
both primary murine bone marrow derived macrophages (BMDM) and a transformed human 
mononuclear cell line (THP-1) to degradation products of two different, commonly used ECM 
                                                 
7 Portions of this chapter were adapted from the following publication: 
Huleihel L, Dziki JL, Bartolacci J, Rausch T, Scarritt M, Cramer M, Vorobyov T, LoPresti S, Swinehart I, 
White L, Brown B, Badylak SF. Macrophage phenotype in response to ECM bioscaffolds. Seminars in 
Immunology. April 2017.  
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bioscaffolds; urinary bladder matrix (UBM-ECM) and small intestinal submucosa (SIS-ECM). 
Quantified cell responses included gene expression, protein expression, commonly used cell 
surface markers, and functional assays. Results showed that the phenotype elicited by ECM 
exposure (MECM) is distinct from both the classically activated IFNγ+LPS phenotype and the 
alternatively activated IL-4 phenotype. Furthermore, the BMDM and THP-1 macrophages 
responded differently to identical stimuli, and UBM-ECM and SIS-ECM bioscaffolds induced 
similar, yet distinct phenotypic profiles. The results of this study not only characterized an MECM 
phenotype that has anti-inflammatory traits, but also showed the risks and challenges of making 
conclusions about the role of macrophage mediated events without consideration of the source of 
macrophages and the limitations of individual cell markers. 
A.2 INTRODUCTION 
Biologic scaffold materials composed of extracellular matrix (ECM) have been used in 
both preclinical and clinical studies to facilitate the functional reconstruction of soft tissues 
including the esophagus102, skeletal muscle107, and myocardium272, among others335-337.  Results 
of such studies have varied from excellent to unacceptable338338, and the reasons for disparate 
results have been attributed to variables such as the methods used to  decellularize source 
tissues116,117,  the use of chemical crosslinking agents that inhibit scaffold degradation100, and 
other factors339,340.  Arguably the most important mechanism by which ECM bioscaffolds 
influence tissue remodeling and functional outcome is the modulation of macrophage 
phenotype99.  In fact, the ratio of M2-like/MIL-4 (regulatory/anti-inflammatory) to M1-
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like/MIFNγ+LPS (pro-inflammatory) macrophages has been shown to be a predictor of favorable 
outcomes in multiple studies76,341-343. 
Macrophages have long been recognized as phagocytes with pro-inflammatory and 
cytotoxic functions.  However, it is now understood that these cells also play essential roles in 
the resolution of inflammation344,345, normal tissue development346, and in blastemal-based 
epimorphic regeneration in species such as the axolotyl129. These “non-classical” macrophage 
activities are increasingly tied to shifts in the balance of M1:M2 macrophages participating in the 
host inflammatory reaction. While the description of macrophages as having an M1 or M2 
phenotype is operationally simple and facilitates discussion, supra-physiologic amounts of 
signaling molecules such as cytokines, toll-like receptor agonists, and growth factors have been 
used in-vitro to induce these extremes of pro-inflammatory or anti-inflammatory 
phenotype327,347,348. However, such conditions do not mimic the in-vivo complexity of 
macrophage activation. In fact, virtually any stimulus will likely elicit a macrophage phenotype 
that exists somewhere between the extremes.  
Given the diversity and broad scope of endogenous signaling molecules resident within 
extracellular matrix (e.g., growth factors, cytokines, cryptic peptides and miRNA), and the 
widespread clinical use of ECM bioscaffolds in tissue reconstruction, the “Mecm” phenotype is 
characterized in the present study. In contrast to commonly used methods of identifying 
macrophage phenotype by one or two markers, within the biomaterials and regenerative 
medicine literature as a whole, the present study includes transcription factor analysis, gene 
expression, protein expression, cell surface markers and functional assays to comprehensively 
characterize cell phenotype. ECM bioscaffolds derived from two separate tissue sources (porcine 
small intestine and urinary bladder) are used to activate two commonly used macrophage 
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populations: primary mouse bone marrow derived macrophages and THP-1 cells (a human 
mononuclear cell line).  Both naive macrophages and macrophages that have been activated with 
IFNγ+LPS are examined to determine whether ECM signaling molecules can contribute to 
phenotype switching. 
 176 
A.3 MATERIALS AND METHODS 
A.3.1 Overview of study design  
The present study determined macrophage phenotype following exposure to degradation 
products derived from ECM bioscaffolds. Two macrophage populations commonly used in in-
vitro studies examined: human THP-1 monocytes [American Type Culture Collection (ATCC)] 
and murine bone marrow derived macrophages. A comprehensive characterization of 
macrophage cell surface markers, gene expression, protein content, phagocytic capacity, and 
nitric oxide production was conducted. Based on previous studies, over 30 different surface 
markers, transcription factors, cytokines and metabolic markers were selected to evaluate the 
ECM-induced macrophage phenotype, termed MECM. Additionally, the production of proteins 
selected based upon PCA analysis was determined by western blotting and immunolabeling.  
Lastly, macrophage phagocytic activity and nitric oxide production post-treatment was 
determined. The methods used to assess the changes in macrophage phenotype are described 
below. 
A.3.2 Preparation of ECM bioscaffolds  
Porcine urinary bladders from market weight (approximately 110 kg) animals were acquired 
from Tissue Source, LLC. (Lafayette, Indiana, USA). Urinary bladder matrix (UBM-ECM) was 
prepared by decellularization using mechanical and chemical methods as previously reported247. 
Briefly, the tunica serosa, tunica muscularis externa, tunica submucosa, and tunica muscularis 
mucosa were mechanically removed. The luminal urothelial cells of the tunica mucosa were 
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dissociated by washing with sterile water. The remaining tissue consisting of basement 
membrane and subjacent tunica propria of the tunica mucosa was decellularized by agitation in 
0.1% peracetic acid with 4% ethanol for 2 hours at 300 rpm. The tissue was then extensively 
rinsed with phosphate-buffered saline (PBS) and sterile water. The UBM-ECM was then 
lyophilized and milled into particulate form using a Wiley Mill with a #60 mesh screen. 
Preparation of SIS-ECM has been previously described253. Briefly, jejunum was 
harvested from market weight pigs and split longitudinally. The superficial layers of the tunica 
mucosa were mechanically removed. Likewise, the tunica serosa and tunica muscularis externa, 
tunica submucosa, and tunica muscularis mucosa were mechanically removed, leaving the tunica 
submucosa and basilar portions of the tunica mucosa. Decellularization and disinfection of the 
tissue occurred by agitation in 0.1% peracetic acid with 4% ethanol for 2 hours at 300 rpm. The 
tissue was then extensively rinsed with phosphate-buffered saline (PBS) and sterile water. The 
SIS-ECM was then lyophilized and milled into particulate form using a Wiley Mill with a #60 
mesh screen. 
 
A.3.3 Derivation of ECM degradation products  
UBM-ECM and SIS-ECM were enzymatically degraded as previously described with pepsin 
from porcine stomach mucosa (MP Biomedicals) by mixing lyophilized, powdered UBM-ECM 
(10 mg/mL) and pepsin (1 mg/mL) in 0.01 M HCl (pH 2.0). This solution was stirred at room 
temperature for 48 hours. After stirring, the UBM slurry was neutralized to a pH of 7.4 in 1× 
PBS (137 mM NaCl, 2.7 mM KCl, 12 mM Phosphate, Fisher Scientific, Waltham, MA) to 
inactivate the pepsin. 
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A.3.4 Macrophage culture  
THP-1 human monocytes (TIB-202™) were obtained from the American Tissue Culture 
Collection (ATCC, Manassas, VA) and maintained in RPMI, 10% FBS, 1% 
penicillin/streptomycin, and 50 uM of 2-Mercaptoethanol in a humidified atmosphere at 37 °C 
with 5% CO2. Two million THP-1 cells were plated with 320 nM phorbol 12-myristate 13-
acetate (PMA) to induce differentiation into macrophages. After 24 hours adherent macrophages 
were washed in PBS and placed in fresh media, followed by 72 hours incubation in fresh media 
to acquiesce. This protocol has been shown to result in a phenotype that is nearly 
indistinguishable from human peripheral blood macrophages79. 
Murine bone marrow derived macrophages (BMDM) were isolated as previously 
described. Briefly, the tibia and femur were isolated from adult, female 6–8-week old C57bl/6 
mice obtained from Jackson Laboratories (Bar Harbor, ME). Bones were kept on ice and rinsed 
in a sterile dish containing macrophage complete medium consisting of DMEM (Gibco, Grand 
Island, NY), 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 10% L929 supernatant, 
0.1% beta-mercaptoethanol (Gibco), 100 U/ml penicillin, 100 ug/ml streptomyocin, 10 mM non-
essential amino acids (Gibco), and 10 mM hepes buffer. In a sterile environment, the ends of 
each bone were transected and the marrow cavity flushed with complete medium using a 30-
gauge needle. Harvested cells were washed and plated at 106 cell/ml, and allowed to differentiate 
into macrophages for 7 days at 37 °C, 5% CO2 with complete media changes every 48 h 
resulting in naïve macrophages. 
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A.3.5 Macrophage activation  
Macrophages were activated for 24 hours with one of the following: (1) 20 ng/ml IFNγ and 
100 ng/ml LPS to promote an MIFNy+LPS phenotype, (2) 20 ng/ml IL-4 to promote an MIL-4 
phenotype, or (3) 250 ug/ml of UBM-ECM, or SIS-ECM to promote an MECM phenotype. An 
equivalent concentration of pepsin was used as control buffer. In a separate group, macrophages 
were just activated with IFNy+LPS for 6 hours, as described above, and then exposed to UBM-
ECM or SIS-ECM for 24 hours. After the incubation period at 37 °C, cells were washed with 
sterile PBS and fixed with 2% paraformaldehyde for immunolabeling or harvested with 
TRIZOL/RIPA buffer for RNA/Protein assessment, respectively. Cells were also assessed for 
phagocytosis and nitric oxide production.   
 
 
A.3.6 RNA isolation and cDNA synthesis  
Cellular RNA was isolated using the miRNeasy Mini kit (Qiagen, Valencia, CA) according to 
the manufacturer's instructions. Reverse transcriptase from RNA to cDNA was performed via 
high capacity RT kit (ABI, Foster City, CA) according to the manufacturer's instructions. 
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A.3.7 Quantitative polymerase chain reaction (PCR)  
Sybr Green gene expression assays (ABI, Foster City, CA) were used to determine the relative 
expression levels of THP-1: iNOS, TNF, STAT1, STAT2, STAT5, IRF3, IRF4, IRF5, IL1RN, 
CD206, TGM2, STAT3, STAT6, KLF4, KLF6, PPARy BFKBF3, GLUT1, HIF1a, PGK1, 
LDHA, HK3, PDK4, RPIA, PPARy, G6PC3 and PCK2.  For BMDM gene expression levels: 
inos, tnf, stat1, stat2, stat5, irf3, irf4, irf5, il1rn, cd206, tgm2, stat3, stat6, klf4, klf6, fizz-1, arg1, 
bfkbf3, glut1, hif1a, hk3, pgk1, pdk4, rpia, ldha, pck1, pck2, g6pc3 and ppary . Results were 
analyzed by the ΔΔCt method using β-glucuronidase (β -GUS) control for human, and 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for mouse, to normalize the results. Fold 
change was calculated taking untreated as the baseline.  Results are displayed in a heat map 
format created by Java Treeview. 
 
A.3.8 Macrophage immunolabeling  
To determine macrophage surface marker expression profiles, activated cells were fixed with 2% 
paraformaldehyde (PFA) for 45 minutes. Primary antibodies used for immunofluorescent 
labeling on BMDM were: (1) monoclonal anti-F4/80 (Abcam, Cambridge, MA) at 1:200 dilution 
for a pan-macrophage marker, (2,3) polyclonal anti-iNOS (Abcam, Cambridge, MA) at 1:100 
dilution and anti-TNF (Abcam, Cambridge, MA) at 1:1000  for an M1-like marker, and (4,5) 
polyclonal anti-Fizz1 (Peprotech, Rocky Hill, NJ) and anti-arg1 (Abcam, Cambridge, MA) at 
1:100 dilution for M2-like markers. Primary antibodies used on THP-1 were: (1) monoclonal 
anti-CD11b (Abcam, Cambridge, MA) at 1:200 dilution for a pan-macrophage marker, (2,3) 
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polyclonal anti-iNOS (Abcam, Cambridge, MA) at 1:100 and anti-TNF (Abcam, Cambridge, 
MA) at 1:1000 for an M1-like marker, and (4,5) polyclonal anti-TGM2 (Abcam, Cambridge, 
MA) and anti-CD206 (Abcam, Cambridge, MA) at 1:1000 dilution for M2 markers. Cells were 
incubated in blocking solution consisting of PBS, 0.1% Triton-X, 0.1% Tween-20, 4% goat 
serum, and 2% bovine serum albumin to prevent non-specific binding for 1 h at room 
temperature. Blocking solution was removed and cells were incubated in primary antibodies for 
16 h at 4 °C. After washing in PBS, cells were incubated in fluorophore-conjugated secondary 
antibodies (Alexa Fluor donkey anti-rat 488 or donkey anti-rabbit 488, Invitrogen, Carlsbad, CA) 
for 1 h at room temperature. After washing again with PBS, nuclei were counterstained with 4′6-
diamidino-2-phenylindole (DAPI) prior to imaging. Images of three 20× fields were taken for 
each well using a live-cell microscope. Light exposure times for ECM-activated macrophages 
were standardized based upon cytokine-activated macrophages (positive control). Exposure time 
was kept constant for each marker. 
 
A.3.9 Western blot  
Western blots were performed on treated macrophage cell lysates. Cell lysates were boiled at 
95 °C for 5 min and electrophoresed on 4-20% gradient acrylamide gels. Specifically, 10 ug of 
protein was loaded into each well. Separated proteins were transferred to Polyvinylidene 
difluoride (PVDF) membranes (Bio-rad) using a wet transfer set up. Following transfer, 
membranes were then blocked for 45 min with Pierce protein-free blocking buffer (Pierce 
Chemical, Rockford, IL) and incubated overnight with the following primary antibodies: iNOS, 
TNF-, STAT1, IRF3 CD206, TGM2, and KLF4, for THPI and iNOS, TNF-, STAT1, Arg1, 
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Fizz-1 and KLF4 for BMDM. Membranes were washed three times for 15 min in 1X PBS, 
before and after they were incubated with appropriate secondary antibody. The washed 
membranes were exposed to chemiluminescent substrate (Bio-Rad) and then visualized using 
chemidoc touch instrument (Bio-Rad). Image Densitometry was evaluated using the shareware 
ImageJ (http://rsbweb.nih.gov/ij/index.html). 
 
 
A.3.10 Nitric oxide quantification  
Bone marrow macrophages and THP-1 cells were cultured and treated as previously described 
above. Following treatment, the supernatant from the wells was transferred to another plate and 
frozen at -80°C. The supernatant was thawed then 50 μL was added to another plate. 50 μL of 
standards consisting of sodium nitrite from 100 μM to 1.56 μM in a 1:2 serial dilution were 
added to the plate. The wells were treated with 50 μL of 1% sulfanilamide in 5% phosphoric acid 
for 10 minutes. Then 50 μL of 0.1% N-1-napthylethylenediamine [NED] dihydrochloride in 
water was added for an additional 10 minutes. The wells were then read at 540 nm and compared 
to the standard curve. Readings were normalized to the amount of DAPI-stained cells in each 
well as quantified by Cell Profiler. 
 
A.3.11 Phagocytosis assay  
Following activation, cells were incubated with Vybrant Phagocytosis Kit FITC-labeled E. Coli 
beads for 2 hours. Wells were then washed once with 1XPBS and fixed with 2% 
paraformaldehyde for 30 minutes. Wells were washed 3 times with 1X PBS then stained with 
DAPI for 10 minutes and washed again three times with 1X PBS. Wells were imaged using an 
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automated Live Cell Scope and quantified for mean intensity of the cells using Cell Profiler 
software. Mean intensity averages were calculated as percent changes from M0 naïve 
macrophage controls. 
A.4 RESULTS 
 
The terminology used to describe various states of macrophage activation (often referred to as 
“polarization”) has contributed to potentially misleading conclusions regarding the role of 
macrophages in various physiologic and pathologic processes.  For example, macrophages have 
been identified as M1 (pro-inflammatory) or M2 (anti-inflammatory), or given labels such as 
“regulatory” based upon selected surface markers or associated effector molecules.  
Recommendations for standard nomenclature based upon definition of the activator were 
published in 201416,24716, and this terminology will be used herein whenever possible (e.g., 
MIFNy+LPS and MIL-4).  Macrophages stimulated with solubilized extracellular matrix (ECM) will 
be designated as MECM (MUBM-ECM and MSIS-ECM). 
 
A.4.1 Overview of study design Human THP-1 monocytes and mouse bone marrow (BMDM) 
were differentiated into macrophages to generate an M∅ phenotype. M∅ macrophages were 
then treated for 24h with IFNγ+LPS to establish an MIFNγ+LPS phenotype, IL-4 to establish an 
MIL-4 phenotype, or either UBM-ECM or SIS-ECM to establish an MECM (MUBM-ECM / MSIS-
ECM) phenotype. In a separate experiment, M∅ macrophages were challenged with IFNγ+LPS 
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for 6 hours followed by a 24 hour treatment with UBM or SIS. Downstream analyses included: 
1) Gene expression of 30 commonly investigated macrophage activation markers, surface 
markers, cytokines, transcription factors and metabolic markers; 2) Protein expression of the 
most highly regulated markers; and 3) macrophage function as assessed by phagocytosis and 
nitric oxide production (Figure 33).   
 
Figure 33. Visual representation of study design 
 
 
 
 
 185 
 
Figure 34. Gene expression of previously described “M1-like” and “M2-like” surface markers, 
cytokines, transcription factors, and metabolic markers. BMDM (left panel) and THP-1 (right panel) 
macrophages were treated with UBM-ECM, SIS-ECM, IFNγ + LPS, and IL-4 for 24 hours. Additionally, 
macrophages were pre-treated with IFNγ+LPS for 6 hours followed by 24 hours of UBM or SIS treatment (n=3). 
Samples were normalized to media treatment. Gene expression was evaluated using qPCR data and is demnostrated 
in heatmap form. Fold changes are presented using a color gradient bar 
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A.4.2. MECM has a distinct gene expression profile  
Thirty commonly used macrophage markers of activation, including surface markers, cytokines, 
transcription factors, and metabolic markers were analyzed by qPCR to better understand the 
gene expression signature of treated macrophages. Gene expression data are displayed as a 
heatmap in Figure 34. Clear differences between the gene expression signature of THP-1 
macrophages and BMDMs were shown. Exposure of THP-1 macrophages to IFNγ+LPS resulted 
in an increase in almost the entire gene panel, while changes following exposure to IL-4 were 
relatively mild. In contrast, exposure to either UBM-ECM or SIS-ECM degradation products 
resulted in only minor changes in gene expression (Figure 34A).  
Exposure of BMDMs to IFNγ+LPS treatment and IL-4 treatment both led to substantial 
changes in gene expression with contrasting profiles. The phenotype generated by exposure to 
UBM-ECM differed from the phenotype generated by exposure to SIS-ECM but there were 
areas of overlap. Notably, IFNγ+LPS and UBM-ECM treated BMDMs have a similar gene 
expression profile (Figure 34B).  
When THP-1 macrophages were challenged with IFNγ+LPS for 6 hours followed by 
exposure to UBM-ECM or SIS-ECM for an additional 24 hours, no major changes in gene 
expression were observed (Figure 34A). However, there was a significant change in the gene 
expression signature in BMDMs (Figure 34B). In addition to the different response between the 
two macrophage populations, there were also clear differences between UBM-ECM and SIS-
ECM treatment groups post-cytokine treatment. Both UBM-ECM and SIS-ECM treatment 
groups showed a decrease in the transcription factor gene expression cluster, particularly when 
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pre-treated with IFNγ+LPS. Gene expression was normalized to untreated macrophages (M∅). 
IFNγ+LPS activated macrophages were normalized to IFNγ+LPS followed by media treatment.  
Principal component analysis (PCA) was conducted to identify the dominant members of 
the transcriptional signature associated with the test groups for further downstream protein 
expression. BMDMs and THP-1 macrophages treated for 24 hours with cytokines or ECM 
degradation products were scored and visually clustered by PCA. For THP-1 macrophages, 
CD206, KLF4 and TGM2 were found to be the genes most associated with IL-4 activation, and 
TNFα, STAT1 and IRF3 were associated with IFNγ+LPS activation (Figure 37A). The BMDMs 
showed Fizz-1, KLF-4 and Arg1 as the most differentially expressed genes associated with IL-4 
activation, and TNFα, STAT1 and iNOS were the most highly regulated genes with IFNγ+LPS  
activation (Figure 37B). Genes that are commonly cited in the literature as macrophage 
activation markers, and the genes identified in PCA data output, were chosen for further 
downstream protein analyses.  
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Figure 35. ECM degradation products promote an immunomodulatory "M2-like" phenotype (A) 
Human monocytes from the THP-1 cel line were cultured in media supplemented with PMA to derive macrophages. 
Macrophages were treated with 20 ng/ml IFNγ and 100 ngml LPS to derive "M1-like" macrophages, 20 ng/ml IL-4 
to derive "M2-like" macrophages, 200 ug/ml SIS-ECM degradation products, or 200 ug/ml pepsin control buffer. 
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Additionaly, "M1-like" macrophages were exposed to either 200 ug/ml UBM-ECM or 200 ug/ml SIS-ECM 
degradation produts to simulate the physiologic scenario of an injury treated with an ECM scaffold. Macrophages 
were fixed and immunolabeled for the pan macrophage marker (Cd11b), and strong indicators of the M1-like (TNFα 
and iNOS) and M2-like (CD206 and TGM2) phenotype. ECM treated cells show increased expression of TGM2 and 
CD206, markers associated with the IL-4 pushed phenotype. (B) Immunolabeling results were corroborated using 
western-blot analysis of the TNFα, iNOS,CD206, and TGM2 markers (bottom panel). (C) Bone marrow was 
isolated from C57bl/6 mice and cultured in media supplemented with macrophage colony stimulating factor (MCSF) 
to derive macrophages. "M1-like" macrophages, "M2-like" macrophages, and ECM-activated macrophages were 
derived as described above. Additionally, "M1-like" macrophages were exposed to UBM-ECM or SIS-ECM 
degradation products as before. Macrophages were fixed and immunolabeled for the pan-macrophage marker 
(F4/80), and strong indicators of the M1-like (TNFα and iNOS) and M2-like (Fizz1 and arginase) phenotypes. ECM 
treated cells show increased expression of Fizz1 and arginase, associated with the IL-4 pushed phenotype, as well as 
TNFα, associated with the IFNγ/LPS pushed phenotype, suggesting that the ECM treated cells adopt a unique 
phenotype. (D) Immunolabeling resuls were further evaluated using western-blot analysis of the STAT1, arginase, 
Fizz1, iNOS, and TNFα markers (bottom panel). (Scale bars = 200 µm). 
 
 
A.4.3 ECM degradation products and IL-4 promote similar protein expression profile 
Protein expression was evaluated by western blot analysis and immunofluorescent labeling. 
THP-1 macrophages activated for 24 hours with UBM-ECM or SIS-ECM induced TGM2 and 
CD206 (MIL-4 associated markers). However, no changes were noted in the MIFNγ+LPS associated 
marker TNFα and only a mild change in iNOS expression with SIS-ECM activation.  CD11b 
was used as a pan macrophage control marker for THP-1 macrophages (Figure 35) Macrophages 
activated with IFNγ+LPS followed by exposure to ECM degradation products showed a similar 
trend to the 24 hours treatment groups. When THP-1 macrophages were exposed to either UBM-
ECM or SIS-ECM following activation with IFNγ+LPS, both ECMs induced TGM2 and CD206 
positive cells. UBM-ECM and SIS-ECM both caused a reduction in iNOS expression by THP-1 
macrophages that had been activated with IFNγ+LPS. However, both UBM-ECM and SIS-ECM 
induced TNFα positive cells when macrophages were activated with IFNγ+LPS (Figure 35A).  
BMDMs show Fizz-1 and Arg1 (MIL-4 associated markers in mice) expression after 
activation with UBM-ECM and SIS-ECM for 24 hours. In addition, BMDMs were positive for 
the MIFNγ+LPS associated marker TNFα after exposure to ECM degradation products, but were not 
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positive for iNOS.  F4/80 was used as a pan macrophage control marker for BMDMs (Figure 
35C). Similarly, macrophages activated with IFNγ+LPS followed by treatment with ECM 
degradation products showed enhanced Fizz-1 expression, but not enhanced Arg1 expression. 
Interestingly, both UBM-ECM and SIS-ECM inhibited iNOS expression and enhanced TNFα 
expression after pre-activation with IFNγ+LPS.  
Western blot analysis was used to determine relative protein expression of the specified 
genes that showed the greatest change in activity in response to specific treatments. For the 
MIFNγ+LPS associated markers, the THP-1 macrophages activated for 24 hours with UBM-ECM or 
SIS-ECM showed that the amount of STAT1 was comparable to that of M∅ and MIL-4 cells, and 
significantly lower than that of the MIFNγ+LPS cells. No changes were noted in TNFα and IRF3 
(Figure 35B). 
For the MIL-4 associated markers, TGM2 and KL4 protein expression were increased after IL-
4 activation. No significant changes were found between the MECM groups and the M∅ and 
MIFNγ+LPS phenotypes. When macrophages were first activated IFNy+LPS, followed by exposure 
to SIS-ECM, a decrease in KLF4 protein expression was noted (Figure 35B). 
BMDMs exposed to UBM-ECM or SIS-ECM degradation products show similar findings to 
THP-1 macrophages with some small differences. For example, BMDMs activated by 24h 
exposure to UBM-ECM showed increased expression of STAT1 to a level similar to that of the 
MIFNγ+LPS treatment group, which was not seen in the THP-1 groups. However, in both 
populations of macrophages, no changes were noted in TNFα expression levels (Figure 35D). 
Notably, an increase in iNOS expression was found only in the BMDM MIFNγ+LPS group. When 
macrophages were activated with IFNγ+LPS followed by UBM or SIS treatment, no changes 
were noted in iNOS and TNFα expression levels when compared to media controls. However, 
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SIS-ECM treatment inhibited STAT1 protein expression for the group first activated by 
IFNy+LPS. For the MIL-4 associated markers, MIL-4 significantly increased Arg1 protein 
expression, and SIS-ECM significantly increased Fizz-1 expression. No changes were noted in 
KLF4 (Figure 35D). β-actin was used as a loading control and the colorimetric intensity of the 
bands for each treatment group was standardized to its respective β-actin band intensity. 
Densitometry evaluation of each blot can be found in Figure 38. 
A.4.4 ECM degradation products affect macrophage functional activity  
THP1 macrophages showed low levels of phagocytosis across all tested conditions. 
Cytokine treatment did not significantly enhance the phagocytic function of THP1 macrophages. 
However, UBM-ECM activation alone caused an increase in THP1 phagocytosis (Figure 36A). 
BMDMs showed measurable basal phagocytic function. Phagocytosis by BMDMs increased 
with IFNγ+LPS and no notable changes were detected following IL-4 activation (Figure 36B).  
Similar to the THP-1 macrophages, UBM-ECM activation resulted in an increase in 
phagocytosis. In both BMDMs and THp1 macrophages, activation with IFNγ+LPS for 6h prior 
to 24h exposure to UBM-ECM or SIS-ECM did not affect the cells’ phagocytic ability. THP1 
macrophages did not produce nitric oxide (NO) in response to IFNγ+LPS or IL-4 stimulus. 
However, UBM treatment did show a slight increase in NO production. Interestingly, THP-1 
macrophages challenged with IFNγ+LPS followed by UBM-ECM exposure did show a 
significant increase in NO production, but such changes were not observed with SIS-ECM 
exposure (Figure 36C). In BMDMs, NO production increased following IFNγ+LPS. BMDMs 
exposed to SIS or UBM alone had a slight increase in NO production. IFNγ+LPS activation 
followed by either UBM-ECM or SIS-ECM enhanced or prolonged cytokine effects compared to 
media controls (Figure 36D). 
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Figure 36. Functional assessment of ECM-treated macrophages. Phagocytosis activity in BMDM (A) 
and THP1 macrophages (B) was assessed using incubation with Vybrant FITC-labeled E.Coli particles then M.F.I 
analysis. Nitric oxide production from BMDM (C) and THP-1 macrophages (D) was assessed using the Greiss 
reagent system on macrophage supernatants following treatment 
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Figure 37. Principle component analysis (PCA) of delta Ct values scaled to unit variance. Biplot 
showign corrected principal component score values t(corr)[x] and loadings p(corr)[x] combined into one plot, 
where x is the component number. Genes that appear closer to the sample contributed to the distinction of that 
sample. The commonly cited genes associated with IFNγ+LPS and IL-4 activation that were chosen for further 
protein analyses for THP1 (A) and BMDM (B) derived macrophages and are highlighted. 
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Figure 38. Densitometry was performed on western blots for all proteins that were probed. Color 
intensity of original blots was quantified using ImageJ for both the protein of interest and the respective loading 
control, β-actin. Intensity of the target protein band was normalized to its respective β-actin band 
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A.5 DISCUSSION 
The results of the present study show clearly that BMDMs and THP-1 macrophages respond 
differently to the same stimulus.  The phenotype of these two macrophage populations following 
activation by an ECM scaffold can appear very similar or vastly different depending upon 
whether gene expression, protein expression, or surface markers are evaluated.  Furthermore, 
although SIS-ECM and UBM-ECM have both been associated with constructive, functional 
tissue remodeling outcomes in both pre-clinical animal models and in clinical applications in 
man, the macrophage phenotype resulting from activation with each ECM is distinct from those 
elicited by activation with either IFNγ+ LPS or IL-4.  Finally, following activation by IFNγ + 
LPS, macrophages then exposed to degradation products of both ECM bioscaffolds show a 
marked downregulation of genes that are typically associated with an inflammatory profile.   
ECM bioscaffolds typically promote a favorable tissue remodeling response when used to 
treat various types of soft tissue injury.  This response includes the recruitment of endogenous 
stem cells, angiogenesis, and dampening of the inflammatory response. This pro-healing 
response has been attributed, in large part, to the effect of ECM on macrophage phenotype. The 
objective of the present study was to comprehensively characterize the MECM phenotype. The 
source of macrophages used in this study; specifically, primary cells isolated from murine bone 
marrow (i.e., BMDM) and a transformed human mononuclear cell line (i.e., THP-1) are 
commonly used, and therefore the results are of interest to the field of macrophage biology349,350. 
Since conclusions from such studies can have far-reaching implications, it is important to 
understand the effect of the source of macrophages upon study results.   
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There was a clear difference between the response of BMDMs and THP-1 macrophages to 
both canonical stimuli such as IFNγ + LPS or IL-4 as well as to SIS-ECM and UBM-ECM 
degradation products. Gene expression analyses showed that THP-1 macrophages were not 
significantly affected by activation with IL-4, SIS-ECM, or UBM-ECM exposure, but there was 
a notable increase in most of the evaluated genes following activation by IFNγ+ LPS.  This 
response was in stark contrast to the BMDM gene expression signature that showed significant 
changes to all of the applied stimuli. We hypothesize that these changes are likely due to the 
endogenous differences between a cell line (i.e., THP-1) and primary cells (i.e., BMDM).   
Another difference between the two macrophage populations was the difference in macrophage 
function following activation. THP-1 macrophages were associated with very little nitric oxide 
(NO) production and phagocytosis regardless of their stimulus, whereas BMDMs showed an 
increase in NO production and phagocytic activity when stimulated with IFNγ + LPS similar to 
the response one would expect in vivo following exposure to a pro-inflammatory stimulus. 
Overall, the present findings suggest that the in vitro response of BMDMs respond more 
similarly than THP1 cells with respect to the behavior observed by macrophages in preclinical 
animal models and clinical studies that have examined ECM-mediated tissue remodeling76,100.   
Both SIS-ECM and UBM-ECM have been associated with an increased bioscaffold-localized 
M2:M1 ratio in preclinical animal studies, and a constructive, functional tissue remodeling 
response, but the macrophage phenotype has typically been characterized based upon a small 
number of cell markers351,352. In the present study, gene expression analysis of resting BMDMs 
showed that the macrophage response to SIS-ECM is similar to that of IL-4 activation. BMDMs 
exposed to UBM-ECM, in contrast, show a gene expression profile that is similar to that of the 
MIFNy+LPS phenotype. However, when macrophages are first activated with a pro-inflammatory 
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stimulus, both SIS-ECM and UBM-ECM down-regulate markers associated with a classic 
inflammatory response including iNOS, STAT1, STAT2, and KLF6 which is consistent with 
observed in vivo events. Both MSIS-ECM and MUBM-ECM augment nitric oxide production after 
IFNy+LPS stimulus in vitro, but the MUBM-ECM phenotype is associated with an increased 
phagocytic capability compared to the MSIS-ECM phenotype. The present work shows that the 
“MECM” phenotype differs depending upon the ECM source tissue and is perhaps more 
accurately defined as “M’source-tissue’-ECM”, for example “MSIS-ECM” or “MUBM-ECM”. We postulate 
that the differences between UBM-ECM and SIS-ECM are due to different signature of cryptic 
peptides, matrix-bound vesicles (MBVs) miRNA cargo or other components within the ECM75. 
Following injury, ECM scaffolds are applied to a soft tissue site following injury. The 
macrophages that interact with the ECM scaffold are likely in an activated state rather than a 
resting state. In an attempt to mimic this scenario, the present study evaluated the phenotypic 
response of both resting macrophages and IFNγ+LPS activated macrophages. There were clear 
differences between the response of “resting” macrophages and “pre-activated” macrophages to 
ECM degradation products. As previously mentioned, the MSIS-ECM and the MUBM-ECM 
phenotypes are distinct from each other when naive macrophages are exposed to degradation 
products of ECM. However, MIFNy+LPS activated macrophages respond similarly to both ECM 
sources with a down-regulation of inflammatory markers. The results of the present study show 
that the activation state of macrophages can influence the phenotypic response to subsequent 
stimuli. These findings are consistent with those of in vivo studies that show ECM bioscaffolds 
promote an anti-inflammatory macrophage phenotype with associated constructive and 
functional outcomes when utilized in response to injury or disease 98,116. The MIFNy+LPS may 
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better represent a physiologic macrophage’s state in response to injury, when investigating the in 
vitro response to a given stimulus.  
 
A.6 CONCLUSION 
The present study provides a comprehensive analysis of the macrophage phenotype associated 
with ECM scaffolds derived from the small intestine and urinary bladder. The results of the study 
demonstrate that the phenotype associated with both SIS-ECM and UBM-ECM is distinct from 
the canonical MIFNy+LPS and MIL-4 phenotypes.  Of note, there were also differences observed 
between SIS-ECM and UBM-ECM, suggesting that the microenvironment of the source tissue 
from which the ECM bioscaffolds are produced also plays a significant role in determining 
patterns of macrophage activation.  Lastly, we note that there are challenges and risks associated 
with drawing conclusions about macrophage mediated events when results are based upon a 
particular macrophage population or a limited subset of macrophage markers.  A greater 
understanding of the effect of macrophage phenotype upon the tissue remodeling process 
associated with ECM scaffolds will enhance both the design and associated production methods 
of such scaffolds materials, and would logically improve the clinical outcomes associated with 
their use. 
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